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The most exciting phrase to hear in science, the one that heralds the 
most discoveries, is not "Eureka!" but "That's funny..."   
 Isaac Asimov 
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ABSTRACT 
 
Influenza infections usually run a mild course, but pandemics with a more severe 
outcome can occur when the fragmented genome of the virus undergoes antigenic 
shift. The continuous threat of a pandemic combined with the ongoing antigenic drift 
makes that development of a universal protective vaccine is currently impossible. 
Therefore it is of great interest to thoroughly study the immune response against 
influenza virus infection as a better understanding of these processes can help to 
develop new protective or therapeutic strategies.  
In this thesis we studied different aspects of the immune system with a focus on the 
heterogeneity of different cell types and immune reactions. A first study focused on 
dendritic cell subsets. We identified a maturation status of cDC2s that acquires typical 
cDC1 functions. This observation draws attention to the fact that a strict delineation of 
subsets and their function during steady-state conditions is not necessarily applicable to 
inflammatory settings. In a second study T cell subsets after influenza infection were 
studied in detail with a focus on the currently weakly defined CD4-CD8- double 
negative T cells. These cells reside in the lung tissue in a preactivated state and are 
recruited and maintained in a dendritic cell dependent manner. Functionally, double 
negative T cells were shown to control the balance of dendritic cell subsets. The scope 
of the last study is the involvement of the early innate IL-1 signal on iBALT formation. We 
show that the lung is already conditioned 2 days post infection to form iBALT structures 
whereas these structures are only fully formed 17 days post infection. In this context 
early IL-1R signaling is crucial for CXCL13 expression and later iBALT formation.
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ABBREVIATIONS 
 
AMF  alveolar macrophage 
BM  bone marrow 
CD  cluster of differentiation 
cDC  conventional dendritic cell 
CDP  common DC progenitor 
cMoP  common monocyte progenitor 
CTL  cytotoxic T lymphocyte 
DC  dendritic cell 
dLN  draining lymph node 
DN T cell CD4-CD8- double negative T cell 
Dpi  days post infection 
DT  diphtheria toxin 
DTR  diphtheria toxin receptor 
FDC  follicular dendritic cell 
Flt3-L  FMS-like tyrosine kinase 3 ligand 
FRC  follicular reticular cell 
GC   germinal center 
GM-CSF granulocyte-macrophage colony stimulating factor 
HA  hemagglutinin 
HEV  high endothelial venule 
IAV  Influenza A virus 
iBALT  inducible bronchus associated lymphoid tissue 
IFN  interferon 
Ig  immunoglobulin 
IL  interleukin 
i.n.  intranasal 
i.t.  intratracheal 
i.v.  intravenous 
LTi cell  lymphoid tissue inducer cell 
LTo cell lymphoid tissue organizer cell 
MC  monocyte-derived cell 
MF  macrophage 
MFI  mean fluorescence intensity 
MHC  major histocompatibility complex 
MLN  mediastinal lymph node 
MoDC  monocyte-derived DC 
NA  neuraminidase 
NET  neutrophil extracellular trap 
NLR  NOD-like receptor 
NK cell natural killer cell 
NP  nucleoprotein 
PAMP  pathogen-associated molecular pattern 
pDC  plasmacytoid dendritic cell 
PRR  pattern recognition receptor 
RLR  RIG-I-like receptor 
RNP  ribonucleoprotein 
RT-PCR reverse transcriptase polymerase chain reaction 
SLO  secondary lymphoid organ 
SP  surfactant protein 
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Tcm cell central memory T cell 
TCR  T cell receptor 
Tem cell effector memory T cell 
TF  transcription factor 
Tfh cell follicular helper T cell 
Tg  transgenic 
Th cell  T helper cell 
TLO  tertiary lymphoid organ 
TLR  toll-like receptor 
Treg cell regulatory T cell 
Trm cell resident memory T cell 
WT  wild type
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Adapted from:  
Neyt K, Perros F, GeurtsvanKessel CH, Hammad H, Lambrecht BN. 2012. Tertiary lymphoid organs 
in infection and autoimmunity. Trends Immunol. 33(6):297-305. 
 
Neyt K & Lambrecht B. 2013. The role of lung dendritic cell subsets in immunity to respiratory 
viruses. Immunol Rev. 255(1):57-67. 
 
Lambrecht BN, Neyt K, GeurtsvanKessel CH, Hammad H. 2013. Lung dendritic cells and 
pulmonary defense mechanisms to bacteria. In Prince A (Ed.), Mucosal immunology of acute 
bacterial pneumonia. Springer Science+Business Media New York. ISBN: 978-1-4614-5325-3 (Print), 
978-1-4614-5326-0 (Online). 
 
Lambrecht BN, Neyt K, van Helden MJ. 2015. The mucosal immune response to respiratory 
viruses. In Mestecky J, Strober W, Russel M, Cheroutre H & Lambrecht B (Eds.), Mucosal 
Immunology. Academic Press Amsterdam. ISBN: 9780124158474 (Print), 9780124159754 (eBook). 
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Influenza 
Influenza, commonly called “the flu”, is caused by infection with an influenza virus. 
Influenza viruses are negative-sense, single-stranded, enveloped RNA viruses with a 
segmented genome and are classified in the family of Orthomyxoviridae. Based on 
differences in the conserved nucleoprotein (NP) and matrix (M) proteins, influenza 
viruses are subdivided in 3 genera: influenza A, B and C1. Influenza virus A and B have 8 
genome segments, whereas influenza C only has 7 genome segments2, 3. Influenza A 
viruses (IAV) are further subdivided into subtypes based on differences in the 
hemagglutinin (H1-18) and neuraminidase (N1-11) surface proteins 
(http://www.cdc.gov/flu/avianflu/influenza-a-virus-subtypes.htm). 
 
Epidemiology of influenza A virus infections 
Annually 5-10% of adults and 20-30% of children get infected with influenza virus 
(www.who.int fact sheet N°211). The virus mainly spreads via aerosols caused by 
coughing and sneezing. The aerosols can infect people directly or reside on the hands 
of infected people and be passed on via poor hand hygiene. Illness is usually mild and 
characterized by fever, coughing, headache, muscle pain, malaise, a sore throat and 
a runny nose. Occasionally, influenza viruses can cause severe illness and even death; 
especially in the high-risk groups including pregnant women, young children, elderly 
and people with underlying immune compromising disease.  
 
Structure and genomic organization of influenza A virions 
IAV is an enveloped virus with a spherical or filamentous form. The lipid envelope is 
derived from the host cell membrane during the process of viral budding and consists 
of only 3 viral surface proteins: hemagglutinin (HA), neuraminidase (NA) and Matrix 
Protein M23(Figure 1). The HA is responsible for binding to the host cell and membrane 
fusion, NA is involved in viral budding and is necessary to release the newly formed viral 
particles from the host cell. The M2 protein is a pH-regulating ion channel necessary for 
viral uncoating. The viral RNA polymerase complex is formed by 3 subunits: Basic 
Polymerase Protein (PB) 1 and 2 and Acidic Polymerase Protein (PA)3. Furthermore, the 
viral particle consists of the M1 matrix protein, which interacts with the viral RNA, the 
RNA binding Nucleoprotein (NP), the Nuclear Export Protein (NEP) and the Nonstructural 
Protein NS1 that regulates gene expression3.  
All viral RNA segments are bound to NP inside the virion and form ribonucleoprotein 
(RNP) complexes4. Historically it was thought that only these 10 proteins are transcribed 
from the 8 viral RNA segments of the IAV virus3(Figure 1) but more recently additional 
splice variants of the polymerase, matrix and non structural protein were defined5. 
Segments 1, 4, 5 and 6 each encode only 1 protein: PB2 (basic polymerase protein 2), 
HA, NP and NA respectively. Segment 2 encodes PB1 and the accessory protein PB1-F2 
and PB1-N40, an N-truncated form of PB1. Segment 3 encodes the acidic polymerase 
protein (PA) and its related proteins PA-X, PA-N155 and PA-N182. Segment 7 encodes 
the matrix protein M1, the ion channel protein M2 and M42. Segment 8 encodes NS1, 
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NEP and NS3, an isoform of NS1. Table 1 summarizes the different proteins that are 
derived from the 8 gene segments and their respective function. 
 
 
Figure 1- Structure of the influenza A virion 
Influenza A virus particles are spherical and consist of a host-derived lipid membrane with three viral surface proteins 
(neuraminidase, hemagglutinin and the M2 ion channel) that surrounds the 8 ssRNA genome segments 
 
Table 1 - Influenza proteins encoded by the gene segments and their respective function 
 
SEGMENT PROTEIN FUNCTION 
1 Basic Polymerase Protein 2 (PB2) Generating cap structure for viral mRNA 
2 Basic Polymerase Protein 1 (PB1) 
 
PB1-F2 
 
 
PB1-N40 
RNA polymerase, RNA elongation 
 
Synergistic effect on PA and PB2, regulation of innate immune 
response, pro-apoptotic, pro-inflammatory 
 
Interaction with PB1 and PB1-F2, not PA 
3 Acidic Polymerase Protein (PA) 
 
PA-X 
 
 
PA-N155, PA-N182 
Helicase and ATP-binding 
 
Repression of cellular gene expression by degradation of host 
mRNA 
 
No polymerase activity, exact function in replication cycle not 
defined 
4 Hemagglutinin (HA) Fusion with host cell by binding to sialic acid containing 
receptors on the cell surface of host cells 
5 Nucleoprotein (NP) Transcription and replication, nuclear import 
6 Neuraminidase (NA) Release of viral particles from infected cells via sialidase activity 
7 Matrix Protein 1 (M1) 
 
 
Matrix Protein 2 (M2) 
 
M42 
Separation of RNP from viral membrane, RNA nuclear export 
regulation, viral budding 
 
pH regulating ion channel, virus uncoating and assembly 
 
Similar to M2 
8 Nonstructural Protein 1 (NS1) 
 
 
Nuclear Export Protein (NEP, NS2) 
 
NS3 
Regulation of cellular and viral protein expression, interferon 
antagonist 
 
Nuclear export of RNA 
 
Host adaptation (hypothesis) 
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Viral replication 
The composition of IAV viruses is relatively simple as their RNA encodes for a limited set 
of proteins. As a consequence, they have to use elements of the host transport, 
replication, transcription and translation machinery in addition to their own proteins to 
successfully complete their life cycle6, 7(Figure 2). Viral HA recognizes and binds to sialic 
acid on the host cell surface. After binding to the host cell, the viral particle is 
endocytosed. This is a process consisting of two steps: firstly the viral envelope merges 
with the endosomal membrane; secondly the virion is internally acidified via the 
M2 ion channel, which allows the release of viral RNPs into the cellular cytoplasm8.  
 
 
Figure 2 - Schematic representation of the replication cycle of influenza virus 
HA = hemagglutinin, NA = neuraminidase, SA = sialic acid, ER = endoplasmic reticulum 
vRNA = viral RNA, mRNA = messenger RNA, cRNA = complementary RNA 
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RNPs are then transported to the nucleus of the cell for RNA synthesis9. The negative 
stranded viral-RNAs (vRNA) serve as a template to synthesize messenger RNA (mRNA) 
and complementary positive stranded RNA (cRNA) that on its turn serves as a template 
to transcribe more vRNAs. The host translation machinery in the cytosol translates viral 
mRNA into proteins. The surface proteins are post-translationally modified in the 
endoplasmic reticulum and transported to the cell membrane via the Golgi complex. 
The IAV core proteins interact with the vRNA to form the RNPs. In the cytoplasm, the 
RNPs are assembled into newly synthesized viral particles that bud from the infected 
cell, thereby obtaining their viral membrane containing viral surface proteins. NA 
activity is crucial during this process to release the newly formed viruses that will next 
use HA to bind sialylated proteins on the host cell membrane10.  
 
Antigenic shift and drift 
The RNA-dependent RNA polymerase mechanism that synthesizes mRNA and cRNA 
from the negative stranded vRNA template lacks proofreading capacity and therefore 
random point mutations can be introduced in the viral genome during replication. 
Owing to this error-prone replication mechanism and the fact that the genome is 
segmented, these viruses are sensitive to undergo so-called antigenic drift and 
shift3(Figure 3).  
Antigenic drift is caused by minor genetic changes that arise as a consequence of 
natural occurring mutations that are not corrected during the replication phase or due 
to selective pressure under the influence of virus-specific antibodies. This process can 
result in changes in the antigenic sites of the viral proteins. When the HA or NA surface 
genes are sufficiently altered, the pre-existing neutralizing antibodies might not be able 
to recognize the HA or NA epitopes and thereby the virus can escape the prior memory 
mechanisms of the immune response of the host, causing the yearly influenza 
epidemics.  
 
 
Figure 3 - Genetic drift and shift of influenza A virus in the host cell 
During genetic drift minor changes are introduced in the influenza A viral genome, which can result in a change in the 
antigenic sites of the viral proteins. When two different viral strains are present in the same host cell antigenic shift can 
occur. During this process gene segments are exchanged. H = hemagglutinin, N = neuraminidase 
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Contrary to the small changes introduced by antigenic drift, a new virus with 
antigenically unrelated surface proteins can arise when 2 or more viruses co-exist in the 
same host and exchange viral segments. This process is called antigenic shift. If the 
newly generated virus is efficiently transmittable from human to human, it can cause 
influenza pandemics like the Spanish flu in 1918 (H1N1), the Asian flu in 1957 (H2N2), the 
Hong Kong flu in 1968 (H3N2) and the more recent outbreak of Mexican flu in 2009 
(H1N1) since no pre-existing imp munity is present in the majority of the population.  
 
 
This flexibility of the viral genome is a great challenge for vaccine development. The 
circulating viruses in humans need to be monitored continuously to follow the genetic 
changes and predict future changes. Based on these observations the composition of 
the vaccine is adjusted every year. The vaccine generally consists of the 3 or 4 most 
relevant circulating viral types: 2 IAV of subtypes H1N1 and H3N2 and one or 2 IBV 
types. The vaccines are most effective when the vaccine viruses antigenically match 
the actual circulating viruses, but since antigenic shift and drift are random processes 
and therefore hard to control and predict, there is never a guarantee for total 
protection with the current vaccine strategies. In depth knowledge about the 
molecular and cellular mechanisms of IAV infection is therefore necessary to develop 
vaccination strategies that overcome the limits of the currently available vaccines11. 
 
 
The innate immune response against influenza A virus 
Epithelial integrity and antiviral soluble innate immunity  
Because of their air-exchange function, the lungs are continuously exposed to particles 
from the environment such as microbes, allergens, mineral and organic dust particles 
and pollutants. Therefore a fine balance must be maintained between tolerating 
non-harmful particles from the environment and mounting a strong and protective 
immune response against harmful organisms that enter the lungs. To avoid immune 
reactions in non-harmful conditions, epithelial cells produce suppressive signals. 
Influenza virus aerosols enter via the respiratory tract and its first target cell is the 
epithelial cell. To be able to enter and infect the epithelial cells, IAV needs to pass 
intrinsic protection mechanisms such as the mucus layer and antiviral peptides that can 
prevent attachment and viral entry. The lining fluid of the lungs that surrounds the cilia 
of the ciliated bronchial epithelial cells is crucial for the functioning of the mucociliary 
blanket as this fluid contains numerous soluble molecules that mediate a first line of 
innate defense. These comprise, lysozyme, lactoferrin, defensins, complement and 
surfactant proteins A and D. Surfactant protein (SP) A and D play an important role in 
innate humoral defense mechanisms of the lung as demonstrated in SPA and SPD 
deficient mice that develop a more severe IAV infection12, 13. SPD serves to balance 
protection against alveolar damage and virus elimination by binding IAV particles, thus 
preventing infection of epithelial cells and facilitating the clearance of these particles 
by phagocytic cells14. Furthermore binding of viral particles to Galectin-1 decreases 
susceptibility to infection15 and viral membranes can be destructed directly by LL-37 
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that is released from neutrophil granules and by epithelial cells16. Recent genetic studies 
linked genetic polymorphisms in the complement system proteins to the outcome of 
IAV infection17, 18. Especially component C3 was shown to contribute to protection19. In 
contrast, complement activation was also linked to acute lung injury20. Defensins can 
be constitutively produced by epithelial cells and neutrophils and in response to 
infection. They inhibit the infection of epithelial cells through direct interactions with the 
virus or through induction of aggregation of the virus21-26.  
Once the virus breaches this first physical barrier, it can infect the epithelial cells, which 
results in the loss of epithelial integrity and subsequent loss of homeostatic signals.  
Besides suppressive signals that are constitutively produced in the lungs, one of the 
earliest soluble antiviral proteins that are induced upon recognition of a viral threat are 
type I interferons (IFN). Type I IFNs consist of 14 IFNα subtypes (only 13 in humans) and 
one subtype of IFNβ, IFNε, IFNκ and IFNϖ that all bind to the type I IFN receptor 
composed of an IFNAR1 and an IFNAR2 chain27, 28. Type I IFNs are crucial for the 
defense against most viruses, including respiratory viruses. According to the classical 
paradigm, type I IFNs induce an antiviral state in neighboring non-infected cells 
whereby they inhibit protein synthesis in host cells and limit viral replication, a process 
often referred to as “viral interference”29. In recent years, many studies using RNA 
sequencing and RNA expression arrays have been performed in virus-infected cells, 
including those lacking type I IFN receptors. From these studies a common “type I 
interferon signature” has emerged. Genes often induced by type I IFNs are summarized 
in Table 2.  
 
 
Table 2 - Interferon stimulated genes and their function 
 
IFN INDUCED GENE FUNCTION REFERENCE 
IFIT family Inhibition of cellular translation 30 
IFITM1-3 
Control of IAV infection by interfering with viral-host receptor binding 
and entry of RNPs into the cytosol 
31, 32 
ISG15 Conjugation of NS1, thereby inhibiting its function 33-37 
Mx1, Mx2 
Interference with viral RNA replication by interacting with RNA helicases 
and viral NP Susceptibility or resistance to IAV infection is associated with 
polymorphisms 
38-41 
OAS1, OASL1  
Creates co-factor for RNAseL which cleaves RNA, stopping (viral) 
replication; cleaved products activate RIG-I providing a positive 
feedback loop for IFN production 
42, 43 
PKR  Limiting viral replication by a general block of translation 44 
Tetherin 
Holds newly produced viral particles at the cell surface; role during IAV 
infection is questionable 
45-48 
TRIM protein family 
Activation of RIG-I signaling pathway, enhancing the type I IFN response 
Interaction with NP leads to proteosomal degradation 
Hampers RNA synthesis 
49-51 
Viperin 
Inhibits budding from the plasmamembrane of infected cells in vitro; not 
confirmed in vivo 
52, 53 
 
Despite the strong antiviral activities that are initiated by these genes before activation 
of the adaptive humoral and cellular immune responses, they are not proficient of 
preventing viral infections as IAV developed evasion strategies to temper the interferon 
response54. In the coming years, it will be important to unravel the precise importance 
of these individual genes in explaining the antiviral state in more detail.  
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Almost all cell types can produce type I IFN. As a consequence, the exact source of 
type I IFN during infections can differ according to the type of virus, the anatomical 
location and structure and the timing. 
 
Activation of antiviral cellular innate immunity by stimulation of pattern 
recognition receptors  
Innate immune cells have evolved to recognize conserved pathogen-associated 
molecular patterns (PAMPs) through specific pattern recognition receptors (PRRs) such 
as Toll-like receptors (TLRs), RIG-I-like receptors (RLRs) and NOD-like receptors (NLRs). 
Viral nucleic acids can be recognized by TLRs located in the endosomal compartment: 
DNA viruses by TLR9, ssRNA by TLR7 and 8 and dsRNA by TLR3. Viral proteins can also 
bind to TLRs located on the cell surface55. The intracellular RLRs RIG-I, MDA5 and LGP2 
are present in the cytosol of most cell types and induced by IFN in a positive feedback 
loop of virus detection. RLRs are essential for induction of innate immune defense 
mechanisms and type-I IFN production in response to RNA virus infection56. RIG-I 
recognizes RNA with 5’ triphosphates whereas MDA5 recognizes long and stable 
dsRNA57. Apart from the conventional RNA helicases RIG-I and MDA5, a new group of 
RNA helicases, DEXDc helicases, able to activate innate immune cells has been 
described58-62. It is currently unknown if lung immune cells rely solely on these helicases 
to recognize particular viral infections or certain phases of the replicating virus. 
NLRs have a N-terminal effector domain for interaction with adaptor proteins. When 
PAMPs are detected, large molecular complexes, called inflammasomes, are formed. 
Activation of inflammasomes leads to the activation of pro-inflammatory genes 
through NFκB signaling in a two-step process63, 64. IAV virus infection predominantly 
activates the NLRP3 inflammasome65-68. In a first step viral RNA is recognized by TLR7, 
which leads to production of pro-IL-1β or pro-IL-18. Consequently a second signal uses 
the M2 ion channel to activate the NLRP3 inflammasome69, leading to activation of 
pro-caspase 1 to caspase 170 and subsequent cleavage of pro-IL-1β or pro-IL-18 into a 
bioactive form.  
The essence of these PRRs is illustrated by the fact that many viruses have evolved 
evasion mechanisms to circumvent the activation of PRRs. For example, the non-
structural proteins of influenza and RSV viruses evade immune recognition via PRRs71, 72.  
Lung resident cells act as sentinels via their PRRs and can initiate the recruitment of 
various cell types to the site of inflammation. Epithelial cells are the first target cells for 
IAV infection73. The virus can cause productive infection of these epithelial cells resulting 
in the release of large numbers of infectious virus progeny74-76. The PRRs on their surface 
will recognize viral particles, which eventually will lead to induction of type I IFN and 
production of cytokines and chemokines such as IL-6, TNF-α, IL-8, CXCL10, CCL2 and 
CCL5 to coordinate the innate immune defense to prevent spreading of the virus77-84. 
Infection of murine tracheal epithelial cells leads to induction of IFNβ, α4 and α5, but not 
the other subtypes, in a RIG-I dependent manner85.  
Alveolar macrophages (AMFs) reside in the lung where they produce IL-10 to dampen 
the immune responses86-89. When pathogens enter the respiratory system, the 
phagocytic AMFs are crucial as a first line of defense against IAV infection as they 
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constitute over 90% of the cells in the naïve lung90-95. Studies in IFNα reporter mice have 
revealed that AMFs can also be massive producers of type I IFNs after intranasal 
infection with certain RNA viruses96, 97. During influenza infection, epithelial cells produce 
CCL2 in a type I IFN dependent manner, which attracts CCR2+ monocytes from the 
blood into the lung91, 98. These monocytes can differentiate into macrophages or 
monocyte-derived dendritic cells and have the duality of being protective and harmful 
for the lung environment91, 99. Furthermore tissue resident macrophages and DCs 
produce CCL2 for self-amplification of early infiltrated Ly6Chi monocytes upon type I IFN 
produced from epithelial cells100. Recruited monocytic cells can serve as reservoirs for 
influenza virus replication early following infection101. 
Neutrophils form the phagocytic compartment together with macrophages and are 
the first white blood cells that are recruited to the sites of inflammation94, 95. They are 
equipped with multiple strategies to eliminate pathogens. Upon encounter with a 
pathogen, neutrophils phagocytose the organism and kill it by production of reactive 
oxygen species102, 103 or by the release of antibacterial peptides from its 
granules16, 21, 24, 104-107. These proteins can also be released directly in the extracellular 
milieu to kill organisms without phagocytosing them. Whether neutrophils take up viral 
particles directly108 or via ingestion of infected epithelial cells95 remains a matter of 
debate. In either case, they are not permissive for productive infection95, 109, 110. An 
additional killing mechanism is the formation of neutrophil extracellular traps (NETs). 
These NETs are composed of a DNA element to which histones, proteins and enzymes 
that are released from the neutrophil granules are attached. This forms a network 
where pathogens can be “trapped” to facilitate phagocytosis and prevent their 
spread111. The recruitment of neutrophils during IAV infection reduces the disease 
severity by limiting viral replication94, 112-114. Besides effector cells participating in the 
early responses, neutrophils can also participate in the adaptive response. They can 
acquire antigen-presenting functions and thereby contribute to the adaptive immune 
response and induce CD8+ T cell responses115-118. 
Another cell type responsible for the first-line defense against infections is the natural 
killer (NK) cell. They reside in the healthy lung, but are further recruited from the blood to 
the lung by type I IFN of epithelial cells within the first days after infection100, 119, 120. 
Neutrophils are required for NK cell homeostasis and function121. During influenza virus 
infection, type I IFN-signaling on NK cells is necessary for their activation and expression 
of the cytolytic effector function and production of IFNγ122-124. NK cells are involved in 
regulating viral clearance125-130 and are also important for epithelial tissue 
regeneration131 thereby limiting morbidity and mortality. The NKp46 NK cell receptor 
interacts with viral HA and this interaction leads to enhanced cytotoxicity against the 
infected cells132-136. NK cells not only limit the viral replication by killing infected cells prior 
to the full activation of the adaptive immune response137, they are also involved in 
initiating this adaptive response138, 139. In contrast to the protective roles of NK cells, 
some studies described an exacerbating role of NK cells on morbidity and 
pathology140, 141. Most likely, the dual role of NK cells depends on the viral dose and 
pathogenicity of the different influenza subtypes142. Because of the import first-line 
defense mechanisms of NK cells, IAV virus has also evolved mechanisms to evade or 
escape NK cell recognition143-146. 
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Dendritic cells bridge innate and adaptive immune responses 
To cope with the continuous exposition to foreign particles, the lung is equipped with 
an elaborate network of dendritic cells (DCs). DCs are the so-called sentinels of the 
immune system that link sensing by ancient innate immune system receptors to 
activation of adaptive immunity. Ralph Steinman identified them in 1973 as cells with 
processes or “dendrites”147-149 that are functionally distinct from macrophages by their 
ability to stimulate naïve T cells in mixed-lymphocyte reactions150, 151.  
Although once identified as a single cell type, it is now clear that DCs have many faces. 
In the lungs, DC subsets perform different tasks of antigen sampling, recognition of 
pathogens and allergens, migration to lymph nodes, induction of cellular CD4 or CD8 
immunity, and production of inflammatory chemokines. As a result many different 
subsets have been described by various investigators in the last 40 years. A major pitfall 
when studying DCs is that the poor consistency in nomenclature that is used to describe 
different subsets makes it hard to compare studies. To create a more robust 
nomenclature, a classification system based on two levels was recently proposed152 
and summarized in Table 3. The first level is based on ontogeny and makes a distinction 
between monocytes and monocyte-derived cells (MCs) that are derived from the 
common monocyte progenitor (cMoP) and dendritic cells (DCs) that are derived from 
the common DC precursor (CDP)153, 154. The second level subdivides the true DCs into 
three major subtypes based on the developmental pathway. The conventional DCs 
(cDC) develop from the CDP via the pre-cDC stage into either cDC1s (BATF3155-157, 
Id2157-159 and IRF8160-162 dependent, CD103+ and CD8α+ DCs) or cDC2s (IRF4162-165, ZEB2166 
and KLF4167, 168 or NOTCH2169, 170 dependent, CD11b+ and Sirp1α (CD172a)+ DCs). The 
pre-pDC gives rise to pDCs in an E2-2 dependent manner171-173. Next to the pre-pDC 
origin, a lymphoid origin has been suggested for the pDC population174-181 but as most 
of these studies were performed in vitro or by transfer of precursors into irradiated mice, 
the true in vivo relevance remains a matter of debate182, 183. 
 
Dendritic cell subsets in the steady state mouse lung 
Any discussion on the biology of DCs needs to consider the heterogeneity of these cells 
in various tissues and anatomical locations. In the absence of inflammation, lung 
conventional DCs can be subdivided in three distinct subsets based on the expression 
of a combination of specific cell surface markers and their ontogeny 
(Table 3): CD11chi CD103+ cDC1s that belong to the CD8α-type cDCs, CD11chi CD11b+ 
cDC2s and CD11cdim pDCs184, 185. Conventional DCs are differentially distributed in the 
lung (Figure 4). In the epithelial layer of the conducting airways a network of 
CD103+CD11b- cDC1s can be found186-188. They form long cellular extensions that run in 
between the basolateral space made up of basal epithelial cells. The lamina propria, 
which is positioned below the basement membrane, contains CD11b+ cDC2s189-191. 
These DCs are CD103-, but upon inflammation some of these cells can acquire a 
CD103+CD11b+ phenotype as observed in the intestine192. Next to conventional DCs, 
the conducting airways also contain pDCs186, 193-195. In the parenchymal compartment 
of the lung, gas exchange is taking place at the alveolocapillary membrane. Both 
CD11b+ and CD11b- cDCs and pDCs are found in the alveolar septa of the lung 
*	  
	   17 
parenchyma196. So-called patrolling monocytes, mainly expressing CX3CR1 and CD11b, 
can patrol the vessel wall of the pulmonary arterial vasculature and can capture 
injected embolic material197, 198. Little is known about the subpleural DCs that were 
described in the first articles on lung DCs199, but it is likely that these are either inside or 
on their way to afferent lymphatics that are found in the visceral pleura and drain 
antigen to the regional lymph nodes.  
 
 
Table 3 - Mapping of the existing dendritic cell subsets according to the new nomenclature 
 
SUBSET 
MOUSE 
SUBSET 
HUMAN 
SUBSET 
PRECURSOR 
TRANSCRIPTION 
FACTOR 
MARKERS USED FOR 
IDENTIFICATION 
cDC1 
CD103+ 
CD8α+ 
XCR1+ DC 
CD141+ 
(BDCA3) 
XCR1+ 
CDP 
 
ê 
 
Pre-cDC 
IRF8 
Id2 
BATF3 (can be 
compensated by 
other BATF 
factors157) 
 
 
CD11chi 
CD11blow 
XCR1+ 
Clec9a/DNGR-1+ 
MAR-1- 
CD64- 
SIRPa- 
CD24+ 
CD103+ 
CD207+(Langerin) 
F4-80low 
cDC2 CD11b+ DC 
CD1c+ 
(BDCA1) 
 
 
CDP 
 
ê 
 
Pre-cDC 
IRF4 
ZEB2 
NOTCH2 
Klf4 
CD11chi 
CD11b+ 
SIRPa+ 
MAR-1- 
CD64- 
CD103+/- (a) 
CD24+/- (b) 
CX3CR1int 
F4-80int 
pDC pDC 
BDCA4+ 
BDCA2+ 
CDP 
 
ê 
 
Pre-pDC 
IRF8 
E2-2 
ZEB2 
CD11cdim 
CD11blow 
Siglec H+ 
MAR-1- 
CD64- 
F4-80low 
Ly6C+ 
BST-2/PDCA1(120G8)+ 
MC 
Ly6Chi 
(TipDC) 
 
 
MoDC 
CD14+ 
CD16- cMoP 
 
ê 
 
monocyte 
IRF8 
PU.1 
CD11chi 
CD11b+ 
Ly6Chi/- (c) 
F4/80+ 
MerTkint 
MAR-1+ 
CD64+ 
 
a: small fraction expresses CD103 upon inflammation in the lung, but this subset is predominant in the gut 
b: can be heterogeneous for CD24 – e.g. in heart and skin 
c: Ly6C is rapidly downregulated when entering the tissue 
cDC = conventional DC, pDC = plasmacytoid DC, MC = monocyte-derived cell 
Markers indicated in italic and bold are used to define DC subsets throughout this thesis 
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Figure 4 - Dendritic cell subsets in the lung 
cDC1s (CD103+ CD11b-) extend their dendrites in between the pulmonary epithelium; cDC2s (CD103-CD11b+) and pDCs 
(B220+PDCA1+) are located in the lamina propria; alveolar macrophages (MF), cDC1s, cDC2s and pDCs reside in the 
alveolar septa. During inflammation, inflammatory monocyte-derived cells (MC) are recruited to the lung in addition to 
cDC1s, cDC2s and pDCs.  
 
Mouse dendritic cell subsets in inflammatory conditions 
When the lungs are challenged with foreign antigen, for example during IAV infection, 
additional CD11b+ monocyte-derived cells (MC) with a DC-like phenotype, historically 
called MoDCs, are recruited to the conducting airways and lung parenchyma 
(Figure 4). Although it is clear that monocytes can acquire features typically associated 
with cDCs (antigen-presentation for example) upon their differentiation during 
inflammation, it is often difficult to distinguish MCs from cDC2s. This is due to the fact 
that both MCs and cDC2s express CD11c, MHC II, CD172a and CD11b. As a 
consequence, it is now clear that many studies have been focusing on a mixture of 
MCs and cDC2s. Ly6C was for example proposed as a marker to distinguish CD11b+ 
cDC2s from CD11b+ MCs because it is highly expressed on monocytes186, 191, 200-202. One 
major drawback to the use of Ly6C as discriminative marker is the fact that Ly6C is 
rapidly downregulated when monocytes differentiate into DC-like or macrophage-like 
cells203-205. Next to the use of Ly6C, caution should also be taken when analyzing the 
monocyte-origin of cell types based solely on their CCR2-dependency. Ly6Chi 
monocytes require CCR2 to egress from the bone marrow into the bloodstream and as 
a result Ccr2-deficient mice have much less LyC6hi monocytes in circulation206, 207. 
Therefore the dependency on CCR2 has been typically used as argument to propose 
the monocytic origin of phagocytes205, 207-209. However, it has recently been shown that 
a fraction of pre-cDC-derived CD11b+ intestinal cDC2s express CCR2 and depend on 
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this receptor for their development and/or survival210, indicating that CCR2-expression 
and CCR2-dependency does not necessarily imply monocytic origin. In my view, a 
good way to complement CCR2-dependency studies is to transfer the pre-cDC and 
monocyte progenitors and follow their fate in vivo with a cell tracer.  
An alternative surface marker that has been proposed to be MC specific is the MAR-1 
antibody directed against the α subunit of the high-affinity IgE receptor (FcεRI). Lung 
DCs recruited in response to viral infection and allergen challenge stain strongly with 
the MAR-1 antibody, whereas steady-state cDC2s do not202, 211. In addition, several 
groups have described the use of the high affinity IgG receptor, CD64, in discriminating 
MCs from cDCs. In the skin, muscle, gut and lung CD64 has been proposed to stain MCs 
and macrophages, but not cDCs165, 205, 208, 209, 212. Therefore the combination of both 
CD64 and MAR-1 expression was proposed as a method to discriminate between MCs 
and cDCs in the lung and mediastinal lymph node (MLN)205. Recent data from the 
Immgen Consortium (http://www.immgen.org) has also identified CD64 and MerTk as 
markers of macrophages and MCs but not cDCs.  
We have previously found that CD64+ cells are already present in the steady-state 
lungs, where they account for about 25% of the CD11b+CD11c+MHCII+ lung cells. The 
fact that MCs are present amongst the CD11b+ population of lung DCs also explains 
why previous work reporting on the use of LysM-Cre mediated lineage tagging found a 
high percentage of LysM-Cre tagged cells in the steady state lung DC population 
whereas only some CD11b+ cDCs express LysM213. Recently, both cDC subsets but not 
MCs were shown to specifically express Zbtb46, a transcription factor that seems highly 
specific for cDCs and which in the future should be helpful for proper identification of 
cDCs214, 215. Zbtb46 is not required for development of cDCs, but is a negative regulator 
of DC activation that is downregulated upon TLR stimulation216. Zbtb46 reporter mice 
only show tagging of up to 50% of lung CD11b+ DCs, whereas virtually all CD103+ cDC1s 
are expressing Zbtb46, indicating the high prevalence of MCs in the CD11b+ gate215. 
The recently developed Zbtb reporter (zDCGFP) mice and conditional knockout mice 
(zDCiCre and zDCCre) now provide powerful tools to study cDCs217, 218. Moreover, once 
the cDC phenotype is determined, one can specifically target cDC1s by using the 
XCR1-DTR219 or Karma mice220,221. These observations point out that results obtained by 
studying CD11b+ DCs should be interpreted with caution as this population is 
heterogeneously composed of cDCs and MCs when no additional markers are used to 
separate both cell types. An overview of the markers, transcription factors and 
developmental signals is shown in Table 3. 
 
What is the true nature of the monocyte-derived cell? 
Macrophages (MFs) are generally long-lived and derived from embryonic 
precursors222-225. They are not one uniform cell type throughout the body, but acquire 
tissue-specific gene expression profiles and specific characteristics based on the 
imprinting by their micro-environment226-228. However, it was recently shown that 
BM-derived monocytes could also differentiate into self-maintaining MFs that are 
transcriptionally and functionally equivalent to their embryonic counterparts when they 
get access to the macrophage niche229, 230. 
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As discussed above, monocytes can also acquire DC characteristics and in this case 
they are often referred to as MoDCs. The standard protocol to culture DCs from bone 
marrow231 and peripheral blood monocytes (PBMCs)232 makes use of GM-CSF. These 
protocols enabled us to isolate large amounts of DCs for in vitro studies. Recent in vivo 
transfer studies showed however that monocytes could develop into DCs when 
GM-CSF is present but that monocytes are not able to reconstitute the cDC 
compartment154, 233-235. This raised questions about the true nature of these GM-CSF DCs. 
The total DC population usually consists of an MHCIIint and an MHCIIhi population, 
historically considered immature and mature MoDCs respectively. However, recently it 
was shown that GM-CSF DCs also contain contaminating cDC2s236. As a result, MHCIIhi 
cells consist of a mixture of cells derived from CDPs and cMoPs, in contrast the MHCIIint 
cells are mainly derived from cMoPs. Although, not recognized as such at the time, 
single-cell RNA-Seq also identified two subsets of cells in these cultures with only one of 
them being very DC-like237. Based on micro-array analysis, the CDP-derived DCs in the 
culture are most closely related to cDC2s. In accordance, their development is 
controlled by IRF4. In contrast, the cMoP/monocyte-derived cells in the culture were 
proposed to be macrophage-like cells but did not cluster with any known in vivo 
macrophage population, underlining the importance of tissue imprinting for 
macrophages. This learns that conclusions made based on in vitro cultured GM-CSF 
DCs should be reconsidered in the light of the fact that these cultures are also 
monocyte-derived cells but contain contaminating cDC2s.  
MCs can simultaneously express macrophage (CD64, MerTK, F4/80) and DC (CD11c, 
MHCII) markers205, 208, 209. They can also display typical DC (present antigen to naïve T 
cells) and macrophage (excel at phagocytosis) features simultaneously209, 238. The 
difficulty of categorizing MCs can be illustrated by intestinal CX3CR1hi MCs, which have 
been well studied. These cells have for example been categorized by some labs as DCs 
due to the fact that they possess transepithelial dendrites and express very high levels 
of CD11c and MHCII239, 240, but have also been categorized as MFs by others due to the 
fact that they excel in phagocytosis and fail to migrate to the intestinal draining lymph 
nodes241. As opposed to these observations, MCs have also been described to be 
located within the T cell zone of lymph nodes and can efficiently present antigen to 
naïve T cells in some cases209. 
The CD64+MHCII+CD11c+ MCs in the lung have not been well characterized yet. These 
cells are of monocytic origin205 but whether these cells possess typical DC and/or 
macrophage features is currently unknown. I have therefore decided to label these 
cells as monocyte-derived cells or MCs in this thesis to avoid that preconceived 
functions would be attributed to these cells solely based on the fact that they would be 
categorized as “MoDC” or “macrophage”. 
During this thesis the recently described gating strategy to separate cDC1s, cDC2s and 
MCs based on CD64 and MAR-1 expression is used205. After gating out the doublets, 
debris, dead cells, T cells and B cells (CD3-CD19-), CD11c+MHCII+ cells are separated 
into CD11b-CD103/CD24+MAR-1-CD64- cDC1s, CD11b+CD103/CD24-MAR-1-CD64- cDC2s 
and CD11b+CD103/CD24-MAR-1+CD64+ MCs (Figure 5). 
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Figure 5 - Flow cytometry gating strategy to define dendritic cell subsets 
Lung cells are pregated for single cells and non-debris. The image is a representative image of the lung 4dpi mock 
infection. L/D = Live/Dead marker 
 
 
Dendritic cell activation in response to respiratory viruses 
Direct activation by viral infection  
DCs reside in an immature state in the periphery of the lung, where they are 
strategically located to detect inhaled particulate and soluble antigen. They express 
specific pattern recognition receptors (PRRs) for conserved pathogen-associated 
molecular patterns (PAMPs) such as Toll-like receptors (TLRs), RIG-I-like receptors (RLRs) 
and NOD-like receptors (NLRs) as discussed above. Immgen array gene expression 
data have for example shown that mouse lung CD103+ cDC1s mainly express TLR3, 
whereas CD11b+CD103- cDC2s mainly express TLR2 and TLR7187.  
It has long been enigmatic whether DCs presenting viral antigen to CD8+ T cells were 
directly infected or acquired viral antigen indirectly via other cells succumbing from 
viral infection in the respiratory tract, a process called cross-presentation. Alternatively, 
some DCs might also acquire preformed MHCI-peptide complexes from other cells, a 
process called cross-dressing242, 243. Besides attachment of HA to SA on the cell surface, 
viral particles can enter into the cell in a SA-independent manner by binding the 
C-type lectin receptors DC-SIGN and L-SIGN with the mannose-rich glycans on the 
surface of the virion244. DC-SIGN is highly expressed on some DC subsets thus rendering 
these DCs susceptible for infection. L-SIGN is only expressed in humans. DCs that 
migrated to the lymph node after IAV can be virus-infected, but this happens only after 
infection with higher inocula245, 246 and only the CD103+ cDC1 subset was shown to carry 
infectious virus to the draining lymph nodes (dLN)247. Others, using an elegant strategy 
with an IAV virus carrying GFP in a non-structural NS1 protein, found that only CD103+ 
cDC1s carry viral antigens in their endosomal compartments during transport to the 
mediastinal lymph nodes (MLN), but demonstrated that the virus did not productively 
infect CD103+ cDC1s97. Moreover, this study identified type I IFN as the major mediator 
of protection of CD103+ cDC1s against infection. This observation was confirmed in a 
more recent study that showed that IFITM3 is induced in DCs in an IRF7 and IRF3 
dependent manner. This inhibits direct infection of DCs, permits migration from lung to 
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LN and optimal priming of virus-specific T cell248. In contrast, it was shown that that type I 
IFN responses are attenuated in CD103+ cDC1s247, rendering them more sensitive to 
infection. Additional studies will be required to settle this issue, but most likely timing, viral 
strain, infection route and dose play an important role in the outcome. 
 
Indirect activation of dendritic cells in trans 
Although direct recognition of viral PAMPS by PRRs is the most likely explanation of how 
DCs respond to virus, it is now clear that recognition of PAMPs by the nearby bronchial 
or alveolar epithelial cells is at least as important in activating the lung DC network191. 
Lung epithelial cells can produce the essential chemokines that attract immature cDCs 
and inflammatory monocytes to the site of antigen exposure: IL-12p80 homodimers are 
produced by bronchial epithelial cells upon viral and mycobacterial infection of the 
lung, and IL12p80 recruits DCs to the lung epithelium249. Epithelial cells not only make 
chemokines that attract immature monocytes or pre-cDCs, but they also produce 
critical maturation cytokines such as IL-1, GM-CSF (Csf2) and TSLP that can activate the 
recruited monocytes and pre-cDCs to differentiate in DCs and induce their maturation 
into fully competent antigen-presenting cells. In contrast to the generally accepted 
dogma that GM-CSF controls the development of inflammatory DCs, it appeared that 
GM-CSF provides survival signals to CD103+ cDC1s and induces CD8+ T cell immunity250. 
The observation that GM-CSF might be dispensable for CD11b+ cDC2s survival is still 
under discussion because of the presence of a contaminating MC population that 
might obscure the results. Additionally, Csf2-/- or Csf2r-/- mice also lack AMFs and 
develop alveolar proteinosis that severely alters lung homeostasis and does not allow us 
to draw firm conclusions about the importance of GM-CSF activation of CD103+ cDC1s 
in these mice. In fact, reconstitution of Csf2r-/- mice with wild-type AMFs was sufficient to 
restore resistance of these mice to the infection, strongly suggesting that the main 
effects observed in Csf2r-/- mice are due to the lack of AMFs. This does of course not 
exclude that Csf2r-signaling in cDC1s may be important, and this can be checked by 
crossing the recently described Csf2r-floxed mice251 onto cDC1-specific Cre mice (for 
example XCR1-Cre mice220). 
TLR4 triggering of bronchial epithelial cells induces IL-1α, which acts in an autocrine 
manner to trigger the release of the DC-attracting chemokines, GM-CSF and IL-33 by 
epithelial cells252. A recent study showed that IL-1 is not only signaling via the epithelium, 
but that IL-1 can also directly stimulate DCs and that signaling through the IL-1R was 
required for induction of virus-specific CD8+ T cell responses after influenza virus 
infection253. TSLP has been shown to activate CD11b+ DCs to support local reactivation 
of CD8+ T cells254.  
Trans-activation of DCs can also be modulated by soluble mediators of the innate 
immune system, like SPD and complement factors, and other innate immune cells. For 
example C3 stimulates migration of dendritic cells to the dLN of the lung255. 
Complement C3 and C5 itself is mainly produced by CD103+ cDCs upon influenza 
infection256. Furthermore SPD has been shown to increase the antigen presenting 
capacity of GM-CSF cultured bone marrow derived DCs in vitro257, 258.  
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Innate type I IFNs induce an antiviral state, but this is not their sole function. Viruses that 
strongly activate type I IFN synthesis are also best at inducing adaptive immunity via 
induction of lung DC maturation259. In a model of co-culture of human DCs with airway 
epithelial cells, it was found that type I IFN from the epithelial cells (together with IL-6) 
was able to modulate DC maturation260. NK cells induce DC migration to the LN and 
virus uptake by DCs by perforin-mediated lysis of infected cells122. Neutrophils that are 
recruited early in the response to virus infection have also been shown to affect the 
activation of DCs261.  
 
Lung dendritic cells and induction of adaptive immunity to respiratory virus 
infections  
Migration to the draining lymph node  
Viral infection of DCs induces maturation-related changes in cell surface chemokine 
receptor expression. Chemokine CCR7 receptor upregulation is crucial for migration of 
lung DCs to the dLN262-265. Activation and migration of cDCs and bone marrow-derived 
GM-CSF DCs to the dLN can also be enhanced by type I IFN signaling266-270 and this can 
lead to enhanced cross-presentation capacity of cDC1s271-273.  
Upon IAV infection, DCs rapidly migrate to the dLN and return to their basal migration 
level after 48h, despite still ongoing inflammation274. This might be explained by the virus 
that renders the DCs insensitive to migration or by the immune system that has a built-in 
protective mechanism against too much damage. DC migration is not dose 
dependent, but defects in respiratory DC migration occur upon ageing. This defect is 
related to an increased level of PGD2 in the lung. PGD2 inhibits CCR7 upregulation, 
which renders DCs unresponsive to migratory signals via the CCR7 receptor275, 276. The 
lack of induction of CCR7 by specific viruses like human metapneumovirus (HMPV) and 
human respiratory syncytial virus (HRSV) can prevent DCs from migrating to the lymph 
nodes and thereby hamper the induction of protective responses277, 278. 
 
Role of conventional dendritic cells in antiviral immunity 
The role of lung DC subsets in promoting antiviral CD4 and CD8 immunity has been 
studied best in the context of IAV infection. During IAV infection, CD11b+ cDC2s and 
CD103+ cDC1s both take up antigen in endocytic vesicles and express high levels of 
costimulatory molecules and antigen presenting molecules in contrast to MCs and 
pDCs279. Initial studies have demonstrated that antiviral CD8+ T cell responses were 
induced mainly by a non-migratory resident CD8α+ cDC1 population of the MLN. 
Antigen was proposed to be carried to this resident population by a migratory lung 
derived CD11b- (i.e. CD103+) cDC1 population280. Our group has demonstrated that 
CD11b-CD103+ airway derived cDC1s can however also directly present viral derived 
antigens to CD8 (and CD4) T cells, in addition to the resident CD8α + cDC1s186, 281. Studies 
using Batf3-deficient mice (that lack CD103+ cDC1s and CD8α + cDC1s) have shown 
that CD103+ cDC1s were crucial for inducing CD8+ T cell immunity to IAV97. 
The reason why CD103+ cDC1s are so efficient at inducing a protective response to 
influenza virus could be because they are the only DC subset able to capture and 
cross-present apoptotic epithelial cells that died from infection97. CD103+ cDC1s express 
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receptors for apoptotic cells along with the machinery to cross-present phagocytosed 
dead cells187 and they have enhanced capacity to process and load viral antigens in 
MHC I molecules282. Cross-priming of antigen delivered by dying epithelial cells has 
been proposed to occur via the dendritic cell receptor DNGR-1 (CLEC9A)283-285. Both in 
human and mouse, the biggest proportion of the DC subset preferentially expressing 
DNGR-1 belongs to the CD8α+-like/CD103+ cDC1s family286.  
Naïve CD8+ T cells encounter antigen in the LN, get activated and then proliferate in an 
ordered way. The tempo is regulated by antigen availability, which is determined by 
antigen delivery by MHCIIhi, so called migratory, CD103+ cDC1s97, 186. Because CD103+ 
cDC1 migration is increased for only a short time after infection and T cell proliferation 
goes on for a longer period, antigen might also be presented by LN resident DCs, which 
received antigen from migrating DCs via cross-presentation280. There is heterogeneity in 
the proliferation status of T cells; this is caused by sequential migration of circulating 
naïve T cells into the lymph node, followed by their activation there and exit back to 
the tissue287. MHCIIlo DCs display lower levels of costimulatory molecules and therefore 
are less likely to be the ones inducing proliferation of T cells. In contrast, they have the 
capacity to induce apoptosis of proliferating CD8+ T cells in an IL-12 induced, FasL 
dependent manner246.  
At later time points coinciding with the peak of viral infection, CD11b+ DCs accumulate 
in the LN and represent the predominant DC subset stimulating CD8+ T cells via 
expression of the costimulatory molecule CD70288. This later wave of antigen 
presentation could potentially be involved in the expansion of activated effector CD8+ 
T cells in the LN. What is not clear from these studies is whether the CD11b+ DCs also 
contained MCs, as no discriminating markers were used.  
Although most studies on lung DCs in viral infection have been performed in the 
context of IAV, the importance of DC subsets might differ according to the type of viral 
infection as well. Despite their good presentation capacity, it is not the CD103+ cDC1 
population that predominates the lung upon RSV and IAV infection, but the CD11b+ DC 
population. During RSV infection, both cDC1s and cDC2s contain RSV RNA and present 
equally well to CD4+ and CD8+ T cells289. In a model of pulmonary vaccinia virus 
infection, CD103+ cDC1s that migrated from the lung to the LN are the best inducers of 
CD8+ T cells proliferation compared to CD11b+ migrating DCs and CD103+ MHCIIlo 
cDC1s.  
 
Role of monocyte-derived cells in antiviral immunity 
Upon IAV infection, monocytes are recruited to the lung and differentiate rapidly into 
cells that share features of both DCs and macrophages99, 290, 291. This process has been 
shown to be dependent on type I IFN signaling292 and CCR291. Human monocyte 
infection with IAV was shown to be sufficient to differentiate monocytes into type I IFN 
producing macrophage-like MCs capable of limiting viral replication in vitro99. These 
MCs do not upregulate MHC II and costimulatory molecules, nor produce 
proinflammatory mediators. They are not able to induce T cell proliferation but secrete 
large amounts of MCP-1 and IP-10, classical monocyte chemoattractants. As a 
conclusion, they fail to function as conventional antigen presenting cells. The strong 
type I IFN induction and upregulation of cytosolic RNA sensors RIG-I and MDA5 point 
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towards a direct antiviral activity. Virus-induced MCs are not the primary DC subset that 
presents antigen to naïve T lymphocytes. They do provide positive feedback to attract 
more monocytes to the site of infection via MCP-1 and IP-10 secretion99, 293. The lack of 
antigen-presenting capacity is further supported by the observation that MCs can 
stimulate naïve CD4+ T cells modestly and CD8+ T cells only minimally after influenza virus 
infection, although they have the capacity to do so when stimulated with 
pre-processed peptide279, 294.  
It is not clear if MCs are capable of migrating to the dLN and actively participate to the 
induction of influenza effector CD8+ T cell responses. On one hand, it was suggested 
that CD11b+ DCs that massively migrated to the LN upon influenza infection were 
MCs288 whereas on the other hand it was argued that the CD11b+ DCs were cDC2s due 
to their low Ly6C expression279. These contradictory views again argue for better 
discrimination between the two CD11b+ subsets and this is one of the major aims of this 
thesis. 
Although MCs were able to limit viral replication, Ccr2-/- mice or mice treated with a 
CCR2 antagonist did not show increased viral loads91 but they did display significantly 
less effector CD8+ T cells in the lungs during influenza infection295. Therefore it is very likely 
that MCs would be crucial in the interaction with effector T cells locally in the infected 
tissues, rather than in the induction of effector T cells in the LN254. CD8+ memory T cells 
can in turn license MCs for effective pathogen killing through the secretion of 
CCL3296,-297. 
 
Role of plasmacytoid dendritic cells in antiviral immunity 
Whereas pDCs are a copious source of type I IFN298-300, their role during respiratory viral 
infections remains debatable as they were shown to react differently upon infection 
with various types of virus and only produce type I IFN upon systemic infection, and not 
upon respiratory virus infection96, 301. 
These conflicting views regarding the contributions of pDCs to antiviral immunity make it 
hard to firmly state how pDCs are involved in antiviral immunity in the lung. The 
importance of pDCs also appears to differ among different viral model systems.  
pDCs are increased in the lung and the LN for a long period after RSV infection. When 
depleted with i.p. injections of 120G8 antibody, it was shown that pDCs play a direct 
antiviral role by secreting IFNα but also modulate T cell-mediated responses leading to 
lung pathology characterized by airway hyperresponsiveness, mucus production and 
inflammation302, 303 via the TLR7-MyD88 dependent signaling pathway300, 304. In contrast, 
in vitro studies have shown that pDCs are unable to express maturation markers 
whereas they were able to produce IFNα 305. This suggests that the role of pDCs might 
be more oriented towards an antiviral response than towards induction of adaptive T 
cell responses. There is also evidence that pDCs do not productively contribute to IFN 
production after RSV306. In addition MCs and cDCs were also shown to produce IFNα 
and β and thus exhibit antiviral activity to prevent infection of neighboring cells307, 308.  
pDCs accumulate in the lung and bronchoalveolar space in response to influenza virus 
infection, but the observation that pDCs can induce a strong influenza specific CD8 
response in vitro309-312 does not translate to in vivo or ex vivo models. IkarosL/L mice that 
lack pDCs313 and mice in which DCs were depleted using 120G8 antibody186 
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demonstrate a similar course of disease and did not have differences in the strength of 
the antiviral type I IFN and CD8+ T cell response. pDCs fail to activate either naïve CD4+ 
or CD8+ T cells when they are not pulsed with pre-processed peptide or exposed to 
antigen-specific immunoglobulins279, 312, 314. pDCs might even be involved in FasL 
mediated killing of CD8+ T cells during lethal influenza infection315. One function that 
could be attributed to pDCs is formation of HA-specific antibodies186, 316. Furthermore it 
has been suggested that pDCs can provide help for cDCs during antigen presentation 
via IFN production, but this seems not to be the case. IFN rather appears to serve as a 
negative feedback loop to control pDC numbers317.  
Using the newly developed BDCA2-DTR mice, pDCs can be depleted conditionally. By 
infecting these mice with MCMV and VSV it was shown that pDCs were involved in 
virus-specific NK and CD8+ T cell induction. However, it remains to be elucidated if pDCs 
will react in the same manner during infection with respiratory viruses318 
These contradictory results regarding the function of pDCs during respiratory infection, 
might be explained by the observation that in fact 3 distinct pDC populations can be 
determined based on CD8α and CD8β expression: CD8α-β-, CD8α+β- and CD8α+β+ cells319. 
These subsets display different cytokine secretion profiles and functional properties in a 
model of airway inflammation. CD8α+β- and CD8α+β+ pDCs can induce tolerance in vivo 
most likely via induction of regulatory T cells. In contrast, CD8α-β- pDCs have 
pro-inflammatory properties. It remains to be determined if respiratory viruses can 
differentially modulate these three pDC subsets and hence influence the outcome of 
the infection. However recently it was hypothesized that the different pDC populations 
are not stable subsets, but that CD8 expression is inducible by TLR stimulation and these 
subsets rather represent a different activation state320.  
 
 
Adaptive immune responses against influenza A virus infection 
Long term adaptive T cell memory to respiratory viruses  
The recovery from influenza virus infection requires cooperation between CD8+ 
cytotoxic T lymphocytes (CTL) and CD4+ T-helper (Th) cells. Naïve T cells migrate to the 
lymph node by expression of the lymph node homing receptors CD62L and CCR7. 
Once in the dLN they are stimulated upon triggering of the T cell receptor (TCR) by 
antigen presented by DCs in a MHC-I or MHC-II dependent manner for CD8+ or CD4+ T 
cells respectively321. Antigenic stimulation of T cells alone (signal 1) is insufficient to 
induce effector cells. T cells will become anergic unless a costimulatory signal via CD28 
and CD80/CD86 or CD40L and CD40 (signal 2) is given322 and when inflammatory 
cytokines stimulate the CD8+ T cells or CD4+ T cells (signal 3)323(Figure 6). After their 
proliferation and differentiation into effector cells, T cells migrate back to the airways by 
downregulation of CD62L and CCR7 and upregulation of the adhesion molecule CD44 
where they can exert their specific function in order to clear the virus from the 
respiratory tract. To produce high levels of cytokines locally, T cells need to reencounter 
their cognate antigen in the lung. The proposed antigen-presenting cell for local 
reactivation of T cells is a CD11b+ DC, thus representing cDC2s and/or MCs324.  
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Figure 6 - The 3 steps of T cell activation 
Besides antigenic stimulation via the T cell receptor (signal 1), T cells need a costimulatory signal via CD28-CD80/86 or 
CD40L/CD40 interactions with dendritic cells (signal 2) and a stimulation by inflammatory cytokines (signal 3) for their 
effective activation. 
 
 
CD8+ T cells acquire cytolytic activity and upregulate chemokine receptors that allow 
them to migrate to the site of inflammation. The function of antiviral CD8+ T effector 
cells depends on the cell type presenting the viral antigen. Firstly, MHCI expression and 
costimulation via CD80 and CD86 on professional antigen presenting cells are 
necessary for pro-inflammatory cytokine production (IFNγ, TNFα, MIP-1α etc.), but this 
cytokine production also contributes to lung pathology and may not be essential for 
virus clearance since viral clearance is not affected when costimulatory signals are 
blocked. Secondly, induction of cytotoxicity is induced by MHCI presentation on 
epithelial cells without the need for costimulatory signals325, 326. When cytotoxic T cells 
detect virally infected epithelial cells, they will kill them indirectly by release of the 
cytolytic molecules perforin and granzyme or directly via Fas/FasL interactions327.  
 
CD4+ T cells can differentiate into different types of Th cells from which the functional 
capacities depend on the environmental context. The most common Th phenotypes 
are Th1 (driven by IL-12 and IFNγ), Th2 (driven by IL-4 and IL-6), Th17 (driven by IL-6 and 
TGFβ), T follicular helper (Tfh) (driven by IL-6, IL-1β and TNFα) and regulatory T cell (Treg) 
(driven by TGFβ) cells328. IAV infection is mostly associated with a Th1 response 
producing IFNγ, TNFα and IL-2; complemented with a Tfh response initiating a robust 
antibody response providing B cell help and orchestrating the germinal center 
reaction329, 330. Furthermore Th17 might influence the recruitment of neutrophils to the 
site of infection331, 332. Additionally, Treg cells are induced after IAV infection. Treg cells 
generally dampen antigen-specific responses thereby limiting the corresponding tissue 
damage333, 334. During acute viral infections Treg cells delay the clearance of the virus, 
but also inhibit the proliferation of infected cells, promote memory formation and influx 
and efflux of the dLN335. Besides the prevention of tissue damage, Treg cells can assist 
directly in recovery of the tissue damage in an amphiregulin-dependent manner after 
the virus is cleared336, 337.  
Whereas CD8+ T cells were seen as the typical T cell fighting influenza infection, the role 
of CD4+ T cells was long underestimated as a helper cell. More and more evidence is 
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accumulating that point towards a broader function of CD4+ T cells338. During IAV 
infection CD4+ T cells promote CD8+ T cell and B cell responses to influenza virus 
infection although they are not critical for this process339-341. Adoptive transfer studies 
demonstrated that CD4+ T cells are also able to control viral load and exert direct 
cytotoxic effector functions in the lung environment342, 343. Phenotypically, CD4+ CTLs 
resemble Th1 effector cells that additionally express granzyme B and perforin and have 
direct cytotoxic activity ex vivo. CD4+ CTLs show perforin-dependent protection against 
lethal IAV infection in both mouse models and human studies of infection and 
vaccination342, 344-347 but the contribution of CD4+ T cell cytotoxicity to viral clearance in 
vivo in the lungs is modest346. Depletion of either CD4+ or CD8+ T cells alone still allows 
recovery from the viral infection, but slower than with fully functional CD4+ and CD8+ T 
cells together343, 348-352 suggesting that cooperation between CD4+ and CD8+ T cells is 
necessary for an optimal immune response or that the division between CD4+ and CD8+ 
T cells is not absolute and that each cell can acquire some characteristics of the other 
when necessary.  
 
Non-conventional T cells that express a functional TCR but lack expression of CD4 and 
CD8 co-receptors (therefore called double negative (DN) T cells), are observed in 
various disease models –auto-immunity, infection, cancer, post-transplantation 
tolerance– in human and mice, in which they were attributed different functions 
ranging from inflammatory cell, to immune suppressive cells and homeostatic cell353. 
The lungs are one of the many tissues where DN T cells were described in steady 
state354-357 and following insults to the lung. In an infection model using Francisella 
tularensis DN T cells produced high amounts of IL-17 and IFNγ358 while they produce 
predominantly IL-5 in a model of Toxocara canis359. Furthermore they are also involved 
in the defense against Mycobacterium bovis infection375, 357, 378, 360. As DN T cells are 
defined by exclusion, they are very heterogeneous, arising either from the thymus or 
extrathymically. Classical DN T cells express intermediate levels of αβTCR, and are 
different from type I CD1d-restricted invariant natural killer T cells and γδTCR+ T cells that 
are often found to lack CD4 and CD8 expression, and therefore fall under the DN T 
definition361, 362  
 
As acute infections are cleared, effector T cells further differentiate into KLRG-1hiCD127lo 
short-lived effector cells and CD127hi memory precursor effector cells capable of 
generating long-lived memory cells363, 364. Memory T cells are a heterogeneous 
population (Table 4). All memory T cells retain expression of CD44 but are 
heterogeneous in expression of CD62L and CCR7. CCR7+CD62L+ cells are lymphoid 
homing and recirculate via lymphoid organs and are called central memory T cells 
(Tcm). They do not have immediate effector functions, but in response to a secondary 
infection they can expand and differentiate into effector cells that subsequently 
migrate back to the lungs. CD62L-CCR7- memory cells are the effector memory (Tem) 
cells that patrol in and out of peripheral tissues365-368 but they can also reside for 
prolonged periods in the lungs as T resident memory cells (Trm) that express high levels of 
CD69, CD11a and/or CD103364. Triggered by retained antigen presented by DCs369, Trm 
cells were shown to reside for months in the lungs of IAV infected mice and infected 
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volunteers, thus providing immunity from reinfection with the same or heterologous 
strain of influenza by rapidly acquiring effector functions364, 370-380. 
As for effector CD4 and CD8 T cells, also Treg cells can differentiate into a memory 
population381. Antigen-specific memory Treg cells control the CD8+ recall response 
upon secondary infection382. 
 
 
Table 4 - Different types of memory T cells compared to naïve and effector T cells 
 
 CHARACTERISTIC 
CELL TYPE CD44 CD62L CCR7 CD69 CD103 Location 
Migratory 
capacity 
Naïve - + + - - Lymphoid tissue Yes 
Effector + - - + - Peripheral tissue Yes 
Tcm int + + - - Lymphoid tissue Yes 
Tem + - - - - Peripheral tissue Yes 
Trm + - - + 
CD4: - 
CD8: + 
Peripheral tissue Resident 
 
 
Cross-reactive cytotoxic T lymphocytes can induce heterosubtypic immunity  
Virus-specific T cells increase in frequency and number during infection. They mainly 
recognize the internal proteins NP, matrix protein and polymerase, which are 
genetically more conserved than HA and NA383. Small mutations in epitopes recognized 
by T cells due to genetic drift can lead to immune-escape; but generally these 
mutations occur less in conserved epitopes since this can have a potential functional 
consequence for the virus384. This makes the virus specific T cells against internal proteins 
ideal candidates to provide heterosubtypic immunity. Although the main role for 
heterosubtypic immunity is attributed to CD8+ T cells385, 386, there is evidence that also 
CD4+ T cells374, 387 and B cells388, 389 can contribute to heterosubtypic immunity.   
 
B cells can provide long-term protection by generation of antibodies 
The generation of antigen specific B cells is orchestrated in the lymphoid organs or 
locally in the respiratory tract in the mucosal-associated or bronchus-associated 
lymphoid tissue in two phases390. Dendritic cells carry virus-derived antigens to the dLN 
and present the antigen not only to T cells but also to B cells. The recognition of antigen 
by the B cell receptor activates a differentiation process during which the B cells 
migrate to the edge of the LN and proliferate391-393. After recognition through the B cell 
receptor, the antigen is internalized and processed to be presented by the B cell. CD4+ 
Tfh cells that recognize antigen presented via MHC II on the B cells provide a CD40-
CD40L costimulatory signal that is necessary to induce affinity maturation, isotype 
switching and memory B-cell development394, 395. The B cells enter the germinal center 
(GC) reaction where they undergo somatic hypermutation, affinity maturation and 
class-switch recombination (from IgM to IgA or IgG) leading to high-affinity antibody 
secreting plasma cells and memory B cells396. Respiratory B cell activation and the 
antibody class switching are mediated by innate type I IFN signaling via the IFNAR 
resulting in a larger amount and better quality of antibody response397-399. As IAV 
infection primarily involves the respiratory mucosa, IgA+ B cells are a major component 
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of the response to infection. The secreted dimeric IgA that is present at the respiratory 
mucosa can provide immediate immunity as it can cross link viral particles before it can 
enter the cells of the host, a process known as immune exclusion400, 401.  
 
The high-affinity antibody secreting plasma cells produce the early antibody wave after 
infection, but this population contracts rapidly after clearance of the virus. Memory B 
cells are in contrast long lived and migrate to the bone marrow and respiratory mucosa 
where they are maintained several months after infection. Upon reencounter with IAV 
virus they differentiate into antibody-producing plasma cells rapidly thus providing 
protection against reinfection402. Studies of IAV-infected mice have shown broad 
dispersion to secondary lymphoid organs and lung localization of virus-specific memory 
B cells403. Strikingly, a recent study showed that B cells are directly infected by IAV virus 
through BCR-mediated internalization404. They subsequently produce viral particles and 
succumb to infection, particularly in the lung epithelium. This mechanism provides 
respite for the virus in the lung epithelium. Infection of the rare virus-specific memory B 
cells impairs the kinetics of the memory response and confers an advantage to the 
virus, ensuring a window for replication even in the immune host that could promote 
horizontal transmission. 
Virus-specific antibodies can neutralize the virus directly by binding the matching 
antigen of the virus and thereby inhibiting the function of the bound antigen. Anti-HA 
antibodies neutralize IAV virus by preventing interactions with sialylated glycoproteins 
on the surface of the host cell or preventing HA-mediated fusion of virus and host 
membranes in the endosome, thereby interfering with viral entry. Furthermore 
antibodies opsonize viral particles by forming antigen-antibody complexes. These 
complexes can facilitate killing of virus-infected cells (antibody-dependent 
cell-mediated cytotoxicity) and phagocytosis of virus-infected cells by binding to Fc 
receptor expressing cells (e.g. macrophages and NK cells) 405, 406. Antigen-antibody 
complexes can also activate the complement cascade and kill the cells by 
complement-dependent cytotoxicity407.  
The HA protein consists of a head region and a stem region. Antibodies that recognize 
the more conserved stem region of the HA protein often can recognize multiple viral 
subtypes and provide cross-reactive immunity. However, stem-specific neutralizing 
antibodies are rare and thus do not provide the main source of cross-reactive immunity.  
Anti-NA antibodies408 do not neutralize the viral particles, but limit viral spread by 
inhibiting the sialidase function of NA and thereby preventing penetration through the 
mucus layer lining the respiratory epithelium409 and release of newly produced viral 
particles from the infected cell410. They also facilitate antibody-dependent 
cell-mediated cytotoxicity, contributing to clearance of infected cells by phagocytes 
and NK cells411 and complement-dependent cytotoxicity407. They may as well interfere 
in the attachment of HA to the host cell by steric hindrance412.  
Antibodies against the highly conserved ectodomain of the M2 protein (M2e) have a 
high potential for long-term protection against multiple subtypes of influenza virus, but 
M2e has a low immunogenicity and therefore antibodies against M2 are only raised to 
a limited extent after natural infection413-417.  
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The last class of antibodies that provides protection against IAV infection is directed 
against the conserved NP protein. In contrast to the previous antibodies, this is an 
intracellular protein and these antibodies can therefore not neutralize viral particles, but 
they can provide protection in a FcR-dependent manner418, 419.  
B cells are not strictly necessary to clear influenza infections since B cell deficient mice 
manage to recover from IAV infection420, mainly through a CD8+ T cell-dependent 
mechanism. Combining the lack of B cells and CD8+ T cells however leads to lethal 
infections421 suggesting that CD4+ T cells alone are not sufficient to clear infections. 
Since CD4+ T cells are described to have important helper functions during the immune 
response against IAV infection, it is clear that the optimal immune response requires 
interaction between CD4+ and CD8+ T cells and B cells.   
 
Innate natural antibodies and antiviral immunity  
Although B cells are traditionally seen as parts of the adaptive immune system, some B 
cells produce natural antibodies that have a broad virus neutralizing capacity. 
Normally the process of antibody generation by conventional B cells only starts upon 
encounter with antigens. Nonetheless, antibodies can be found in the serum prior to 
contact with pathogens and in germ free mice. This antibody pool consists mainly of 
IgM antibodies and is generated independently of antigen challenge by B-1 cells422-424. 
B-1 cells are fundamentally different from the conventional B-2 cells, which might be 
the reason for their antigen-independent regulation, however the mechanisms of 
natural antibody generation are still poorly known425-427. B-1 cells are not very 
abundantly present in lymph nodes, but are the major B cell population in the 
peritoneal and pleural cavities425. Nonetheless, the spleen and bone marrow were 
shown to be the major source of secreted natural IgM antibodies428. Many of the 
circulating IgM antibodies are directed against self-antigens, which gives them the 
potential to induce auto-immunity429-431 but due to their polyreactivity they can also 
bind PAMPs of microbial432-435 and viral436 particles. 
Natural antibodies bind antigens with low affinity because they did not undergo affinity 
maturation during germinal center reactions437, but due to their pentameric structure 
they are capable of binding antigens with a high avidity. This specific characteristic 
provides an important defense mechanism against pathogen replication prior to 
establishment of specific immune responses438. As an example, the airways contain 
natural IgM antibodies that provide a powerful tool to fight influenza infection since 
survival is abrogated in the absence of these natural IgM439. Natural antibodies can 
neutralize influenza virus440 via two possible mechanisms: either transport to the mucosal 
surface via the poly-Ig receptor441 or via complement-dependent cytotoxicity442. 
Furthermore, natural IgM can activate complement prior to the development of an 
effective antibody response442. 
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Inducible bronchus associated lymphoid tissue is formed in the lungs after 
respiratory viral infection 
Definition and structure of tertiary lymphoid organs 
The immune system has evolved in a way that optimizes the chance of encounter 
between the rare antigen-specific T and B cells of the adaptive immune system with 
antigen presenting cells of the innate immune system in organized lymphoid tissues, 
such as the spleen, lymph nodes and Peyer’s patches. These so-called secondary 
lymphoid organs (SLOs) have three unique features. First, they filter lymph or blood and 
sample the antigens in these fluids. Second, they allow entry of antigen-loaded DCs 
and other innate immune cells. Third, they allow recirculating naive T and B cells that 
have encountered antigen to extravasate, arrest temporarily, proliferate and 
differentiate443. To achieve this goal, the LNs and spleen are connected during 
embryogenesis to the lymph and bloodstream and are organized into well-defined 
areas rich in T cells or B cells. These areas are supported by a network of mesenchymal 
cells that provide the chemokine cues and extracellular matrix on which cells can 
meaningfully migrate and find each other in such a complex structure444, 445. This highly 
efficient structural organization of antigen encounter and lymphocyte migration and 
activation can also be recapitulated after birth, in the form of tertiary lymphoid organs 
(TLOs), particularly when there is continued need for extravasation of leukocytes and a 
persistent source of antigen, such as seen in zones of infection, transplant rejection, 
auto-immune attack and cancer (summarized in table 5).  
It is well known that when inflammation becomes chronic, plasma cells and 
lymphocytes gradually increase in number, lymphangiogenesis is induced, and blood 
vessels acquire characteristics of high endothelial venules (HEV) specialized in allowing 
extravasation of lymphocytes. In some conditions, the chronic infiltrate organizes into 
structured lesions, such as those seen in chronic granulomatous inflammation in 
tuberculosis, Crohn’s disease, and sarcoidosis. Sometimes, the chronic infiltrate 
organizes into distinct T cell-rich and B cell-rich aggregates. Various terms, such as 
ectopic lymphoid tissue, lymphoid tissue neogenesis and TLOs, have been used to 
describe the occurrence of these organized structures. These structures can also be 
named according to their anatomical site, such as inducible bronchus associated 
lymphoid tissue (iBALT) and vascular associated lymphoid tissue (VALT).  
A problem that arises in defining TLO structures is that the difference between a chronic 
infiltrate and a TLO resides in the degree of its internal organization. According to 
pathologists, the term TLO can only be used when all the following criteria are fulfilled:   
 
1) The organized infiltrate contains anatomically distinct yet adjacent T cell and B cell 
compartments 
2) The T cell area contains an extensive network of fibroblast reticular cells (FRC)  
3) PNAd+ or MECA79+ HEVs are present in the T cell area  
4) There is evidence of B cell class switching and GC reactions in the B cell follicles  
5) The AID enzyme is present  
6) Follicular dendritic cells (FDCs) are present  
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Often, it appears that strictly speaking not all criteria are fulfilled, while the organized 
structure can still function as a TLO. Although in most disease models the structures do 
not fully cover the proposed TLO definition, we use the term TLO because we believe 
the functional resemblance with SLOs is much more relevant than the structural 
resemblance.   
 
Table 5 - Diseases and experimental models in which tertiary lymphoid organs have been identified 
 
DISEASE LOCATION SPECIES Ag SPECIFIC? REF 
Microbial causes 
Influenza iBALT mouse yes 446, 447 
Vaccinia virus Ankara lung mouse naive T cell activation 448 
Intestinal microbiota 
isolated lymphoid 
follicles in intestinal wall 
mouse, human ? 
449,450, 
451 
Helicobacter pylori gastric wall mouse, human yes 452 
Helicobacter hepaticus liver mouse ? 453 
Borrelia burgdorferi 
multiple sites 
Lyme’s disease 
human ? ? 
Chlamydia pneumoniae iBALT mouse ? 
454 
 
Chronic LPS exposure iBALT neonatal mice LPS ? 455 
Autoimmune disease 
Common variable 
immunodeficiency 
iBALT human Yes: Ko67+ GC 456 
Rheumatoid arthritis 
synovial space 
 
lung interstitium 
human 
mouse 
human 
yes 
 
yes 
457, 458 
 
459 
Ankylosing spondylitis Synovium human Yes 460 
Primary biliary cirrhosis liver human 
No: absence of any clonal T 
or B cell proliferation 
461 
Hashimoto’s thyroiditis thyroid gland human 
thyroglobulin, 
thyroperoxidase 
462 
Diabetes 
periductally in 
pancreatic 
parenchyma 
non-obese 
diabetic mouse  
yes, anti-insulin Ab responses 463, 464 
Secondary progressive 
multiple sclerosis 
meninges at deep 
cerebral sulci 
mouse (EAE), 
human 
myelin and neuronal 
antigens: suggested 
465, 466 
Myasthenia gravis thymus human 
acetyl choline receptor: 
correlation of autoantibodies 
with infiltrates 
467 
Autoimmune gastritis gastric lamina propria mouse parietal cells 468 
SLE tubulointerstitial nephritis human 
Yes (clonal restriction and 
mutated antibodies) 
469, 470 
Chronic transplant rejection 
 
Heart, lung, kidney 
human 
mouse 
Yes, alloantigens 471-473 
Degenerative/environmental causes 
Cigarette smoke 
end-stage COPD lung, 
iBALT and interstitial 
human 
mouse 
autoimmune or latent 
infection 
474-476 
Inhaled organic dust 
interstitial TLO in 
hypersensitivity 
pneumonitis 
human fungal spores in moldy hay 459 
Diesel particles iBALT mouse ? 477 
Hypercholesterolemia atherosclerotic plaques mouse ? 478 
Metal-on-metal prosthetic 
joints 
soft tissues around joints 
human cobalt or nickel ? 479, 480 
Protein-cage nanoparticles iBALT mice  481 
Pristane adjuvant 
(2,6,10,14-tetramethyl-
pentadecane) 
peritoneal cavity (milky 
spots) 
mice 
 
470 
“Idiopathic” disorders 
Usual interstitial pneumonia, 
idiopathic lung fibrosis 
lung interstitium human 
autoimmune component ? 
459, 482 
Idiopathic pulmonary 
arterial hypertension 
perivascular lesions of 
the lung 
human 
rat 
likely autoimmune 
component 
483 
484 
Cancer	  
Breast, lung, colorectal, 
pancreatic, renal, germ 
cell, skin cancer  
Mostly peritumoral 
Rarely intratumoral 
Human, mouse Tumor-associated antigens 
485, 486  
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Development of organized lymphoid tissues before birth 
Before discussing the mechanisms controlling TLO development during chronic 
inflammation, it is important to summarize organogenesis of SLOs, reviewed in detail 
elsewhere444 and summarized in figure 7. SLOs develop in predefined areas in the 
embryo, often at the crossroads of lymphatics. The lymph node anlagen are first 
identified in mice on embryonic day 14.5 by the presence of RORγ+ lymphoid tissue 
inducer (LTi) cells487. During SLO development444 it is crucial that CD3-CD4+CD45+ LTi cells 
interact with stromal lymphoid tissue organizer (LTo) cells in a process involving 
lymphotoxin α1β2 (LTa1b2) signaling to the lymphotoxin-β receptor (LTβR). When these 
cells interact, LTo cells express several adhesion molecules (VCAM1, ICAM1, 
MADCAM1) and homeostatic chemokines (CCL19, CCL21 and CXCL13). These 
molecules act as the driving force for recruitment of lymphocytes. In addition, 
production of lymphangiogenetic growth factors, such as VEGF-C, VEGF-D, FGF-2 and 
HGF, leads to formation of Lyve-1+ lymphatic vessels488, 489. 
LTo cells develop further into FDCs and FRCs that provide the conduit framework on 
which T cells and B cells migrate and interact with each other. Before LTi cells can 
cluster, an LTα1β2-independent instructive signal is given to local fibroblasts to start 
producing the initial CXCL13 to attract LTi cells. Recent insights indicate that signals 
derived from the nervous system could provide this first signal for LN development490, 491. 
Together, these studies have highlighted the importance of interactions between 
hematopoietic cells and stromal cells, and between LTα1β2 signaling and homeostatic 
chemokines in the complex organization of SLOs. 
 
Induction of tertiary lymphoid structures 
Which cytokines and chemokines are involved in TLO formation?  
Formation of TLOs at sites of chronic inflammation follows many of the pathways also 
used by lymphoid organogenesis before birth. Indeed, when LTα, CCL21, or CXCL13 are 
overexpressed from a tissue specific promoter, ectopic lymphoid tissues are induced 
before or soon after birth492-499. Conversely, in experiments in which either CXCL13, its 
receptor CXCR5, CCR7 or LTα was genetically absent or neutralized, TLO structures did 
not develop in various infectious and autoimmune models452, 458, 478, 500-502. Like in SLO 
formation, LTα-seems to instruct stromal cells to develop into FDCs and HEVs, whereas 
CCL19 and CCL21 acting via CCR7 control the organization of the T cell zones of the 
TLO446, 458, 500, 503. 
The homeostatic cytokine IL-7 deserves separate mentioning. Il7-/- mice lack lymph 
nodes and Peyer’s patches, whereas overexpression of IL-7 induces development of 
additional lymph nodes504. IL-7 is involved in stimulating LTi cells and in maintaining 
survival of T lymphocytes. IL-7 produced by lymphatic endothelial cells has been linked 
to the retention of Th2 memory cells in iBALT structures upon allergic airway 
inflammation505. IL-7 expression is augmented in the synovial tissue of RA patients, and 
there is a strong correlation between IL-7 expression and LTβ expression506. In the 
perivascular TLOs of patients with idiopathic pulmonary hypertension (IPAH) we found 
strong immunoreactivity for IL-7 very close to ER-TR7+ FRC cells483.  
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Figure 7 - Development and structure of secondary lymphoid organs 
During development of secondary lymphoid organs, the earliest instructive signal is given by a neuronal cell that induces 
the local fibroblasts to upregulate CXCL13 and thus attract lymphoid tissue inducer cells (LTi). These cells express LTb and 
instruct the local fibroblasts to become LT organizer cells (LTo) that start producing chemokines for B cells (CXCL13), T 
cells and DCs (CCL19, CCL21). At the same time, the fibroblasts upregulate cell adhesion molecules to allow LTi cells and 
recruited T and B cells to stick together. Local angiogenic growth factors are also made to allow the development of 
high endothelial venules (HEVs), as well as afferent and efferent lymph vessels. As a result, a well-organized structure with 
a separate B cell (blue) and T cell zone (red) is formed. This allows cell-cell contact at the appropriate time; and entry 
and exit of lymphocytes and antigen via the HEVs and lymphatics.  
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Together these data illustrate that homeostatic chemokines and cytokines are both 
sufficient and necessary for the induction of TLOs. Given this, it has been suggested that 
inflammation-induced TLOs might have developed during evolution before SLOs did.  
 
Are lymphoid tissue inducer cells necessary for inducing formation of tertiary lymphoid 
organs? 
In contrast to the involvement of CD3-CD4+CD45+ LTi cells in the formation of lymph 
nodes, their necessity for TLO induction is controversial444. The differentiation of LTi cells 
from lymphoid progenitors involves the transcription factors Id2 and retinoic acid 
receptor-like orphan receptor RORγt. Mice lacking these factors do not develop most 
LNs (except nasal associated mucosal tissues, NALT, and tear duct associated lymphoid 
tissue, TALT)487, 507-509. When Id2-/- or Rorc-/- mice lacking LTi cells were infected with 
influenza virus, they developed normal iBALT structures in the lung446, 449, 455. Other 
phenomena that do not depend on LTi cells are postnatal development of omental 
milky spots (these are organized lymphomyelopoietic tissue in the peritoneal cavity), 
isolated lymphoid follicles and TLOs in the intestine caused by DSS-induced colitis, and 
TLOs in autoimmune thyroiditis or insulitis449, 495, 510, 511. The controversy surrounding the role 
of LTi cells stems from three observations. First, adoptive transfer studies provide 
evidence that injection of LTi cells into normal skin is sufficient to induce TLO structures512. 
Second, LTi cells have been observed in models of spontaneous TLO development, 
such as the perivascular TLOs seen in hypercholesterolemic Apoe-/- mice and the iBALT 
structures seen in neonatal lungs exposed to LPS455. Human TLOs, such as those seen in 
IPAH, also contain adult LTi-like cells that are CD4-, cKit+ and OX40L positive, and also 
express RORγt and Id2 483. Third, overexpression of homeostatic chemokines under a 
tissue-specific promoter to induce TLOs (e.g. the rat insulin promoter or the 
intestine-specific villin promoter driving expression of CXCL13) and transgenic 
overexpression of IL-7 both resulted in increased numbers of LTi cells and dependence 
of TLO formation on LTi cells511. However, in these systems lymphoid organogenesis starts 
before birth, which means that the requirement for LTi cells in induction of TLO formation 
could be overestimated. Nevertheless, most groups agree that LTα1β2 is necessary for 
TLO induction500, 502. 
 
Which other cells can act as lymphoid tissue inducer cells in chronic inflammation? 
In the models in which LTi cells have been shown to be redundant, the question arises 
as to which other LTα1β2-expressing cell type could be providing the instructive signal to 
activate stromal organizer cells and initiate TLO formation? It has been proposed that B 
cells, T cells or DCs could substitute for LTi cells in their inductive function, especially 
when they are activated and express LTα1β2 on their surface447, 449, 513, 514. Progression 
towards mature, fully structured TLOs is dependent on LTβ-sufficient B cells503 most likely 
via a positive feedback loop of CXCL13 production and LTβ expression as shown in 
lungs of COPD patients515. According to this hypothesis B cells are activated via TLR 
signaling, induce expression of LTβ on their surface and interact with LTβ R bearing B 
cells. This LTβ signaling will induce CXCL13 production and release, which attracts more 
B cells and upregulates LTβ expression.  
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T cells can also play a role as LTi cells as was shown in a model of thyroid overexpression 
of CCL21 that CD3+CD4+ activated T cells interacted with DCs at sites of chronic 
inflammation, and subsequently the activated T cells acted as LTi cells in the absence 
of Id2 activity495. CD4+ memory T cells different from Th1, Th2, Treg and Tfh cells isolated 
from the synovial tissue of patients with rheumatoid arthritis were able to secrete 
CXCL13 and attract B cells; rendering them a possible candidate to function as LTi cells 
during ectopic lymphoid structure formation in the synovium516. In two recent studies on 
neonatal mice exposed to endotoxin inhalation and on mice with experimental 
autoimmune encephalomyelitis respectively, an activated Th17 CD4 T cell population 
was found to be involved in inducing TLO structures455, 517. RORγt+ IL-17–producing cells 
were also found inside TLOs of patients with IPAH. In humans, Th17 cells express the 
CCR6 receptor, and in the bloodstream of IPAH patients circulating CCR6+ cells were 
fewer, while the ligand CCL20 was produced in the perivascular TLOs483. However, TLOs 
seem to develop normally in Ccr6-/- mice455. The induction of TLOs by Th17 cells was 
dependent on expression of podoplanin, but why this is the case remains unknown. 
One possibility is that podoplanin is required for retention of Th17 cells at sites of TLO 
formation455, 517, a process that is inhibited by IL-27518. It remains to be seen whether all 
forms of TLO depend on IL-17 production, and whether IL-17A and/or IL-17F is involved. 
In this regard, iBALT induced by infection with modified vaccinia virus ankara or 
influenza virus is not affected by deficiency of IL-17A while Pseudomonas Aeruginosa-
induced iBALT is dependent on IL-17 signaling519, 449. LTβR signaling is not triggered only 
via LTα1β2; LIGHT (TNFSF14) can also bind the LTβR. In a model of non-obese diabetes, 
LIGHT expressed on T cells was shown to be important in the development and 
maintenance of TLO structures520. 
Finally, LTi functions have also been attributed to DCs. In almost all TLO structures that 
have been described, the T cell area contained antigen-presenting DCs447, 483. As DCs 
activate T cells, it has been suggested that DCs are sufficient for TLO induction463. 
Repeated injection of DCs into the lungs of mice is sufficient for induction of iBALT 
structures accompanied by induction of myofibroblast differentiation447, 521. During 
formation of Peyer’s patches, a CD11c+ cell type expressing LTαβ accumulates at the LN 
anlagen and is necessary for stromal instruction491. DCs might also directly instruct 
stromal cells irrespectively of their effects on T cells. In TLO structures induced in the 
thymus, DCs were specifically necessary for induction of lymphangiogenesis from 
stromal cells522. How DCs induce TLOs is less clear. In virus-induced iBALT, mainly CD11b+ 
DCs accumulate; these cells express instructive LTα1β2 while also producing the 
homeostatic chemokines CXCL13 and CCL19/CCL21447. However, in some models 
mostly pDCs accumulate, suggesting a functional role for type I IFN. This is the case in 
TLOs found in end-stage COPD patients and in a murine SLE model470, 476. Three studies 
have shown that depletion of DCs leads to disappearance of existing TLO structures, 
suggesting that DCs are necessary for structural organization and maintenance of TLOs, 
most likely through transpresentation of chemokines, or by provision of a continuous 
source of antigen presentation to T cells447, 448, 522.  
Overall, there is no strong evidence pointing towards one specialized lymphoid tissue 
inducer cell type in TLO induction. LTi cells, B cells, T cells and DCs all remain candidate 
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cell types to instruct organizer cells. Presumably the different cell types are redundant 
and the model defines which cell type exerts the dominant role of LTi cell. 
 
What is the nature of the stromal organizer cell? 
Stromal cells, such as FDCs of the B cell area, FRCs of the T cell area, lymphatic 
endothelial cells and HEVs, play an important role in the functioning of SLOs by 
producing cytokines, chemokines and forming the connective tissue conduits on which 
immune cells interact523. It has become clear that TLOs have the same complicated 
network of stromal cells and conduits, although their function remains undetermined511. 
Upon LTβR triggering by LTi cells or inflammatory cells, LTo cells express cell adhesion 
molecules and produce chemokines that attract B cells and T cells, produce cytokines 
that maintain lymphocyte viability (e.g. IL-7), and differentiate into FRCs and FDCs. LTβR 
signaling from host cells is involved in formation of lymphatic vessels in thyroid TLO502, 522 
and in formation of the reticular network511. Several studies have suggested that LTo 
cells and FRC cells of the T cell zone, like myofibroblasts, stain positive for α-smooth 
muscle actin and produce desmin524. It was elegantly demonstrated that inflammation 
could induce this program of myofibroblast differentiation in tissue resident fibroblasts, 
while at the same time inducing the production of the homeostatic chemokines 
CXCL13 and CCL21, and of lymphangiogenic cytokines. This programming did not 
require adaptive immunity, innate lymphoid cells, LTi cells, inflammasomes, or pattern 
recognition receptors, but was dependent on a myeloid cell population, most likely 
neutrophils. The molecular signal released by these myeloid inflammatory cells is not 
known489. Myofibroblasts are typically seen at sites of scarring and fibrosis, which might 
explain the occurrence of TLOs in patients with COPD, scleroderma, lung fibrosis and 
primary biliary cirrhosis474, 482, 525. In a model of atherosclerosis, it was shown that mouse 
aorta smooth muscle cells could differentiate into a cell type that resembles the LTo 
cell478, 526.  
During neuroinflammation the macrophages of the brain, the microglia, are the main 
source of CXCL13 in the central nervous system, making them ideal candidates to 
function as LTo cells during lymphoid follicle formation in multiple sclerosis527.  
In several instances where TLOs have been found in humans, they were also closely 
associated with c-Kit+ mast cells483, 506. Mast cells produce cytokines (e.g. TNFα) and 
express surface molecules (CD40L) that could help in structuring TLOs. They are also an 
important source of VEGF-C, which induces lymphangiogenesis. 
Finally, our views on TLO formation are even fundamentally changing. It has always 
been assumed that a cell-cell dependent interaction between LTo cells and LTi cells is 
necessary for TLO induction. Recently, an interaction via soluble factors has also 
been proposed in the model of atherosclerotic-related TLO formation528. In this model 
vascular smooth muscle cells are conditioned to become LTo cells in an LTβR-
independent manner by M1 type macrophages. 
 
In conclusion, TLO formation (Figure 8) follows the same basic set of rules also 
implicated in formation of the lymph nodes and Peyer’s patches (Figure 7).  
Controversies remain however on the precise nature of the LTi and LTo cell, and how 
they communicate with each other. Most likely the nature of the inducer and organizer  
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Figure 8 - Development and structure of tertiary lymphoid structures 
During chronic immune responses or transplant rejection, DCs continuously present antigens to T cells and B cells.  
Activated B cells express LTb and can act as potent LTi-like cells, to induce an LTo phenotype in local myofibroblasts.  
Alternatively, chronic antigen presentation by DCs might also lead to induction of a Th17 cell response that can also 
induce TLOs through unclear mechanisms. Th17 cells are held in place via interactions with podoplanin. As in SLOs, TLOs 
are divided into discrete B (blue) and T (red) cell areas. Although, fully formed TLO structures often contain only a single T 
cell area and a larger B cell area, in which germinal center reactions (GC) can be seen. These also contain DCs and 
follicular DCs. At the periphery, an elaborate network of lymphatics (Lyve1+ and Prox1+) is commonly found but it is 
currently unknown if these are afferent or efferent lymphatics.  
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cell depends on the anatomical environment where TLOs develop as well as the 
initiating antigen. 
 
The function of tertiary lymphoid organs 
TLOs develop in areas of chronic immune stimulation. However, although different 
infectious and immune or inflammatory triggers exhibit the same degree of chronic 
inflammation and inflict similar damage, their capacity to induce TLOs can vary widely. 
Moreover, tertiary lymphoid tissues develop more easily in neonates455. There is 
accumulating evidence that TLOs represent an adaptation of the body to increased 
demand for a localized immune response. The evolutionary pressure could be the 
constant equilibrium between commensals and the mucosal immune system, such as 
occurs typically in the gut and the lung. Isolated lymphoid follicles (ILF) are a 
specialized type of TLO that forms postnatal in the intestinal wall, through epithelial 
recognition of NOD1 ligands derived from commensals529. Although the deeper lung 
was once considered sterile, there is now evidence that it is not, particularly following 
viral infection or chronic cigarette smoking, typical  triggers of TLO formation in the 
lung530. Here again, commensals could be a driving force for TLO development. 
 
Tertiary lymphoid organs as immune inductive sites for protective immunity to 
(re-)infection  
Just like SLOs that bring together naive T cells, B cells and DCs, TLOs have been shown 
to allow the activation of recirculating naive T cells and the activation of B cells within 
germinal centers. One caveat is that these studies were performed in mice lacking LNs, 
which could lead to overestimation of the potential of TLOs446. However, recent work 
has suggested that TLOs can be immune inductive even in mice with normal LN 
anatomy and a fully functional immune system. Dendritic cells in TLOs often have an 
activated phenotype, suggesting that they are the predominant antigen presenting 
cells stimulating immunity470. The function of DCs in TLO biology has been studied mainly 
in iBALT structures induced by modified vaccinia ankara virus or influenza virus447, 448. 
Preformed iBALT structures collect DCs that are injected into the trachea, but it is 
unclear how these DCs reach the T cell area of iBALT448. One possibility is that iBALT 
structures are connected to afferent lymphatics located immediately underneath the 
epithelial basement membrane525. In many instances, the TLOs are found immediately 
next to lymphatics, but no study so far has been able to determine if these lymphatics 
are afferent (bringing antigen to the TLO) or efferent (exporting lymphocytes). It is also 
possible that the remodeling around blood vessels and the subepithelial areas leads to 
formation of a conduit system that provides a path for the encountered antigens to 
reach the TLO. This is supported by the close resemblance between the type of 
extracellular matrix found in atherosclerosis-associated or IPAH-associated TLOs 
compared with the one found in the FRC network and conduit system of LNs478, 483. 
Whatever the mechanism, TLO structures do allow the extravasation of naive T cells and 
their differentiation into effector T cells upon contact with DCs448. 
Major constituents of TLOs are the B cells that accumulate on the FDC network. Almost 
all TLOs described exhibit signs of B cell class switching, as exemplified by the presence 
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of high amounts of the AID enzyme and the presence of germinal center 
reactions447, 483. Such B cells provide an important source of memory B cells that are 
activated upon reinfection447, 459. Plasma cells are found in the immediate vicinity of the 
TLOs and secrete antibodies specific for the pathogen that induced the TLO, such as 
influenza virus or Helicobacter species447, 453. Although some of the B cells generated in 
the TLO also seem to reach the bone marrow, where they could reside as long lived 
plasma cells, the iBALT system that forms after influenza virus infection and the ILFs that 
form in response to intestinal commensals mainly serve to produce local mucosal 
IgA447, 475, 531.  
It is not known why some infections leave behind TLO structures whereas others do not. 
In a model of influenza, for T cell immunity to persist, there is continued dependency on 
lung DCs that take viral antigens from the lung to the MLN, even long after the virus has 
been cleared, for presentation to memory T cells. As CD11b+ DCs could be found 
mainly in iBALT in the lung long after virus was cleared, it is possible that they capture 
retained viral antigens from the FDC network532.  
It remains to be determined if persistence of Trm cells after IAV infection depends on the 
induction of TLOs as a sanctuary for TLO survival. In the skin at least, Trm cells accumulate 
in organized clusters resembling TLOs.  
 
Therapeutic applications of tertiary lymphoid organs 
Exploiting the induction of TLOs by vaccines could be a valuable option in promoting 
long-lasting, local antimicrobial immunity in the lung and gut533. Mice pre-treated with 
protein-caged nanoparticle (PCN) adjuvants in the absence of any specific viral 
antigens were protected against both sub-lethal and lethal doses of two different 
influenza viruses, a mouse-adapted SARS-coronavirus, and a mouse pneumovirus. 
Treatment with PCN significantly increased survival, enhanced viral clearance, 
accelerated induction of virus-specific antibody production, and significantly 
decreased morbidity and lung damage; these changes were attributed to prior 
development of iBALT481. A deeper understanding of the mechanism of action of this 
protection is needed before we can rationally design adjuvants that induce TLOs. 
As TLOs are found in many chronic diseases with an autoimmune component and in 
chronic transplant rejection, interfering with their induction or maintenance could be 
developed into a novel therapeutic approach. One possibility is to interfere with the 
LTβR. In a model of autoimmune diabetes in NOD mice, disrupting TLOs by antagonizing 
the action of LIGHT with LTβR inhibited formation of autoaggressive T cells and 
progression to diabetes520. Similarly, disruption of TLOs in the salivary glands that develop 
in the NOD model of Sjögren’s disease also led to partial restoration of salivary 
function501. Another approach could be to target crucial TLO chemokines or their 
receptors, such as CXCL13 or the CXCR5 receptor. In a model of rheumatoid arthritis, 
Cxcr5-/- mice had significantly reduced joint destruction458. In a model of diabetes in 
NOD mice, neutralization of CXCL13 led to disorganized TLOs, yet there was no clear 
effect on diabetes incidence534. Clearly, more preclinical studies on these compounds 
are needed before we can envisage an intervention study in humans. 
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Given the fact that the function of TLOs are similar to those of SLOs, the basic question 
for the field is why exactly our defense system mounts this at first sight redundant 
response. The capacity of TLOs to generate of tissue-directed autoantibodies, argues 
that targeting TLO formation could be beneficial in autoimmune diseases. On the other 
hand, stimulating the formation of TLOs can be beneficial in the fight against viral and 
bacterial infections.    
 
 
Pulmonary immune responses: a fine balance between protection and 
immunopathology 
To efficiently eliminate a viral infection from the lungs, the activation of both the innate 
and adaptive immune system is necessary. As a consequence, this results in the release 
of several cytokines, proteins and reactive oxygen species that have beneficial effects 
in defending the body against the insult, but may also induce tissue damage.  
Type I IFNs counteract a viral infection by inducing an antiviral state, inducing apoptosis 
and interfering with the viral replication cycle. These antiviral actions can be responsible 
for side effects and pathological damage. The apoptotic TRAIL535, 536 and FAS-FASL537 
pathway are induced to inhibit the spread of IAV but if the apoptosis-inducing proteins 
are expressed on the surface of structural cells, tissue damage can be induced. This 
mechanism can be linked to the susceptibility to IAV infection. More pathogenic strains 
were found to induce a stronger and more sustained type I IFN signal that leads to 
successive upregulation of TRAIL expression by monocytes and the TRAIL-ligand DR5 on 
epithelial cells538.  
Besides induction of apoptosis, type I IFNs also lead to the production of 
pro-inflammatory cytokines and chemokines such as CCL2 that recruit 
monocyte-derived DCs and macrophages to the site of infection, resulting in 
infection-associated pulmonary pathology and mortality as they are extensive cytokine 
secretors and can mediate TRAIL-induced cell death of the respiratory epithelium91, 535. 
In contrast to these pathology-inducing characteristics of type I IFN, it has also been 
described that type I IFNs have the potency to limit tissue inflammation by induction of 
the immune regulatory cytokine IL-10 and by inhibiting neutrophil recruitment and 
affecting monocyte differentiation539, 540. 
One of the first cell types recruited to the lungs after IAV infection is the neutrophil. 
Improper or prolonged activation of neutrophils leads to an increased exposure to 
reactive oxygen species541 and the proteolytic enzymes on the NETS92, 93, 542, which can 
lead to tissue injury and can cause pneumonia and acute respiratory distress 
syndrome543, 544. The host inflammatory response is of greater impact on the lethality of 
IAV infection than the effect of the pathogen itself. For example, a reduced infiltration 
of neutrophils mostly correlates with reduced pathology and lethality545-547. More 
specifically gene-expression analysis learned that lethality correlates better with 
neutrophil activation than with viral load548. In contrast to the possible severe side 
effects of neutrophil products, they are beneficial as their antibacterial peptides can 
prevent secondary bacterial superinfection549-551.  
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CD8+ T cells are highly associated with lung injury caused by the pulmonary 
inflammation. Excess T cell infiltration into the virus-infected lung compromises lung 
function and compliance. One of the main factors that contribute to this inflammation 
is TNFα. Inhibition of TNFα can significantly reduce lung damage, but TNFα was shown to 
be essential for proper viral clearance as inhibition of TNFα results in a delayed viral 
clearance552. To protect the host against the detrimental effects, interaction of CD8+ T 
cells with NK cells activates a negative feedback loop to limit TNFα production553.  
 
Lung dendritic cells and virus-induced immunopathology 
After activation in the lung, DCs can play dual roles during the immune response 
against respiratory viral infections. On the one hand, they are necessary to mount the 
antiviral CD8 cytotoxic T cell response in the draining lymph node (LN) that leads to viral 
clearance. On the other hand, the inflammation induced by DCs contributes to disease 
severity and even death from acute lung injury554. This implies that an unbalanced 
immune response can have detrimental effects on systemic illness and survival. 
When effector cells return to the lung after being generated in the MLN, there is 
evidence that DCs are also necessary locally for boosting effector function, which 
could eventually lead to immunopathology326, 555. MCs (or TIP-DCs) have been 
proposed to be the predominant cause of immune pathology caused by influenza and 
RSV virus infection554, 556. High pathogenic strains induce more TNF and iNOS producing 
(TIP)-DC recruitment to the lung. They promote immune-induced pathology, but their 
complete depletion is detrimental295. This might be related to the fact that iNOS-derived 
nitric oxide also has direct antiviral activity to IAV557. 
The final function of antiviral CD8+ T cell effector cells is instructed by the phenotype of 
the cell type presenting the viral antigen. MHC class I expression and costimulation via 
CD80 and CD86 on professional antigen presenting cells are necessary for 
pro-inflammatory cytokine production, whereas induction of cytotoxicity is induced by 
MHCI presentation on epithelial cells without the need of costimulatory signals. This 
cytokine production also contributes to lung pathology and may not be essential for 
viral clearance since viral clearance is not affected when costimulatory signals are 
blocked325, 326.  
 
Tertiary lymphoid organs in immunopathology  
The presence of TLOs in models of chronic autoimmunity and in chronic transplant 
rejection (see Table 5) and their association with tissue destruction449, 465, 466, 472, 473, 558 has 
led to the suggestion that they are important inductive sites for self-reactive T 
lymphocytes and antibodies that contribute to pathology. However, the evidence for 
this is rather sparse. In the TLOs associated with diabetes in NOD mice, T lymphocytes 
are detected that destroy islets and plasma cells with specificity for insulin464, 520. The 
expansion of B cells inside an individual TLO around islets is often oligoclonal, suggesting 
the presence of an autoantigen559. In the lungs of patients with rheumatoid arthritis, B 
cells in the TLO were found to produce rheumatoid factor and antibodies against 
citrullinated proteins, typical self-antigens in this disease525. In human autoimmune 
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thryroiditis, most B cells inside ectopic GCs bound the autoantigens thyroglobulin and 
thyroidal peroxidase462. 
However, it is less clear which antigens the lymphocytes might react to in more severely 
degenerative diseases such as COPD induced by cigarette smoke and atherosclerosis 
induced by western diet. Although it has been proposed that there is an autoimmune 
component in many chronic tissue-destructive diseases such as COPD, another 
explanation could be colonization of the lung by latent adenovirus or unexpected 
commensals in the lung560. Until we know the antigen-specificity of the B cell and T cell 
responses in TLOs, we can only speculate on the nature of the antigens presented in 
diseases such as IPAH and cirrhosis. In any case, the extensive formation of 
myofibroblast-like cells that constitute part of the stromal organizing network might 
contribute to local fibrosis that could compromise organ function. 
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As was pointed out in the introduction, IAV infection evokes a complex immune 
response. A common theme of the thesis is that the heterogeneity and complexity of 
the immune system and its components are taken into account to understand the 
immunology of IAV infection. By using a mouse model for mild seasonal IAV infection 
(X31 virus, H3N2) three diverse aspects of the immune response against IAV infection 
were studied:  
 
- What is the precise functional contribution of the recently described subsets of 
cDCs and MCs? 
- What is the precise contribution of a rare population of CD4-CD8- “double 
negative” T cells? 
- Is there a role for the innate immune response in driving organized lymphoid 
tissues (iBALT) development in response to infection? 
  
First, even if DCs have already been studied in the context of IAV, It is important to 
realize that each lung DC subset can activate a different functional program in 
response to viral infections. Most studies on viral lung infection thus far have not 
incorporated DC heterogeneity into the conceptual framework. On the other hand, 
the same DC subset can react differently depending on the type of virus that is 
detected. Therefore in chapter 3 we are focusing on the different dendritic cell subsets 
during influenza infection. More specifically DC subsets in the lung and MLN during IAV 
infection are reexamined with more precision by using a gating strategy including CD64 
and MAR-1. By applying this gating strategy the origin, kinetics and the migratory 
capacity of the different subsets after infection are defined and the previously never 
described MAR-1+ cDC2 is characterized in detail.  
  
Secondly, the same degree of heterogeneity and complexity is also seen in T cells. 
Traditionally, T cells have been subdivided in CD4 and CD8 T cells and this is also how T 
cells have been mainly studied in IAV infection. In chapter 4 the T cell response after 
influenza infection is described and more specifically the often-ignored CD4-CD8- T 
cells. These cells are a rather small part of the total population of T cells, but our 
experiments showed that these cells can also exert immunoregulatory functions. The 
new concept that some T cells become resident memory cells is incorporated and the 
relationship between DCs and conventional and CD4-CD8- T cells is studied.  
 
Finally in chapter 5 we study in greater detail how TLO formation is initiated following 
IAV infection. We describe that IL-1 plays a role and provide evidence on how innate 
cytokines like IL-1 that are produced very early after infection can modulate the lung 
environment and condition it to promote iBALT development, an event that is only fully 
completed after viral clearance.  
 
To end, the findings of this thesis are extensively discussed and put in perspective in 
chapter 6. 	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Abstract 
 
Dendritic cells play a crucial role during the immune response against influenza A virus 
infection as they can take up viral antigen and present it to T cells to induce a T cell 
response. Historically several subsets have been introduced and many different 
functions were attributed to these different subsets. It is generally accepted that 
CD103+ cDC1 DCs have the best cross-presenting capacities, but an important antigen 
presenting function was also attributed to CD11b+ cDC2s. Recent insights in dendritic 
cell biology provide potential to study the functional specialization of DC subsets during 
influenza A virus infection. We applied a novel gating strategy implementing CD64 and 
MAR-1 antibodies to clearly differentiate between conventional and monocyte-derived 
cells and study the DC functions on well-defined populations. By applying this gating 
strategy on a mouse model for mild seasonal influenza infection, a conventional cDC2 
population that acquired expression of the monocyte markers MAR-1 and CD64 and 
expression of IRF8, the terminal selector of the cDC1 lineage, was identified. 
Functionally this MAR-1+ cDC2 has a more mature phenotype than MAR-1- cDC2s and 
has better cross-presenting capacities. This population is induced in a type 1 interferon 
dependent manner but is not dependent of IRF8 for its development. Rather, IRF8 
controls a functional module in these cells and confers increased antigen 
cross-presentation and increased T cell stimulating capacities.  
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Introduction 
Influenza A virus (IAV) is a respiratory pathogen that causes seasonal infections that 
usually run a mild course. Pandemics with a more severe outcome can occur when the 
fragmented genome of the virus undergoes antigenic shift. Combined with the 
continuous antigenic drift it is currently not possible to develop a long-term effective 
vaccine. Therefore it is important to understand the immune response against IAV 
infection thoroughly to find new protective or therapeutic strategies.   
Dendritic cells (DC) are the sentinels of the immune system that activate the adaptive 
immune system after sensing viral particles by innate immune receptors. Within the DC 
compartment, IRF8 and IRF4 are two transcription factors involved in driving the 
development towards the CD103+ cDC1 lineage or the CD11b+ cDC2 lineage 
respectively1-9. Functionally, IRF4 and IRF8 are involved in DC maturation, IL-12 
production, migration and induction of the MHCI and MHCII presentation machinery 
genes2, 9, 10. Both directly or indirectly, these transcription factors can regulate T cell 
responses, like the acquisition of helper functions in CD4 T cells and induction of CD8 
cytotoxic T cells3, 4, 11-20. During the course of primary IAV infection, DCs can acquire viral 
antigens through direct infection or through the acquisition of exogenous antigens by 
phagocytosis of dying infected cells or viral particles and prime CD8+ T cells by a 
process called MHC-I presentation or cross-presentation respectively. In the past, 
several studies were undertaken to define which DC subsets induce T cell proliferation 
and how this process is induced. Generally CD103+CD11b- DCs were shown to have the 
best cross-presenting capacity during IAV infection14, 21-23. Other groups described that 
CD11b+ DCs and late arriving presenting cells (LAPC) were the major 
antigen-presenting DC subsets controlling adaptive CD8 and CD4 T cell immunity to 
IAV24, 25.  
The observed inconsistencies in the results of these early studies on the function of 
various DC subsets have generated a lot of discussion on why results could be so 
diametrically different. Recent insights in DC biology now warrant further exploration 
and offer some explanations. Firstly, the paradigm that cDC1s are the exclusive cross-
presenting cells that activate and induce cytotoxic CD8+ T cells (CTL) and that cDC2 
are the antigen presenting cells that activate CD4+ T cells to acquire a Th phenotype 
has recently been questioned. It was shown that also cDC2s can induce CTL responses 
under the condition that antigen is seen in the presence of a TLR signal, that might differ 
from the cDC1 subset26. For cDC1 DCs, TLR3 triggering (dsRNA) is necessary whereas for 
cDC2 DCs TLR7 triggering (ssRNA) is crucial. The exact molecular mechanism driving the 
acquisition of cross-presenting potential by cDC2s is currently unknown. Presumably, a 
gene module switch is induced by a transcriptional network downstream of TLR7. 
Secondly, the lack of robust identification markers to distinguish pure cDC 
subpopulations has obscured the results of many experiments, as many markers that 
define a lineage in steady state can be profoundly upregulated when cells get 
activated by cytokines or PRR signals27. In this paper, we apply the recently described 
gating method based on CD64 and MAR-128 to identify the DC subsets during mild IAV 
infection, greatly improving the correct identification of cDCs, as contaminating 
macrophages and monocyte-derived cells (MCs) are gated out. This led to the 
identification of a maturation state of conventional cDC2s that expressed the 
*	  
	   73 
monocyte-marker MAR-1 and thus called MAR-1+ cDC2 DC. MAR-1 expression on 
cDC2s was induced in a type 1 IFN dependent manner and these cells were more 
mature than conventional cDC2s and acquired expression of the cDC1-associated 
transcription factor IRF8. Functionally, IRF8 controlled a functional module in cDC2s, 
responsible for maturation and induction of a CD8+ T cell response rather than a CD4+ T 
cell response. These findings show that the transcription factor IRF8, traditionally 
associated with cDC1 development, is co-opted by cDC2s to drive a functional 
module associated with cDC1 functions. 
 
 
Results 
A population of MAR-1+ CD11b+ DCs is present in the lung and MLN during Influenza A 
virus infection  
We have recently described that dendritic cells (DCs) in the lung consist of both 
conventional DCs (cDCs) and monocyte-derived DCs (recently termed MCs, to reflect 
their origin from circulating monocytes)28, 29. In the steady-state lung and MLN, cDCs, 
which express CD11c and MHCII but lack expression of CD64 and MAR-1, can be 
subdivided into two subsets, cDC1s and cDC2s that are distinguishable by CD103 and 
CD11b expression28. MCs express CD11c, MHCII, CD11b, CD64 and MAR-1. Thus 
inclusion of CD64 and MAR-1 in the gating strategy is required to distinguish cDC2s from 
MCs. Unfortunately, many papers describing the function of DCs during IAV infection 
discriminate the DC subsets based on expression of CD11b and CD103 only. Thus we 
first aimed to reexamine the DC subsets present in the lung and MLN during IAV 
infection with more precision using a gating strategy including CD64 and MAR-1. Similar 
to steady-state mice, this analysis revealed three DC subsets to be present in the lungs 
of mock-infected mice (Fig 1A): CD103+ cDC1s, CD11b+ cDC2s which made up almost 
half of the DC population, and CD11b+ CD64+ MCs which were the smallest fraction of 
pulmonary DCs (Fig 1B). At 4 days post infection (dpi) with IAV, the proportion of cDC1s 
and cDC2s was decreased while the proportion of MCs was significantly increased 
(Fig 1B). However, also a previously undescribed DC population within the 
CD11b+CD11c+MHCII+ cells expressing intermediate levels of CD64 (CD64int) and MAR-1 
(MAR-1+) was identified (Fig 1A), which we termed MAR-1+ DCs. Following viral 
clearance all DC populations returned to baseline and MAR-1+ DCs were no longer 
identifiable in the lung (Fig 1C).  
To assess if this MAR-1+ DC population migrated to the draining lymph node, the same 
gating strategy was applied to the MHCIIhi DCs of the MLN. After mock-infection, 
analysis of the MLN revealed a slight increase in cDC2s compared with cDC1s while no 
MCs or MAR-1+ DCs were found (Fig 1D,E). However, at 4dpi with IAV, while again no 
MCs were identified, there was a significant increase in both cDC1s and cDC2s and a 
substantial population of MAR-1+ DCs. Indeed these MAR-1+ DCs represented over half 
of the total DC population at 4dpi (Fig 1D,E). Similar to the situation in the lung, cDC1s, 
cDC2s and MAR-1+ DCs returned to baseline levels following viral clearance (Fig 1F).  
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Interestingly, the generation of MAR-1+ DCs was not unique to infection with IAV. When 
mice were infected with a low dose of the murine paramyxovirus pneumonia virus of 
mice (PVM), MAR-1+ DCs in the lung and MLN were similarly detected(Fig 1G) from 8dpi 
with PVM onwards.  
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Figure 1 - MAR-1+ CD11b+ DCs are induced after influenza infection 
(A) Representative flow cytometry plots showing gating of lung CD11c+ MHCII+ DC subsets 4dpi with X31 virus (bottom 
panel) compared with mock-infected controls (upper panel). Plots are pre-gated on single, live, CD3-CD19- cells. 
Histograms show expression of MAR-1 and CD64 on the different CD11c+ MHCII+ DC subsets. (B) Pie charts showing 
distribution of lung DC subsets in steady state conditions and 4dpi with mock or X31 virus as percentage of living DCs. The 
size of the pie is proportional to the total amount of DCs in the lung. (C) Kinetics of different lung DC subset numbers after 
mock (white circles) or X31 (black circles) infection. (D) Representative flow cytometry plots showing the gating strategy 
used to define MHCIIhi DC subsets in the mediastinal lymph node (MLN) in mock (upper panel) and X31 virus (bottom 
panel) infected mice at 4dpi. Plots are pre-gated on single, live, CD3-CD19- cells. Histograms show expression of MAR-1 
and CD64 on the different CD11c+ MHCIIhi DC subsets. (E) Pie charts showing distribution of MHCIIhi DC subsets in steady 
state and 4dpi with mock or X31 virus in the MLN as percentage of living MHCIIhi DCs. The size of the pie is proportional to 
the absolute number of MHCIIhi DCs in the MLN. (F) Kinetics of different MHCIIhi DC subset numbers in the MLN after mock 
(white circles) or X31 (black circles) infection. (G) Kinetics of different lung (upper panel) and MHCIIhi MLN (lower panel) 
DC subset numbers after PVM infection. Data are representative of at least two independent experiments with 4-6 mice 
per group. 
 
 
MAR-1+ DCs are bona fide cDCs 
As MAR-1 is a marker typically used to define monocyte-derived cells, including the 
cells historically known as MoDCs28, we next questioned whether the MAR-1+ DC 
population was of monocytic or pre-cDC origin, like cDC1s and cDC2s. To examine this 
directly, pre-cDCs were sorted from the bone marrow of wild-type CD45.2 mice, 
labeled with a cell tracker dye and transferred into CD45.1/CD45.2 mice at 1dpi with 
IAV. The expression of the congenic marker within the DC subsets was analyzed 4 days 
later (Fig S1, Fig 2A). The transferred pre-cDCs gave rise to cDC1s, cDC2s and the 
MAR-1+ DC population, but not to the CD64+MAR-1+ MC population (Fig 2A). To 
determine if the origin of MAR-1+ DCs was restricted to cDC-committed progenitors, we 
next examined the dependence of this population on the chemokine receptor CCR2 
using Wt:Ccr2-/- mixed BM chimeras. CCR2 is required on monocytes for the egress from 
the BM to the blood and hence CCR2 dependency is often used to define monocyte 
origin. Analysis of the DC populations in these chimeras revealed MAR-1 DCs to be 
CCR2 dependent but this dependence was less pronounced than for the MC 
population (Fig S2). As it has recently been reported that some cDCs can also be 
CCR2-dependent30 we next assessed whether MAR-1+ DCs could also derive from 
monocytes. Monocytes were sorted from the bone marrow of CD45.1 wild-type mice, 
labeled with a cell tracker dye and transferred into CD45.2 Ccr2-/- mice at 1dpi. The 
expression of the congenic markers on DC subsets was analyzed 4 days later (Fig S1, Fig 
2B). Ccr2-/- mice were used as hosts to give the transferred monocytes a competitive 
advantage over the endogenous population aiding their identification following 
transfer. Four days after the monocyte transfer, the transferred cells were present 
exclusively in the CD11b+ gate in the lung and within this gate only in the CD64+ MAR-1+ 
MC gate (Fig 2B). Thus MAR-1+ DCs generated during IAV infection are strictly derived 
from pre-cDCs and hence represent a bona fide population of cDCs. No transferred 
monocyte-derived cells could be identified in the MLN indicating that MCs do not 
migrate to the draining LN at this time point after infection.  
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Figure 2 - MAR-1+ CD11b+ DCs are of conventional origin 
(A) CD45.2 pre-cDCs were sorted from eFl450+ cell tracker labeled bone marrow and transferred i.v. into CD45.1/CD45.2 
wild-type recipient mice at 1dpi with IAV. 4 days later donor cells were identified in the lung (upper panel) and MLN 
(lower panel) as cell tracker+ CD45.1- cells and were subsequently examined for CD103 and CD11b expression and for 
CD64 and MAR-1 expression. The graphs represent the distribution of the different DC subsets in the endogenous 
population (white) and the pre-cDC derived population (black). Data are pooled from 2 independent experiments 
(circles and squares) with 4 transferred mice in total are analyzed with a Two-way ANOVA with Sidak correction for 
multiple comparisons. The plots showing transferred pre-cDCs in the MLN is a pooled sample of two transferred mice. (B) 
CD45.1/CD45.2 monocytes were sorted from eFl450+ cell tracker labeled bone marrow and transferred i.v. into CD45.2 
CCR2-/- recipient mice at 1dpi. 4 days later donor cells were identified in the lung (upper panel) and MLN (lower panel) 
as cell tracker+ CD45.1+ cells and were subsequently examined for CD103 and CD11b expression and for CD64 and 
MAR-1 expression. The graphs represent the distribution of the different DC subsets in the endogenous population (white) 
and the monocyte-derived population (black). Data are from 2 independent experiments (circles and squares) with 5 
transferred mice in total are analyzed with a Two-way ANOVA with Sidak correction for multiple comparisons. (C) 
Representative histograms showing expression of CD26, MerTk, XCR1 and SIRPα on lung and MLN DC subsets at 4dpi with 
IAV. Data are representative of 2 independent experiments with 4-6 mice per group. (D) Expression of CD64 and MAR-1 
on lung and MLN DC subsets over time, expressed as MFI. 
* = p ≤ 0,05; ** ≤ 0,01; ns = not statistically significant.    
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As CD26 and MerTk have recently been described by the Immgen consortium to be 
conserved in cDCs and macrophages respectively31-33 we next stained for these 
markers in the lung and MLN during IAV infection to assess their expression on MAR-1+ 
cDCs compared with the other DC populations. Correlating with their pre-cDC origin, 
MAR-1+ cDCs expressed high levels of CD26 and low levels of MerTk, similar to cDC1s 
and cDC2s (Fig 2C). Conversely and fitting with their distinct origin, MCs expressed 
intermediate levels of both CD26 and MerTk (Fig 2C). Expression of CD11b is not enough 
to categorize DCs as cDC2s as CD11b can be induced on DC subsets, like pDCs as part 
of an activation module34. XCR1 and SIRPα (CD172a) have been identified as 
conserved surface markers that can be used to identify cDC1s and cDC2s respectively 
throughout different tissues and species29, 33, 35, 36. MAR-1+ cDCs in the lung and MLN 
expressed SIRPα but did not express XCR1 identifying them as members of the cDC2 
lineage and further described as MAR-1+ cDC2s (Fig 2C). As MAR-1 expression, and to a 
lesser extent CD64 expression, was induced over time on the total cDC2 population (i.e. 
MAR-1- cDC2s and MAR-1+ cDC2s) and on the MCs and returned back to baseline 
levels once the infection is cleared, this suggests that MAR-1 and CD64 may represent 
temporal activation markers of cDC2s (Fig 2D).  
 
MAR-1+ cDC2s represent a hyper activated state of cDC2s 
To further characterize the MAR-1+ cDC2s, DC subsets were sorted 4 days post mock 
and IAV infection and were subjected to a micro-array analysis. By performing a 
principal component analysis (PCA, Fig 3A), the first principal component (PC1) 
corresponded to the ontogeny of the DCs whereas the second principal component 
(PC2) corresponded the activation status (mock versus IAV). The MAR-1+ cDC2s 
appeared to be in a more extreme activation state than MAR-1- cDC2s at 4dpi IAV 
infection. This was also confirmed when the 30 most upregulated genes and the 30 
most downregulated genes between mock cDC2s and MAR-1+ cDC2s were plotted on 
a heat map (Fig S3A). MAR-1- cDC2s from IAV infected mice always showed an 
intermediate gene expression profile between MAR-1- cDC2s from mock infected mice 
and MAR-1+ cDC2s from IAV infected mice. In a next step we sought to identify unique 
genes that were expressed in the different DC subsets, using a novel triwise comparison 
algorithm37. Therefore the gene expression profiles from the 3 different subsets were 
plotted on a triwise plot representing total gene expression under mock  
or IAV condition (Fig 3B). Even in mock condition hardly any cDC2 specific genes could 
be defined, while Xcr1, Clec9a and Irf8 were highly specific for cDC1s and Mertk, Emr1 
(F4/80) and Fcgr1 were specific for MCs. The cDC2s rather shared most genes with 
either cDC1s (Dpp4 (CD26) and Zbtb46) or MCs (Sirpa). Furthermore cDC1s shared 
almost no genes with MCs whereas they did share genes with their conventional cDC2 
counterparts.  
To determine which genes are differentially expressed upon IAV infection, and which 
genes remained reliable identifiers of cDC subsets, a pairwise comparison of cDC1s, 
cDC2s and MCs in mock versus X31 condition was made and the differentially 
expressed genes were plotted on a triwise plot representing the total gene expression 
profile 4dpi with IAV (Fig 3C). Only a very low number of genes were upregulated in 
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only one cellular subset. The genes upregulated in cDC1s were mostly shared with 
cDC2s and MCs during IAV infection. For cDC2s the upregulated genes were either 
shared by cDC1s (e.g. Irf8, Il12b, Il12rb, Cd80, Cd86, Tnfsf4), MCs (e.g. Cxcl10, Cxcl11, 
Fcgr1, Ccl7, Tlr7, Batf2) or all subsets. The genes shared with cDC1s were classified by 
Ingenuity pathway analysis (IPA) to belong to the canonical pathways involved with T 
helper cell differentiation, DC maturation and IL-12 signaling (Fig S3B). In contrast, the 
shared genes with MCs were classified in the canonical pathways linked with 
recognition of viruses by pattern recognition receptors (PRR), IFN induction, and 
activation of IRF by cytosolic PRR and RIG-I like receptors (Fig S3C). This suggests that 
MAR-1+ cDC2s acquired a hybrid phenotype sharing typical cDC1 and MC gene 
modules. The differentially expressed genes in MCs were shared with all the subsets or 
shared with cDC2 DCs but not with cDC1s. However, most of the genes that were 
upregulated in the different subsets upon infection were mostly shared by all the 
subsets. This common “influenza signature” in the DCs consists mainly of type I IFN genes 
(e.g. Ifit family, Irf7, Oas family, Mx2, Stat1) (Fig 3D, cluster 1).  
Another cluster of genes represented the genes that are specifically expressed in mock 
cDC1s, but are acquired by cDC2 and/or MCs but caution should be taken as these  
genes are separated into 3 different clusters upon IAV infection (Fig 3E): only a small 
fraction of surface markers remained cDC1 specific (e.g. Xcr1, Cadm1, Clec9a, Tlr3 and 
Itgae; cluster 5). The remainders of genes were either also expressed by cDC2s (e.g. Irf8, 
Il12b, Il15, Stat4 and Tnfrsf4; cluster 3) or by both cDC2s and MCs and became shared 
by all DC subsets (e.g. Tap1, Bcl2l1, Slfn1; cluster 2). This indicates that caution should be 
taken when studying DCs during inflammatory conditions.  
Despite the fact that MAR-1+ cDC2s were FACS-purified on the basis of expression of the 
MAR-1 epitope of FcεR1, the gene, Fcer1a, was not identified as being differentially 
expressed between MAR-1- and MAR-1+ cDC2s and also appeared not to be 
specifically expressed in MCs (Fig 3B). As we found this quite surprising, we next sought 
to investigate if the MAR-1 antibody was indeed specifically staining FcεR1 on DCs and 
MCs. To this end, we infected WT and Fcεr1-/- mice with IAV and examined MAR-1 
expression by the DC subsets. Despite lacking FcεR1, MAR-1+ cDC2s were readily 
identifiable in the lung and MLN of Fcεr1-/- mice (Fig S4). Furthermore, there was no 
difference in either their proportion or number compared with WT controls. This 
demonstrates that the MAR-1 antibody also recognizes another surface protein than  
 
 
 
Figure 3 - Gene expression changes dramatically upon IAV infection 
(A) PCA analysis of lung DC subsets 4dpi mock (lighter colors) or IAV (darker color) infection. (B) To visualize differential 
gene expression between the DC subsets after mock (left) and IAV infection (right) each gene was plotted in a 
hexagonal triwise diagram in which the direction of a point represents an up-regulation in ore or two populations, 
whereas the distance from the origin represents the magnitude of this up-regulation. Genes that are >32 fold 
differentially expressed are plotted on the outer grid line. Rose diagrams (top right) show the percentage of genes in 
each orientation. Brown dots represent genes that are not differentially expressed. Green dots represent statistically 
significant differentially expressed genes. (C) Triwise diagrams of the gene expression after IAV infection. Red dots 
represent the upregulated genes in cDC1s (left), cDC2s (middle) and MCs (right) after IAV infection. Rose diagrams (top 
right) show the percentage of the red dots in each orientation. (D) Heat maps showing relative expression of 
differentially expressed genes between DC subsets from mock and IAV infected mice. (E) Triwise diagrams of the gene 
expression after mock (upper diagram) and IAV (lower diagram) infection. The red dots represent the genes that are 
cDC1 specific in mock conditions. Rose diagrams (top right) show the percentage of the red dots in each orientation. 
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the FcεR1 expressed on mast cells and basophils. The precise nature of this epitope in 
cDC2s and MC remains enigmatic.  
One major observation in the micro-array analysis was that Irf8 expression, which was 
previously shown to be a terminal selector of the cDC1 lineage38, shifted during IAV 
infection towards a shared expression pattern with cDC2s (Fig 3B,E). We next aimed to 
confirm these differences at the protein level. To this end, intracellular IRF4 and IRF8 
were stained in all DC subsets in the lung and MLN during IAV infection. This analysis 
confirmed that both MAR-1- and MAR-1+ cDC2s upregulated IRF8 after IAV infection 
while retaining IRF4 expression (FIG 4A), but the MAR-1+ cDC2s expressed higher levels 
of IRF8 than their MAR-1- cDC2 counterparts. Other than in the lung, where the 
expression of IRF8 in MAR-1+ cDC2s remained modest compared to the expression in 
cDC1s (Fig 4A), IRF8 expression by MAR-1+ cDC2 DCs in the MLN was further increased 
and almost equaled the IRF8 expression level of cDC1s (Fig 4B).   
As the transcription factor IRF8 is induced in cDC2s during IAV, we next addressed 
whether IRF8 drove the expression of MAR-1 on cDC2s. Irf8fl/fl x Cd11c Cre mice that 
lack IRF8 specifically in CD11c-expressing cells were infected with IAV and DC subsets 
were analyzed at 4dpi. The transgenic mice indeed showed a loss of cDC1s consistent 
with previously published data1, 38-42, however, no reduction in the MAR-1- or MAR-1+ 
cDCs in the lung and MLN compared with Cre- littermate controls was observed 
(Fig 4C,D). Thus, unlike cDC1s, MAR-1+ cDC2s are not dependent upon IRF8 for their 
development.   
 
MAR-1+ cDC2s acquire expression of IRF8 in a type I IFN dependent manner 
Contrary to cDC1s requiring IRF8 for their development, cDC2s have been shown to 
require IRF4 for their terminal differentiation, survival and migration4, 5, 43-46. Thus we also 
examined the prevalence of the distinct DC subsets in Irf4fl/fl x Cd11c Cre mice, which 
lack IRF4 specifically in CD11c-expressing cells. While lack of IRF4 in CD11c+ cells 
resulted in a reduction of CD24+ cDC2s in the lung and a severe reduction of migratory 
cDC2s in the MLN in the steady state1, this dependence on IRF4 was overcome during 
the inflammatory setting of IAV infection where the proportion and absolute numbers of 
all of the conventional DC subsets was similar to that in Cre- littermate control mice 
(Fig 4E and F). Thus IRF4 is dispensable for development, survival and migration of cDC2s 
during inflammation.   
Based on the micro-array data, IPA analysis suggested that IRF8, IFNAR, STAT1, IRF3 and 
IRF7 were potential upstream regulators of the differential gene expression between 
cDC2s in mock condition and MAR-1+ cDC2. A deeper analysis of the canonical 
pathways linking these upstream regulators showed that IFNAR signaling could be the 
initiating factor (Fig S3E). To validate this, Ifnar -/- mice were infected with IAV and DC 
subsets were quantified at 4dpi. This analysis revealed that MAR-1+ cDC2s were almost 
completely absent in Ifnar-/- mice (Fig 5A) demonstrating their dependence on type 1 
IFN signaling. Additionally, the intensity of MAR-1 expression was found to be decreased 
within the MC population, showing that IFNAR-signaling is involved in inducing MAR-1 
expression on all DC subsets, also those derived from monocytes and sharing 
macrophage characteristics (Fig 5A). Conversely, MAR-1- cDC2s were increased in both 
 
 
*	  
	   81 
 
Figure 4 - MAR-1+ cDC2s express IRF8 but do not depend on IRF8 or IRF4 for their induction 
(A,B) Representative flow cytometry plots showing IRF4 and IRF8 expression (upper panel) and pooled MFIs (bottom 
panel) in (A) lung and (B) MLN DC subsets at 4dpi with IAV compared with mock infected controls. Data are 
representative for 3 independent experiments with 3-6 mice per group and are analyzed with a Two-way ANOVA with 
Tukey correction for multiple comparisons. (C,D) Representative flow cytometry plots (upper panel), absolute numbers 
(middle panel) and distribution of DC subsets as a % of live DCs (lower panel) in the (C) lungs and (D) MLN of Irf8 x Cd11c 
CreWT and Irf8 x Cd11c CreTg mice 4dpi with IAV. The size of the pie chart is proportional to the total amount of DCs. Data 
are representative for 2 independent experiments with 4-5 mice per group. (E,F) Representative flow cytometry plots 
(upper panel), absolute numbers (middle panel) and distribution of DC subsets as a % of live DCs (lower panel) in the (E) 
lungs and (F) MLN of Irf4 x Cd11c CreWT and Irf4 x Cd11c CreTg mice 4dpi with IAV. The size of the pie chart is proportional 
to the total amount of DCs. Data are representative for 2 independent experiments with 3-6 mice per group and are 
analyzed with a Two-way ANOVA with Sidak correction for multiple comparisons. 
* = p ≤ 0,05; ** ≤ 0,01; ns = not statistically significant.   
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Figure 5 - IFNAR signaling is necessary for the generation of MAR-1+ cDC2s and their expression of IRF8 
(A) Representative flow cytometry plots showing identification of DC subsets in the lung (upper panel) and MLN (lower 
panel) in Ifnar+/+ and Ifnar--/- mice 4dpi with IAV. Representative histograms showing expression of MAR-1 on Ifnar+/+ and 
Ifnar-/- DC subsets 4dpi with IAV. Data are representative for 3 independent experiments with 4-5 mice per group. (B) 
Absolute number (upper panel) and distribution as a percentage of live DCs (lower panel) of DC subsets lung and MLN 
of Ifnar-/- and Ifnar+/+ mice 4dpi with IAV. Data are representative for 3 independent experiments with 4-5 mice per group. 
(C) Expression of IRF4 and IRF8 by DC subsets in lung and MLN of Ifnar-/- and Ifnar+/+ mice 4dpi with IAV. Upper panel 
shows representative flow cytometry plots. Bottom panel shows MFIs. Data are representative for 2 independent 
experiments with 4-5 mice per group and are analyzed with a Two-way ANOVA with Sidak correction for multiple 
comparisons. * = p ≤ 0,05; ** ≤ 0,01; ns = not statistically significant.    
 
 
proportion and number in the lung and MLN which lead to an unchanged total 
amount of cDC2s (Fig 5B). Additionally, we confirmed that type I IFN signaling is an 
upstream regulator of IRF8, as IRF8 expression was significantly reduced in the cDC2s in 
Ifnar-/- mice compared with WT controls (Fig 5C). 
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MAR-1+ cDC2s gain the capacity to stimulate CD8 T cells  
Given the observation that expression of Cd80, Cd86, Il12 and Irf8 was induced in 
MAR-1+ cDC2 DCs during IAV infection (Fig 3C) and that these genes are typically 
linked to antigen presentation, we sought to address the functional capacity of the  
IRF8hi MAR-1+ cDC2 DCs. Therefore the WSN-OVA virus, encoding the OVA257-264 Kb 
restricted MHC I epitope in the neuraminidase gene, was used to infect wildtype mice. 
DC subsets were sorted from the MLN at 4dpi and put in coculture with CFSE-labeled 
CD8+ OT-I T cells. After 4 days of coculture, the cells were restimulated for 5 hours and 
CFSE dilution and production of IFNγ and Granzyme B were examined by flow 
cytometry. In the MLN, cDC1s were found to induce strong proliferation of OT-I T cells. 
Strikingly, MAR-1+ cDC2s also induced proliferation of OT-I T cells, whereas MAR-1- cDC2s 
only induced a modest degree of proliferation (Fig 6A). The same results were obtained 
with lung DC subsets, but MCs did not induce T cell proliferation (data not shown). 
These results were further reflected in the cytokine production of responding T cells; 
MAR-1+ cDC2 DCs had the tendency to induce stronger IFNγ and Granzyme B 
production than MAR-1- cDC2 DCs, although to a lesser extent than cDC1 DCs (Fig 6B). 
In contrast to an enhanced presentation to OT-I CD8+ T cells, the capacity of cDC2s to 
present antigen to CD4+ OT-II cells was diminished when they acquired the MAR-1+ 
state (Fig 6C). These results suggest that MAR-1+ cDC2s acquire an intermediate 
phenotype in which they can acquire cDC1 functions depending on the environmental 
milieu. 
Examination of expression of the T cell costimulatory molecules CD80 and CD86 at 
protein level by flow cytometry showed that all DC subsets were activated by IAV 
infection and moreover that MAR-1+ cDC2s are in a hyper activated state compared to 
classical MAR-1- cDC2s potentially explaining their enhanced ability to cross-present 
antigen to naïve OT-I cells (Fig 6C). In addition to the increased expression of 
maturation markers, a significant increase was observed in the proportion of MAR-1+ 
cDC2s producing IL-12 compared with MAR-1- cDC2s after 5 hours of ex vivo 
restimulation (Fig 6C).  
Other genes involved in presentation in the MHCI pathway such as Tapbpl were 
induced in MAR-1+ cDC2 after IAV, whereas this is a gene normally expressed higher in 
cDC1s (Fig 3E). To delineate the underlying signaling cascade responsible for this hyper 
mature state of MAR-1+ cDC2s we assessed the maturation state and IL-12 production 
capacity in Ifnar-/- and Irf8 x Cd11c Cre mice. This revealed that in addition to inducing 
MAR-1 expression on cDC2s, IFNAR signaling was also required to induce the hyper-
mature state of cDC2s, with MLN cDC2s from Ifnar-/- mice expressing less CD80, CD86 
and IL-12 compared with WT controls (Fig 6E). Similarly, the increased IRF8 expression 
observed on MAR-1+ cDC2s was also essential to induce this hyper mature state as this 
was not induced in MAR-1+ cDC2s from Irf8 x Cd11c Cre MLNs (Fig 6F).  
Thus taken together, these data demonstrate that type 1 IFN signaling during IAV 
infection leads to the generation of a MAR-1+ cDC2 which upregulates IRF8 causing 
them to be hyper-activated and acquiring an enhanced ability to induce CD8+ T cell 
proliferation rather than CD4+ T cell proliferation.  
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Figure  6
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Figure 6 - MAR-1+ cDC2s represent a hyper-activated cDC subset 
(A) Proliferation profile (left) and absolute number of T cells (right) following 4 days of coculture of CFSE-labeled OT-I T 
cells and DC subsets sorted from the MLN of WSN-OVA infected mice. (B) Representative flow cytometry plots showing 
IFNγ (upper row) and Granzyme B (lower row) expression by OT-I T cells following 4 days of coculture with DC subsets 
from MLN. Data are representative for 2 independent experiments with DC subsets sorted from 10-15 mice per group. 
Graphs with amount of cells show the individual replicates from 1 experiment. Data are analyzed by a One-way ANOVA 
and Tukey correction for multiple comparisons. (C) Percentage and absolute number of proliferating T cells following 5 
days of coculture of eFl450 proliferation dye labeled OT-I (left) or OT-II (right) cells and DC subsets sorted from the MLN of 
X31 infected mice together with 10ug/ml ovalbumin. Data are analyzed by a One-way ANOVA and Tukey correction for 
multiple comparisons. (D) Expression of CD80 and CD86 expressed as MFI on MHCIIhi DC subsets from the MLN and % of 
MHCII hi MLN DCs expressing IL-12 after 6h of restimulation in X31 virus infected mice compared with mock-infected 
controls at 4dpi. (E-F) Same analysis for Ifnar+/+ and Ifnar-/- (panel E) and Irf8 x Cd11c CreWT and CreTg mice (panel F). 
Data are representative for 2 independent experiments with 3-4 mice per group and are analyzed with a Two-way 
ANOVA with Sidak correction for multiple comparisons. * = p ≤ 0,05; ** ≤ 0,01; ns = not statistically significant.  
 
 
Discussion 
Previously published data about the division of labor between different DC subsets 
during IAV infection often led to results that are inconclusive and hard to compare. The 
variability between the used strains, the infectious dose, the route of administration and 
the timing of the read-outs is one major influencing factor. Next to this, the strategy to 
define the different DC subsets lacked consistency between different reports14, 21, 23, 24, 47. 
In addition, until recently no flow cytometry staining strategy was available to study the 
different subsets without contamination, as CD11b+ DCs were a mixture of conventional 
and monocyte-derived DCs due to the lack of good monocyte markers. Therefore, we 
applied a new gating strategy based on expression of MAR-1 and CD64 to define the 
monocyte-derived compartment of the CD11b+ gate (MC). MCs expanded during 
infection and became the majority of the pulmonary DC population 4dpi with IAV while 
they were absent in the MHCIIhi DCs in the MLN, suggesting that they do not migrate 
from the lung to the MLN. Remarkably, we also identified a CD11b+ DC with 
intermediate expression of CD64 and MAR-1 in mice infected with IAV and PVM. It has 
been shown that infection with Sendai virus also induces expression of MAR-1 on lung 
DCs, and MAR-1 was proposed by these authors to stain specifically the alpha chain of  
the FcεRI receptor47. In our hands however, MAR-1 staining was also observed on  
lung MCs and cDC2s of FcerI-/- mice. Which protein is causing the cross-reaction with 
the MAR-1 antibody on DCs and MCs is a matter of intense study in our lab. 
Transfer of pre-cDCs and monocytes pointed out that MAR-1+ CD64int DCs represented 
bona fide cDCs as they developed from pre-cDCs but not monocytes and they shared 
the expression pattern of CD26 with MAR-1- cDC2 DCs, while lacking expression of 
MerTk found on macrophages and MCs. Despite the fact that MAR-1+ DCs were 
pre-cDC derived, they were partially CCR2 dependent. Together with the description of 
a conventional DC in the gut that is partially CCR2 dependent30 this shows that caution 
should be taken when Ccr2:Wt mixed chimeras are used to define the monocyte origin 
of a cell population. MAR-1+ cDC2s expressed Sirpα on their surface, but no XCR1 just 
like MAR-1- cDC2s. MAR-1+ cDC2s can thus be seen as a special activation status of the 
cDC2 population.  
The induction of MAR-1 is dependent on IFNAR signaling since no MAR-1+ population 
could be detected within the cDC2 gate in Ifnar-/- mice, as was previously reported by 
others as well47. Analysis of the gene expression data obtained by micro-array pointed 
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out that a strong type I IFN signature was induced upon IAV infection in the 3 different 
DC subsets. It is however not clear which cell type is the source of the IFN as many cells 
can produce it. Given the anatomical structure of the lung environment, epithelial cells 
are one of the first targets of IAV infection48. In vitro infection of murine tracheal 
epithelial cells leads to induction of IFNβ, α4 and α5, but not other subtypes, rendering 
epithelial cells ideal candidate sources of type I IFN that on its turn can induce MAR-1 
upregulation on cDC2s49. But amongst many other cell types, DCs can also produce 
type I IFNs themselves. In the blood of infected people, DCs appeared to be the 
highest producers of IFN50. Although it was previously thought that pDCs are responsible 
for much of the type I IFN production51, more recent studies showed that cDCs also 
produce considerable amounts of type I IFNs52, 53. As we were limited to the use of full 
Ifnar deficient mice and could not deplete Ifnar in specific cell types, it remains to be 
elucidated if IFNAR signaling induces MAR-1 on cDC2s in a direct or indirect manner. In 
cDCs, type I IFN production after viral infection seems to occur in two distinct waves. 
The first wave is driven directly by viral recognition acting on TLR3, TLR7 or RIG-I like 
receptors. The second wave is driven by a feedback mechanism whereby type I IFN 
signaling induces IRF8, which subsequently further boosts type I IFN production54. 
Gene expression profiling suggested that transcription factor IRF8 was a possible 
upstream regulator of the differentially expressed genes when comparing mock cDC2s 
and IAV cDC2s. Furthermore, IRF8 got upregulated in cDC2s and acquired an 
expression pattern shared with cDC1s whereas in mock conditions IRF8 is specific for 
cDC1s. IRF4 and IRF8 are structurally very similar and therefore can compete for binding 
the same gene elements55. Potentially the ratio of IRF4 and IRF8 expression can 
determine a switch in cell development or differentiation. This concept of IRF4 and IRF8 
being the driving forces behind the switch of phenotypes has been described before in 
other cell types. IRF4 is involved in the polarization of macrophages towards a M2 rather 
than a M1 phenotype56, 57 and IRF4 is essential for the acquisition of Th1, Th2, Th9, Th17, 
Tfh and Treg phenotypes15-20, 58. In this process of polarization, IRF4 and IRF8 can also 
have counteracting functions. For example IRF4 regulates Rorγt, thereby promoting 
Th17 cell differentiation11, 12 whereas IRF8 silences the Th17 differentiation by interfering 
with Rorγt and repression of IL-17 associated genes13. In B cell development expression 
of IRF8 and IRF4 mutually counteracts each other59. IRF4 and IRF8 expression is also 
involved in the cDC1-cDC2 lineage decision during DC development. IRF8 is expressed 
already in the common DC progenitor60 whereas IRF4 expression only comes up in the 
pre-cDC stage and cDC2s only develop when IRF4 expression is induced. The final 
numbers of cDC2s and cDC1s most likely depend on the levels of IRF4 and IRF8 in the 
tissues1.  
In this paper, we describe that the expression of IRF4 and IRF8 are not limited to 
respectively cDC2s and cDC1s. We observed that IRF8 could be acquired by cDC2s in 
an inflammatory situation. This observation questions on its turn the dogma that different 
DC subsets are specialized in particular functions. According to this dogma, cDC1s are 
specialized in induction of CTLs, whereas cDC2s are specialized in induction of CD4 Th 
cells61, 62. We showed that by the acquisition of IRF8 a functional module leading to 
enhanced CD8+ T cell stimulation and proliferation was induced in cDC2s. This 
enhanced MHCI-dependent antigen presentation capacity was induced by an 
*	  
	   87 
induction of the maturation status of the MAR-1+ cDC2 as these DCs expressed higher 
levels of the activation markers CD80 and CD86 on their surface, and by acquisition of 
processing machinery necessary for MHCI presentation. Recently it was already argued 
that cDC2s are capable to induce CD8+ T cell responses on the condition that they are 
provided with a strong TLR7 signal26. Our micro-array data indicated that Tlr7 is 
upregulated in cDC2s upon IAV infection, which can equip the cDC2s with a more 
MHCI prone machinery. Furthermore they have an enhanced capacity to produce 
IL-12 upon ex vivo restimulation. These changes in activity status are induced in a 
DC-intrinsic IRF8-dependent manner. Type I IFN signaling and IRF8 expression in cDC1s 
licenses them to produce IL-12 and thereby promote Th1 immune responses63-68 while 
IRF4 can inhibit IL-12 production and skew the responses towards a Th2 profile69-72. Based 
on these data, it was somewhat surprising that we observed a decreased ability to 
present antigen to OT-II CD4+ T cells in vitro and to induce Th cell proliferation whereas 
the ability to present antigen to OT-I CD8+ T cells and to induce CTL proliferation was 
enhanced. Nevertheless, IL-12 has also been described to contribute to the proliferation 
and IFNγ production of cytotoxic T cells during influenza infection, but not their cytolytic 
activity73, 74 and for memory CTL induction75 which supports our observations in the in 
vitro cocultures. Recently it was shown that IRF4 is superior to IRF8 in providing DCs with 
the machinery to process antigen and present it in a MHCII-dependent manner to 
initiate T helper cell responses2. Given the capacity of IRF4 and IRF8 to bind the same 
gene elements, it can be hypothesized that the induction of IRF8 in cDC2s results in a 
competition with IRF4 for their binding partners resulting in less IRF4 able to activate the 
genes driving MHCII antigen presentation and thereby favoring IRF8 to activate the 
genes necessary for CTL induction.  
All together, we have shown that during IAV infection cDC2s evolve towards a hybrid 
DC type that combines the capacity of cDC1s for CTL induction with the capacity of 
MCs for inducing an antiviral response. This shows the extraordinary flexibility of cDC2s, 
and their potential to react to environmental cues like type I interferons, and exploiting 
a gene module that is mainly used for development and function of cDC1s. It is possible 
that this flexibility is required during later phases of infection, when cDC1s tend to be 
depleted by IAV infection. Future studies will have to unravel the precise genes bound 
by IRF8 in cDC1s and activated cDC2s, to understand the full functional implications of 
our observations. We finally want to caution against the use of IRF8 as a universal 
lineage defining transcription factor for cDC1s that could be used to knock out this 
lineage. Our data clearly show that genetic deficiency of IRF8 selectively in DCs will 
greatly impact also on cDC2 function. 
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Materials and methods 
 
Ethics statement 
All experiments were approved by the independent animal ethical committee 
“Ethische Commissie Dierproeven – faculteit Geneeskunde en Gezondheids-
wetenschappen Universiteit Gent” (identification number: ECD 14/49). Animal care and 
used protocols adhere to the Belgian Royal Degree of May 29th 2013 for protection of 
experimental animals which incorporates European guideline 2010/63/EU.  
 
Mice 
C57Bl/6 mice (6-10w) were purchased from Harlan Laboratories. CD45.1/2, OT-I Tg, OT-II 
Tg, FcεRI-/- and IRF8fl/fl x CD11c Cre mice were bred and housed in specific pathogen-
free conditions at the animal facility of Ghent University. Ifnar-/- mice were kindly 
donated by Prof. Claude Libert. 
 
Influenza virus infection 
Mice were infected intranasally with 105 TCID50 H3N2 X31 influenza A virus, 103 TCID50 
WSN influenza A virus encoding the OVA257-264 Kb restricted MHC I epitope in the 
neuraminidase gene (Topham et al. J Immunol 2001 - Doherty) or mock virus (allantoic 
fluid of uninfected eggs); all diluted in 50µl PBS. Weight loss was monitored daily. 
- 
PVM virus infection 
Mice were infected intratracheally with 35pfu PVM virus (J3666) diluted in 80µl PBS. 
Weight loss was monitored daily. 
 
Isolation of lung and MLN cells 
Mice were sacrificed and the MLN and lung were isolated and mechanically cut. Single 
cell suspensions were prepared by digestion in collagenase/DNase (Roche) solution; 
lungs were digested for 30 minutes at 37°C, MLNs were digested 15 minutes at 37°C. 
After digestion, the suspension was filtered over an 100µm filter and red blood cells in 
the lung suspension were lysed with osmotic lysis buffer.  
 
Flow cytometry and cell sorting 
Staining of DC subsets was done by staining with MAR-1 (conjugated to biotin, 
eBioscience) combined with streptavidin (conjugated to PE-CF594, BD biosciences), 
CD3 (conjugated to PE-Cy5, eBioscience), CD19 (conjugated to PE-Cy5, eBioscience), 
CD11c (conjugated to PE-Cy7, eBioscience), MHC II (conjugated to APC-Cy7, 
Biolegend), CD103 (conjugated to PE, BD biosciences or Pacific Blue, Biolegend), 
CD11b (conjugated to BV605 or Horizon V450, BD biosciences), CD64 (conjugated to 
AF647 or PE, BD biosciences), CD24 (conjugated to eFl450, eBioscience) and a fixable 
live/dead marker in eFl506 (eBioscience). Following additional markers were used: XCR1 
(conjugated to PE, Biolegend), Sirpa (conjugated to PerCp-eFl710, eBioscience), CD26 
(conjugated to Fitc, BD biosciences), MerTk (Unlabeled, R&D systems) combined with a 
donkey-anti-goat (conjugated to AF647, Invitrogen), CCR2 (conjugated to PE, R&D 
systems), CD45.1 (conjugated to BV605, Biolegend ), CD45.2 (conjugated to AF700, 
eBioscience), IRF4 (Unlabeled, Santa Cruz) combined with an donkey-anti-goat 
(conjugated to AF647, Invitrogen), IRF8 (conjugated to PerCp-Efl710, eBioscience), 
CD40 (conjugated to PE, BD biosciences), CD80 (conjugated to PerCp-Cy5.5, BD 
biosciences ), CD86 (conjugated to PE-Cy7, Biolegend).  
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Acquisition of 12-color samples was performed on a Fortessa cytometer equipped with 
FACSDiva software (BD98 biosciences). Final analysis and graphical output were 
performed using FlowJo software (Tree Star, Inc.). 
For sorting of DC subsets, cells were stained as described and cell sorting was 
performed on a FACSAria II (BD biosciences).  
 
Pre-cDC transfer 
To expand pre-cDCs, CD45.2 wildtype mice were injected every other day with 10µg 
Flt3L (PSF, VIB). Mice were killed 8 days after the first treatment and bone marrow was 
isolated. Red blood cells were lysed by osmotic lysis buffer. Cells were labeled with 
eFl450 cell proliferation dye (eBioscience) and pre-cDCs were sorted as CD45+, Lin- 
(CD3, CD19, MHC II, CD49b, CD11b, B220), CD11cint, Sirpaint. 8x105 cells were injected 
i.v. into CD45.1/2 wildtype mice 1dpi. Lung and MLN cells were analyzed 4 days later 
(5dpi).  
 
Monocyte transfer 
Bone marrow cells were isolated from CD45.1/2 wildtype mice. Red blood cells were 
lysed by using osmotic lysis buffer. Cells were labeled with eFl450 cell proliferation dye 
(eBioscience) and monocytes were sorted as Lin- (CD3, CD19, MHC II, Siglec F, Ly6G), 
CD11c-, c-kit-, CD11bhi and Ly6Chi. 8x105 cells were injected i.v. into CD45.2 CCR2-/- mice 
1dpi. Lung and MLN cells were analyzed 4 days later (5dpi).  
 
Micro-array  
10 000 cells of each of the DC subsets were isolated from the lung and MLN 4dpi as 
described above. RNA was obtained with an RNEasy Plus Micro Kit according to the 
manufacturer's instructions (Qiagen) and RNA integrity was assessed with a Bioanalyser 
2100 (Agilent). With a WT Expression Kit (Ambion) 50ng of total RNA per sample 'spiked' 
with bacterial poly(A) RNA positive control (Affymetrix) was converted to double-
stranded cDNA in a reverse-transcription reaction. Samples were fragmented and 
labeled with biotin in a terminal labeling reaction according to the Affymetrix WT 
Terminal Labeling Kit. A mixture of fragmented biotinylated cDNA and hybridization 
controls (Affymetrix) was hybridized on a GeneChip Mouse Gene 1.0 ST Array 
(Affymetrix), followed by staining and washing in a GeneChip fluidics station 450 
according to the manufacturer's procedures (Affymetrix). For analysis of raw probe 
signal intensities, chips were scanned with a GeneChip scanner 3000 (Affymetrix). 
Samples were subsequently analyzed with software of the R project for statistical 
computing (Bioconductor). All samples passed quality control, and the robust 
multiarray average procedure was used for normalization of data within arrays (probe-
set summarization, background correction and log2 transformation) and between 
arrays (quantile normalization). In a subsequent step, probe sets that either mapped to 
multiple genes or had low variance were filtered out. The final analysis of the obtained 
data was performed by using Ingenuity Pathway Analysis (IPA, Qiagen).  
 
DC–OT-I T cell coculture 
Mice were infected with WSN influenza virus encoding the OVA257-264 Kb restricted MHC I 
epitope in neuraminidase. OT-1 transgenic T cells were isolated from spleens and LN of 
OT-1 transgenic mice, enriched by MACS purification with a CD8 T cell isolation kit 
according to the manufacturer’s protocol (Miltenyi Biotec) and labeled with CFSE 
(Invitrogen). 10 000 sorted DCs were co-cultured with T cells in a 1:10 DC:T cell ratio for 4 
days. T cells were restimulated for 5h with a cell stimulation cocktail containing PMA, 
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ionomycin, Brefeldin A and monensin (eBioscience). T cell divisions and cytokine 
production were measured by flow cytometry.  
 
DC–OT-II T cell coculture 
Mice were infected with the X31 influenza virus. OT-II transgenic T cells were isolated 
from spleens and LN of OT-II transgenic mice, enriched by MACS purification with a CD4 
T cell isolation kit according to the manufacturer’s protocol (Miltenyi Biotec) and naive 
T cells were isolated by FACS purification. The cells were labeled with cell proliferation 
dye eFl450 (eBioscience). 5 000 sorted DCs were co-cultured with T cells in a 1:10 DC:T 
cell ratio for 5 days in the presence of 10ug/ml ovalbumine (endograde, Hyglos). T cells 
were restimulated for 5h with a cell stimulation cocktail containing PMA, ionomycin, 
Brefeldin A and monensin (eBioscience). T cell divisions and cytokine production were 
measured by flow cytometry.  
 
Statistical analysis 
All experiments were performed using 3-6 animals per group. All experiments were 
performed at least two to three times. Statistical analysis was performed with Prism 
version 6 (GraphPad Software, Inc.). Data are depicted as mean +/- SEM. Differences 
were considered significant when p<0,05. * = p ≤ 0,05; ** ≤ 0,01; ns = not statistically 
significant.     
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Supplementary material 
 
 
Figure S1  
Flow cytometry plots illustrating the gating strategy to FACS purify pre-cDCs and monocytes (upper row) 
and the purity after the sort (lower row). 
 
 
 
Figure S2 
(A) CD45.1/2 wildtype recipient mice were irradiated and reconstituted with mixed CD45.1 WT and CD45.2 
CCR2-/- bone marrow in a 50:50 ratio. 3 months after irradiation, the proportion of DC subsets from wildtype 
and CCR2-/- origin were defined. Graphs show the ratio of wildtype over CCR2-/- origin of DC subsets 4dpi in 
lung (left) and MLN (right). (B) CCR2 expression on lung DC subsets in mock (upper row) or X31 virus (lower 
row) infected animals at 4dpi. (C) CCR2 expression on MHCIIhi DC subsets in the MLN of mock (upper row) 
or X31 virus (lower row) infected animals at 4dpi.  
For irradiation experiments 9 mice were irradiated in two independent rounds and analyzed in 3 different 
independent experiments (and also 10 for mock infection, but not shown).  
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Figure S3 
(A) Heat maps showing the relative expression of the top 30 downregulated (left) and upregulated (right) 
genes in lung DC subsets after mock and IAV infection. (B) IPA analysis for the potential canonical 
pathways driving the genes that are upregulated upon IAV infection in cDC2 DCs that are shared with 
cDC1s. (C) Same analysis for genes shared with MCs.  
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Figure S3 
(E) IPA analysis for the possible upstream genes regulating the differential gene expression between mock 
cDC2s and MAR-1+ cDC2s. (F) Possible hierarchical clustering of the proposed upstream regulators of the 
differential gene expression between mock cDC2s and MAR-1+ cDC2s. 
 
E
F
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Figure S4 
(A) Representative flow cytometry plots showing DC subsets in the lung (left) and MLN (right) of wild-type 
and FcεRI-/- mice at 4dpi with IAV and distribution of DC subsets as percentage of live DCs in the lung and 
MLN in WT and FcεRI-/- mice 4dpi with IAV. The size of the pie is proportional to the total amount of DCs. (B) 
Absolute number of each DC subset in the lung and MLN of WT and FcεRI-/- mice at 4dpi with IAV. Data are 
representative for 2 independent experiments with 4-6 mice per group.  
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Abstract 
Immunity to Influenza A virus (IAV) is controlled by conventional TCRαβ+ CD4+ and CD8+ 
T lymphocytes that mediate protection or cause immunopathology. Here, we 
addressed the kinetics, differentiation and antigen specificity of CD4-CD8- double 
negative (DN)T cells. DN T cells expressed intermediate levels of TCR/CD3 and could be 
further divided in γδ T cells, CD1d-reactive type I NKT cells, NK1.1+ NKT-like cells and 
NK1.1- DN T cells. NK1.1- DN T cells had a separate antigen specific repertoire in the 
steady-state lung, and expanded rapidly in response to IAV infection, irrespectively of 
the severity of infection. Up to 10% of DN T cells reacted to viral nucleoprotein. 
Reinfection experiments with heterosubtypic IAV revealed that viral replication was a 
major trigger for recruitment. Unlike conventional T cells, the NK1.1- DN T cells were in a 
preactivated state, expressing memory markers CD44, CD11a, CD103 and the 
cytotoxic effector molecule FasL. DN T cells resided in the lung parenchyma, protected 
from intravascular labeling with CD45 antibody. The recruitment and maintenance of 
CCR2+ CCR5+ CXCR3+ NK1.1- DN T cells depended on CD11chi dendritic cells. 
Functionally, DN T cells controlled the lung DC subset balance, suggesting they might 
act as immunoregulatory cells. In conclusion, we identify activation of resident memory 
NK1.1- DN T cells as an integral component of the mucosal immune response to IAV 
infection.  
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Introduction 
Mucosal tissues such as the lung are frequently exposed to pathogens that can cause 
life threatening pulmonary infections. These infectious agents like influenza virus (IAV) 
must be quickly and efficiently controlled by the immune system, without causing overt 
damage to the gas exchange apparatus of the lung1. Upon IAV infection, CD103+ and 
CD11b+ dendritic cells (DCs) take up and process viral particles and migrate to the 
mediastinal lymph node where they encounter naïve CD4+ and CD8+ T cells2. These T 
cells undergo a stepwise process of activation, proliferation and differentiation towards 
a helper or cytotoxic phenotype respectively, and migrate back to the lung as effector 
cells in a process requiring the chemokine receptors CCR2, CCR5 and CXCR33, 4. CD8 
effector T cells are crucial for viral clearance, but their effector functions need tight 
regulation since they can also cause immunopathology and damage to the lung 
microenvironment5,6. CD4 T cells promote CD8 T cell and B cell responses to IAV 
infection although they are not critical for this process7-10. Adoptive transfer studies 
demonstrated that CD4 T cells are also able to control viral load and exert direct 
cytotoxic effector functions in the lung environment11, 12, yet the contribution of CD4 T 
cell cytotoxicity to viral clearance in vivo in the lungs is modest13.  
As acute infections are cleared, effector CD8+ T cells further differentiate into 
KLRG-1hiCD127lo short-lived effector cells and CD127hi memory precursor effector cells 
capable of generating long-lived memory CD8+ T cells, and a similar process occurs in 
CD4 T cells14, 15. Long lived memory cells can recirculate via lymphoid organs as T 
central memory cells (Tcm), patrol in and out peripheral tissues as T effector memory 
(Tem) cells or reside for prolonged periods in the lungs as T resident memory cells (Trm), 
that express high levels of CD69, CD11a and/or CD10315. Triggered by retained antigen 
presented by DCs, CD4 Trm and CD8 Trm cells were shown to reside for months in the 
lungs of IAV-infected mice and -infected volunteers, thus providing immunity against 
reinfection with the same or heterologous strain of influenza15-22. 
Non-conventional T cells that express a functional T cell receptor (TCR) but lack 
expression of CD4 and CD8 co-receptors (therefore called double negative (DN) T 
cells), can be observed in various disease models in human and mice in which they 
were attributed different functions23. The lungs are one of the many tissues where DN T 
cells were described in steady state and following insults to the lung24-30. As DN T cells 
are defined by exclusion, they are very heterogeneous, arising either from the thymus or 
extrathymically. Classical DN T cells express intermediate levels of αβTCR, and are 
different from type I CD1d-restricted invariant natural killer T cells and γδTCR+ T cells that 
are often found to lack CD4 and CD8 expression, and therefore fall under the DN T 
definition31, 32.  
The involvement of the different DN T cells in IAV infection is currently unknown. We 
therefore carefully addressed the phenotype, origin, antigen specificity and TCR 
repertoire, kinetics of recruitment and activation, and acquisition of effector and 
memory markers of αβTCR+ DN T cells and conventional T cells during and following 
infection with the H3N2 X31 influenza A virus (IAV) strain, or reinfection with the 
heterosubtypic H1N1 PR8 IAV strain. We observed a predominant accumulation of 
NK1.1- αβTCR+ DN T cells in the lung after primary influenza infection, but not after 
heterosubtypic infection and these cells had characteristics of Trm cells situated in the 
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lung interstitium. The induction and maintenance of the NK1.1- DN T cell response was 
dependent on lung DCs that caused DN T accumulation through recruitment. 
Functionally these cells may act as immunoregulatory cells by controlling the lung DC 
subset balance.   
 
Results 
Influenza infection induces accumulation of unconventional CD4-CD8- double negative 
T cells in the lung 
Studies on T cell responses to airway infection with influenza A virus (IAV; H3N2, strain 
X31) have mainly focused on MHCI-restricted CD8+ and MHCII-restricted CD4+ 
conventional T cells, which can be easily identified within the αβTCR+ CD3+ cell 
population of a lymphocyte gate (FSClo SSClo) on dispersed lung cells (Fig 1A;A and B 
respectively). Within these αβTCR+ lymphocytes, a CD4-CD8- double negative (DN) 
population can be consistently observed. As this population of DN T cells is defined 
mainly by exclusion of CD4 and CD8 expression, we sought to further define it using 
multi-color flow cytometry26. A significant proportion of CD3+ DN T cells expressed a γδ 
TCR receptor (Fig 1A; population C), consistent with the notion that pulmonary γδ T cells 
often lack expression of CD4 and CD8. Another well-known population of 
unconventional T cells are NKT cells, sharing some phenotypic markers with NK cells 
(NK1.1 expression in C57Bl/6 mice), variably expressing CD4 depending on tissue 
residence, and many of which can be identified by staining with α-galactosylceramide 
(α-GalCer) loaded CD1d tetramers (TM). Based on CD1d TM binding and NK1.1 
expression, lung DN T cells could be further classified as DN type I NKT cells (Fig 1A; 
population D). After gating out γδ T cells and type I NKT cells, the remaining lung DN T 
cells could be further divided into NK1.1- CD1d TM- αβTCR+ DN T cells (Fig 1A; population 
E) and NK1.1+ CD1d TM- αβTCR+ DN T cells (Fig 1A; population F). Whether NK1.1 
expression represents an activation state of some lymphocytes or a truly different cell 
population of DN NKT-like cells remains a matter of debate33, 34. Up to 15% of NK1.1- 
CD1d TM- αβTCR+ DN T expressed B220, a marker previously found on peripheral DN T 
cells (data not shown). All DN T cells, including the NK1.1- CD1d TM- αβTCR+ DN T cells 
expressed intermediate TCR levels compared with conventional CD4+ or CD8+ T cells, a 
finding previously also reported for other DN T cells (Fig 1A, histograms)24. We next 
analyzed the relative distribution and kinetics of accumulation of all DN T subsets 
following IAV or mock infection. Both in mock and IAV infected mice, CD4+ and CD8+ 
conventional T cells represented the majority of T cells in the lung 9 days post infection 
(dpi), unconventional T cells each representing less than 2.5% of T cells (Fig 1B). When 
absolute numbers of DN T cells were studied over time (Fig 1C), only the population of 
NK1.1- CD1d TM- αβTCR+ DN T cells expanded significantly following infection, in a kinetic 
that closely resembled the expansion of CD4 and CD8 conventional T cells (Fig 1E). The 
more than 20 fold expansion of NK1.1- αβTCR+ DN T cells at the peak of the response 
(8dpi) was followed by a steep contraction phase also seen in conventional T cells. 
Since the NK1.1- CD1d TM- αβTCR+ population is the only one that is induced after 
infection, this is the population that was studied in further detail and will be called 
NK1.1- DN T cells throughout the paper. 
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Figure 1 - αβ TCRint double negative T cells accumulate in the lungs of influenza virus infected mice 
(A) Gating strategy used to subdivide the T cell populations into conventional CD4+ (population A) and CD8+ 
(population B) T cells and non-conventional T cells: γδ TCR+ DN T cells (population C),   αβ TCR+ CD1d TM+ DN T cells (type I 
NKT, population D), αβ TCR+ CD1d TM- NK1.1- DN T cells (population E) and αβ TCR+ CD1d TM- NK1.1+ DN T cells (population 
F). As an example, plots were generated 9dpi. Histograms show αβ TCR expression intensity on lymphocyte subsets: CD4+ 
T cells (black), CD8+ T cells (black dashed line) and the total CD4-CD8- T cells population (red) on the upper panel, type I 
NKT (black dashed line), NK1.1- DN T cells (gray filled line) and NK1.1+ DN T cells (black) (B) Distribution of conventional 
and non-conventional T lymphocyte subsets in the lungs 9dpi after X31 (black) or mock (white) virus infection, expressed 
as % of total CD3+ alive T cells. (C) Kinetics of accumulation of non-conventional T cells in the lungs of X31 (black) or 
mock (white) virus infected mice. (D) Kinetics of accumulation of conventional CD4+ (squares) and CD8+ (dots) T cells in 
the lungs of X31 (black) or mock (white) virus infected mice. (E) CD4 and CD8 expression profile of αβ TCR+ T cells (left) 
and γδ TCR+ T cells (right) in the lungs of athymic nude mice (lower row) compared to 1 wild-type mouse (upper row) at 
2dpi and absolute cell number of conventional and non-conventional T cells. Cells were pregated as singlets, alive, 
CD19- and CD3+. All experiments were performed at least twice and figures are representative for each separate 
experiment. 
 
Origin of lung DN T cells  
We next addressed the origin of the DN T cells of the lungs, which can develop like 
classical T cells in the thymus or outside of the thymus. DN T cells of the gut have indeed 
been described in thymectomized mice, but the origin of lung DN T cells is less clear35-37. 
We therefore infected athymic nude-Foxn1nu mice and defined T cell subsets 2dpi. 
Some remaining αβ and γδ T cells could be observed, and there was a shift towards 
more CD8+ γδ  T cells in athymic nude-Foxn1nu mice, consistent with the notion that 
many γδ T cells develop extrathymically. Some lung CD4+ and CD8+ αβTCR+ T cells were 
still present, indicative of extrathymic development (Fig 1D). Unexpectedly, lung DN T 
cells were almost completely lacking in Foxn1nu mice. These observations point towards 
a thymic origin of the type I NKT, NK1.1- and NK1.1+ DN T cell populations during IAV 
infection. 
 
NK1.1- DN T cells resemble CD8+ T cells 
As DN T cells are defined by lack of CD4 and CD8, and as the kinetics of accumulation, 
and the thymic origin closely resembled those of conventional T cells, we questioned 
whether some of the DN T cells represent revertant conventional T cells, losing surface 
expression of CD4 and/or CD8 after ligation of the TCR, as previously described38. NK1.1- 
DN T cells and conventional T cells were therefore sorted from lungs 9dpi. T cell lineage 
determination is molecularly controlled by the balance between Thpok (promoting 
CD4 T cell differentiation) and Runx3 (promoting CD8+ T cell differentiation) transcription 
factors39. Like CD8+ conventional T cells, NK1.1- DN T cells had low expression of the CD4 
lineage transcription factor Thpok by qPCR and were negative for the transcription 
factor Rorγt that is typical for Th17 and some subsets of γδ T cells (data not shown). 
Expression of the CD8 lineage transcription factor Runx3 was lower in NK1.1- DN T cells 
than in conventional CD8+ T cells but higher than in CD4+ T cells. Although the ratio of 
Runx3 over Thpok suggests that NK1.1- DN T cells are transcriptionally more related to 
CD8+ T cells than to CD4+ T cells (Fig 2A), these results do not show a clear bias towards 
CD4 or CD8 lineage imprinting for the entire NK1.1- DN T cell population. Intracellular 
staining for CD8 and CD4 revealed that 10% of the NK1.1- DN T cells had 
intracytoplasmic CD8 (but not CD4) expression (Fig S1) to the same extent as 
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conventional CD8+ T cells, indicating that at least part of the DN T cells might indeed be 
revertant CD8+ T cells. 
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Figure 2  - NK1.1- DN T cells are transcriptionally related to CD8+ T cells, yet have a different T cell repertoire 
(A) Quantification of the expression level of Runx3 (CD8 lineage) and Thpok (CD4 lineage) by Q-PCR on sorted CD4, 
CD8 and NK1.1- DN T cells from the lungs of X31 virus infected mice 8dpi. Expression levels were normalized to expression 
of the housekeeping gene hprt. B) NP tetramer staining (Kb-ASNENMETM) of CD8 and NK1.1- DN T cells on lungs of X31 
infected mice 8dpi and kinetic of TM+ T cells expressed as percentage of CD4 (dots), CD8 (squares) or αβ TCR+ CD1d TM- 
NK1.1- DN T cells (triangles). (C) Screening of the T cell receptor Vβ repertoire of CD4, CD8 and NK1.1- DN T cells in the 
pooled lungs of 6 mock (white bars) and 6 X31 (black bars, TM+ cells: gray bars) infected mice 8dpi expressed as % of 
CD4, CD8 or NK1.1- DN T cells. (D) Quantification of granzyme B (left) and perforin (right) expression on CD4, CD8 and 
NK1.1- DN T cells in the lungs of X31 (black line) or mock-infected (grey line) mice 4dpi (upper panel) and 9dpi (lower 
panel). The FMO staining for granzyme and perforin is indicated as a filled gray line (E) Quantification of FasL expression 
on CD4, CD8 and NK1.1- DN T cells in the lungs of X31 (black) or mock-infected (white) mice 9dpi. (F) Quantification of 
IFNγ  production by CD4, CD8 and NK1.1- DN T cells in the lungs of X31 (black) or mock-infected (white) mice. Lung cells 
were isolated 9dpi and restimulated for 4 hours with NPASNENMETM peptide in the presence of Golgi Stop before staining for 
IFNγ. (G) Expression of exhaustion marker PD-1 was determined on CD4+ and CD8+ T cells and NK1.1- DN T cells 9 days 
after mock (white) or X31 (black) infection. All experiments were performed at least two times and figures are 
representative for every separate experiment. ** = p < 0,01, * = p < 0,05, ns = not statistically significant different. 
 
TCR repertoire of NK1.1- DN T cells  
Following influenza infection, conventional CD8+ T cells react to a restricted set of 
immunodominant epitopes derived from various antigens, and these CD8+ T cells 
undergo oligoclonal expansion. Indeed, at 8dpi, close to 40% of the lung conventional 
CD8+ T cells had a receptor specific for the IAV nucleoprotein (NP) peptide 
ASNENMETM, as revealed by TM staining using the Kb-ASNENMETM tetramer (Fig 2B). 
A considerable proportion of NK1.1- DN T cells also stained for this tetramer, but at the 
peak of the response, this fraction represented only 10% of DN T cells followed by a slow 
contraction phase (Fig 2B).  
To further delineate if there would be oligoclonal expansion of DN T cells resembling the 
one seen in CD8+ T cells, we performed a more elaborate profiling of TCR Vβ usage at T 
cell population level in subsets of lung T cells (Fig 2C). In mock-infected animals, Vβ 
usage was broad across conventional  
CD4+ and CD8+ T cells, whereas in NK1.1- DN T cells, there was an overrepresentation of 
Vβ 8.1/8.2 cells to 14% of the repertoire. As previously reported, the entire influenza 
specific CD8+ T cell pool has a TCR Vβ repertoire skewed towards TCR Vβ8.3, Vβ4 and 
Vβ740 and type I NKT express an oligoclonal TCR repertoire (Vα 14)41, 42 combined with 
one of three Vβ chains (Vβ2, Vβ7, Vβ8.2). Whereas in CD8+ T cells there was enrichment 
for Vβ7 and Vβ8.3 in the total pool of CD8+ T cells following influenza infection, there was 
no further enrichment in NK1.1- DN T cells post infection and TCR Vβ8.1/8.2 and 5.1/5.2 
remained the most prominently expressed TCR Vβ in the total NK1.1- DN T population. In 
NPASNENMETM-reactive CD8+ T cells, there was strong enrichment for Vβ4 and Vβ8.3 usage, 
and the same phenomenon was seen in NPASNENMETM-reactive NK1.1- DN T cells. 
 
Effector functions of NK1.1- DN T cells  
As at least some NK1.1- DN T cells were transcriptionally related to CD8+ T cells and 
shared NP-reactivity with CD8+ T cells, we measured some of the effector molecules 
involved in CD8 function. An increase in Granzyme B content of CD4+, CD8+ and NK1.1- 
DN T cells was observed in reaction to IAV infection already 4dpi, compared with 
mock-infected mice. The difference in mean fluorescence intensity (MFI) between 
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mock and virus infected mice was 441, 648 and 773 for CD4+, CD8+ and NK1.1- DN T 
cells respectively (Fig 2D). At 9dpi however, the Granzyme B content was further 
increased in all cell types. Conventional CD8+ T cells showed the largest increase in 
Granzyme B content with a difference in MFI of 5018 compared to mock-infected mice, 
whereas the difference in MFI for CD4+ T cells and NK1.1- DN T cells was 1631 and 2242 
respectively (Fig 2D). Perforin expression did not change dramatically upon virus 
infection compared to mock infected mice (Fig 2D).  
Conventional CD8+ T cell mediated cell killing is not only induced via release of 
intracellular Granzyme B, it can also be mediated via surface expression of FasL 
(CD95L). In mock-infected animals, NK1.1- DN T cells expressed the highest level of FasL, 
followed by CD8+ conventional T cells that expressed significantly more FasL than CD4+ 
T cells. After IAV infection FasL was upregulated further, but only in CD4 T cells this 
reached statistical significance (Fig 2E).  
Conventional cytotoxic T cells are a major source of IFNγ during infection. The IFNγ 
production was indeed increased in CD8+ T cells after IAV infection. In NK1.1- DN T cells 
however the capacity to produce IFNγ was reduced upon IAV infection (Fig 2F). This 
suppression of cytokine production might indicate that the NK1.1- DN T cells have an 
exhausted phenotype after IAV infection. One of the signs of T cell exhaustion is 
expression of the co-inhibitory B7 family receptor PD-1 on the cell surface. Upon IAV 
infection, PD-1 was expressed on about 60% of CD4 T cells and 70% of CD8+ T cells. In 
contrast, the percentage of PD-1 expression on NK1.1- DN T cells was low (20%) and did 
not increase upon infection (Fig 2G). Therefore NK1.1- DN T cells are unlikely to become 
exhausted upon IAV infection.   
 
Lung NK1.1- DN T cells display an activated phenotype of resident memory T cells 
The high levels of surface FasL and intermediate levels of intracellular IFNγ present 
already in mock-infected mice suggested that lung NK1.1- DN T cells might be in a 
pre-activated state prior to infection. To address this issue further, we employed a panel 
of T cell activation markers. In mock-infected animals, up to 20% of lung conventional T 
cells expressed the memory/effector T cell marker CD44, whereas close to 80% of NK1.1- 
DN T cells expressed CD44 (Fig 3A). At 4dpi, CD44 expression was further induced on 
CD8+ T cells, and by 9dpi, when the virus was cleared, 60-80% of conventional T cells 
expressed CD44 (Fig 3B). Expression of CD44 on NK1.1- DN T cells remained high at 9dpi. 
The early activation marker CD69 was induced on all studied T cells after IAV infection; 
25% of NK1.1- DN T cells expressed CD69, whereas only 15% of CD4+ T cells and 5% of 
CD8+ T cells expressed CD69 at 4dpi (Fig 3C). Even at 9dpi, the levels of CD69 were still 
elevated on all subsets (Fig 3D). During the clearance of respiratory virus infection, 
conventional effector T cells can give rise to different cell fates, either giving rise to 
immediate and short lived effector cells, or to effector cells with the potential to 
generate long lived memory cells43. The phenotype and fate of CD44hi effector T cells 
can be studied in more detail by using the markers KLRG1 and CD12714 (Fig 3E). Within 
the CD8+CD44+ effector memory population (population A), short-lived effector cells 
(SLEC) are enriched in the KLRG1+CD127- cells (population D), whereas memory  
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Figure 3 - NK1.1- double negative T cells display a pre-activated memory phenotype and expand as 
KLRG1- CD127- cells  
(A) Mice were infected with X31 (black) or mock (white) virus, at 4dpi the expression of the memory marker CD44 was 
measured in conventional and NK1.1- DN T cells, gated as in Fig1. (B) Identical analysis at 9dpi. (C) Identical analysis for 
CD69 at 4dpi. (D) Identical analysis for CD69 at 9dpi. (E) Gating strategy for studying the phenotype of memory T cells. T 
cells were gated as CD3+ CD19- αβ TCR+ cells. Memory T cells were gated as CD44+ (population A), naïve cells were 
gated as CD44- (population B). On memory cells, KLRG1-CD127- cells were effector cells (population C, Teff), 
KLRG1+CD127- cells were identified as short-lived effector memory cells (population D, SLEC), and KLRG1-CD127+ cells are 
memory precursor effector cells (population E, MPEC). (F) Distribution of the memory populations (MPEC: black, SLEC: 
dark grey and KLRG1-CD127- cells: light grey) of CD4, CD8 and NK1.1- DN T cells the lungs of X31 or mock-infected mice 
9dpi expressed as percentage of CD44+ cells. All experiments were performed at least twice and figures are 
representative for every separate experiment. ** = p < 0,01, * = p < 0,05, ns = not statistically significant different. 
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precursor effector cells (MPEC) are enriched in the KLRG1-CD127+ population of cells 
(population E) (Fig 3E). Whereas this staining has mainly been employed to follow the 
fate of CD8+ T cells, we also employed it to CD4+ and NK1.1- DN T cells (Fig 3E). In 
mock-infected cells, very few NK1.1- DN T cells expressed KLRG1 indicative of 
immediate effector potential, whereas a major population of CD127+ memory cells was 
observed. Viral infection mainly led to expansion of KLRG1-CD127- early effector cells 
(population C; Fig 3E), of which the ultimate fate is hard to predict.  
Memory cells can reside in the central lymphoid organs (as T central memory cells, Tcm) 
and recirculate via the blood to other lymphoid tissues.  Alternatively, a considerable 
part of antiviral memory T cells reside in peripheral tissues as T resident memory (Trm) 
cells44. Trm cells have been identified by expression of various markers including CD69, 
CD103 and CD11a15, 44. In the lung, Trm cells are hard to discriminate from recirculating 
blood Tcm or naïve T cells that firmly adhere to lung capillaries, even after extensive 
flushing of the lung capillary bed. To delineate intravascular DN T cells and 
conventional T cells simultaneously, we injected an AF700-labeled antibody to the pan 
leukocyte marker CD45 intravenously, and obtained blood and lung homogenates 
5 minutes after injection. Using this labeling protocol, 100% of circulating peripheral 
blood CD3+ T cells was readily labeled with AF700-CD45 (Fig 4A). In mock-infected cells 
(Fig 4B), the majority of lung CD4 and CD8+ T cells were labeled with CD45, 
demonstrating that most lung lymphocytes were still in the lung vascular pool, even 
after extensive exsanguination and flushing. The majority of lung NK1.1- DN T cells were 
protected from CD45 in vivo labeling already in mock-infected mice (Fig 4B), identifying 
these cells as tissue resident cells. At 9dpi, up to 90% of lung conventional CD4+ and 
CD8+ T cells were protected from CD45 labeling and these cells also expressed CD69 
(data not shown), as previously described3, 15. Tissue resident lymphocytes express 
various levels of CD11a and/or CD1033, 15. Like CD4 and CD8 Trm cells, 10-15% of CD45- 
NK1.1- DN T cells co-expressed CD11a and CD103 and around 60-70% expressed CD11a 
but not CD103 (Fig 4C).  
 
Reinfection with homologous or heterologous virus does not trigger NK1.1- DN T 
accumulation  
Primary infection with IAV led to induction of an immune response of antigen-specific 
conventional T cells and NK1.1- DN T cells, which acquired Tem and Trm memory 
characteristics, and conventional T cells have been shown to control heterosubtypic 
immunity to re-exposure with a heterologous virus45. We therefore set up primary 
infections using X31 (H3N2) followed by reinfection with the same X31 or the PR8 (H1N1) 
virus to test the reactivity of DN T cells to reinfection with the same or heterologous virus. 
X31 usually causes a mild and self-limiting viral infection, whereas PR8 leads to 
progressive infection that ultimately leads to death. We therefore used a much lower 
inoculum of PR8 virus to reinfect (5 TCID50 compared with 1x105 TCID50 for the X31 virus). 
In the mice that first received a mock infection, comparisons between X31 and PR8 
primary infection were possible. Due to the low inoculum, PR8 infection initially led to 
less weight loss compared with the higher inoculum of X31, but nevertheless caused 
more weight loss when infection advanced to 8dpi. The amount of NK1.1- DN T cells  
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Figure 4 - NK1.1- DN T cells are protected from intravenous CD45 staining and have a Trm phenotype 
(A) In vivo labeling of circulatory T cells by intravenous injection of an AF700 labeled antibody against CD45 or PBS 6dpi 
combined with an in vitro staining of surface CD3 on blood and lung cells. Gated on living CD3+ αβ TCR+ cells. (B) 
Proportion of protected CD45- cells (white boxes) and intravascular CD45+ cells (black boxes) within conventional CD4+ 
or CD8+ T cells and NK1.1- DN T cells. (C) CD11a and CD103 expression on CD45+ blood cells (upper panel), intravascular 
CD45+ lung cells (middle panel) and protected CD45- lung cells (lower panel). Cells were gated as in Fig1, but images 
were acquired from mechanically dispersed lung cells, after performing bronchoalveolar lavage. All experiments were 
performed twice and figures are representative for every separate experiment. 	  
*	  
	  112 
obtained after infection with the X31 virus at 8dpi was not significantly different from the  
amount obtained after infection with the PR8 (H1N1) virus, despite the observed 
difference in weight loss at 8dpi (Fig 5A and B, mock-X31 versus mock-PR8). As 
expected, when mice were first infected with X31, re-infection with X31 did not cause 
weight loss, as replication and infection was prevented due to antibody-mediated 
sterilizing immunity. There was however an increased accumulation of CD8+ and CD4+ 
conventional T cells, whereas NK1.1- DN T cells failed to expand (X31-X31 versus 
X31-mock). Boosting of cellular immunity was most likely due to enhanced presentation 
of opsonized viral antigens, as antibodies to H3 and N2 are induced in these mice. 
Upon reinfection with the heterologous PR8 virus, heterosubtypic CD8+ T cell-mediated 
immunity has been described to protect mice from becoming sick46 and consequently 
mice did not loose weight (X31-PR8 versus mock-PR8). In these mice, there was no 
boosting of conventional CD4+, CD8+ nor NK1.1- DN T cells. When we studied NP-specific 
T cells, re-infection of mice led to strong increases in NP-specific CD8+ conventional T 
cells in mice reinfected with X31 and PR8, but no such increase was seen in NK1.1- DN T 
cells (Fig 5C). Together, these observations suggested that viral replication and/or a 
strong inflammatory signal is needed to induce NK1.1- DN T cells. In contrast to 
conventional CD8+ T cells, NK1.1- DN T cells did not mount a recall response upon the 
mere presentation of viral antigens. 
 
Induction and maintenance of the NK1.1- DN T response depends on chemokine 
production by conventional DCs  
The increased numbers of NK1.1- DN T cells in the lungs of primary infected, but not 
reinfected, mice could be due to increased local proliferation or local recruitment of T 
cells with Tem or Trm phenotype. To address this, we injected BrdU and measured 
instantaneous cell division by measuring BrdU uptake in conventional and DN T cells 
3,5h later. Whereas 14 and 24% of conventional CD4+ and CD8+ T cells respectively 
were dividing within the 3,5h pulse-chase experiment at 6dpi, only a minority of NK1.1- 
DN T cells incorporated BrdU (Fig 6A), indicating that local proliferation is unlikely to be 
the explanation for the increase in NK1.1- DN T cell numbers. We next infected mice 
and measured the amount of NK1.1- DN T cells per 100µl of whole blood every other 
day following infection. A drop early after infection followed by an increase suggested 
that increased recruitment from the bloodstream is causing the increase in pulmonary 
NK1.1- DN T cells (Fig 6B) after infection.   
As previously reported, administration of DT efficiently depleted all hematopoietic 
CD11c+ cells from the lungs (Fig S2)48. DT was administered either 1 day prior to 
infection, 7dpi or at both time points and numbers of conventional CD4+ and CD8+ T 
cells, as well as NK1.1- DN T cells were analyzed 2 days after the last treatment (9dpi). As 
shown in Fig 6C, the accumulation of cytotoxic CD8+ T cells was strongly reduced in 
infected DT treated mice, when treatment was given before or after primary infection. 
Likewise, the accumulation of NK1.1- DN T cells was strongly reduced in animals given 
DT early and late in infection. However, CD4+ T cells were not reduced by DT treatment 
early in infection, and only minor reductions of CD4+ T cells were seen when DT was 
given late in infection.   
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Figure 5 - Viral replication triggers accumulation of  NK1.1- double negative T cells irrespective of severity of 
infection  
(A) Weight loss after second infection expressed as % of initial weight: Mock (dots), X31 (squares) and PR8 (triangles) after 
mock (white) or X31 (black) infection. (B) Quantification of conventional and NK1.1- DN T cells after primo infection or 
reinfection with the same or with a heterologous virus, carrying shared nucleoprotein T cell antigens, yet lacking 
overlapping hemagglutinin and neuraminidase to which neutralizing antibodies are generated. Mice were first infected 
with mock or X31 (H3N2) virus and reinfected with mock, X31 (H3N2) or PR8 (H1N1) virus 30dpi. Lungs were analyzed 38 
days after initial infection. (C) Proportion of TM+ conventional CD8+ T cells and NK1.1- DN T cells 38dpi. All experiments 
were performed at least two times and figures are representative for every separate experiment. ** = p < 0,01, * = p < 
0,05, ns = not statistically significant different. 
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Lung CD8+ T cells are recruited by DCs to the lung interstitium via production of CCL3, 
CCL4, CCL5 and CXCL10, acting on chemokine receptors CCR2, CCR5 and CXCR3. To 
investigate which DC-derived chemokines could signal to NK1.1- DN T cells to attract or 
maintain them in the lung, CD4+, CD8+ and NK1.1- DN T cells were sorted from the lung 
8dpi. Like conventional CD8+ T cells, NK1.1- DN T cells expressed CCR2, CCR5 and 
CXCR3, suggesting that DCs might induce recruitment and retention of these cells via 
these chemokine receptor interactions (Fig 6D).  
 
NK1.1- DN T cells balance the ratio of dendritic cell subsets 
We finally wanted to address the potential function of NK1.1- DN T cells recruited to the 
lungs by CD11chi cells. In transplantation and autoimmunity models it has been 
suggested that DN T cells have an immunoregulatory capacity by controlling DCs51, 
and the fact that CD11chi cells attracted these cells, led us to study the impact of 
NK1.1- DN T cells on DCs. We therefore performed an experiment in which we sorted 
lung DCs (carefully excluding CD11chi macrophages) and NK1.1- DN T cells from the 
lungs of infected mice at 9dpi and cocultured them for 36h. We observed that the 
presence of DN T cells stimulated the survival of lung DCs in culture, whereas in the 
absence of sorted DN T more apoptotic and dead cells were present in the culture 
(Fig 6E). CD11chi cells of the lungs can be divided in CD103+ cDC1, CD11b+ cDC2 and 
CD64+ monocyte derived cells. Within the total population of CD11chi lung cells, only 
CD11b+ DCs and monocyte-derived cells had a survival benefit. 
 
 
Discussion 
Prior to the discovery of NKT cells, CD4-CD8- double negative T cells were found as a 
major fraction of lung lymphocytes, expressing an intermediate level of TCR, and 
representing up to 20-60% of all lung CD3+ cells52. However, since NKT cell and γδ TCR 
specific antibodies have been used in combination with the αGalCer CD1d tetramer in 
multi-color flow cytometry, the frequency of classical TCRint DN T cells was found to be 
much lower, in the range of 1-2% of lung CD3+ T lymphocytes28, 32. We found that the 
only population of DN T cells that accumulated following IAV infection with X31 or PR8 
infection was characterized by intermediate expression of αβTCR, yet lacking expression 
of NK1.1. Analysis of αGalCer CD1d tetramers showed that these cells were not type I 
NKT cells. A minor contamination of NKT-like cells or type II NKT cells in the CD1d 
TM-NK1.1- DN T cell gate cannot be excluded since those cells can also lose expression 
of NK1.153, 54. 
The precise origin of these cells has been unclear, but it has been suggested that they 
originate from the thymus by escaping negative selection55, 56. The fact that the 
numbers of TCRint DN T cell are unaffected in the lungs of athymic nude mice, led to the 
suggestion that these cells might also arise extrathymically, very similar to the 
intraepithelial lymphocytes of the lamina propria of the gut27, 28. However, in our hands 
the number of DN T cells in the lungs was severely reduced in athymic mice. This 
suggests that NK1.1- DN T cells develop via the thymus. In the context of immune  
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Figure 6 - NK1.1- DN T cells are recruited from the blood in a DC-dependent manner and control the DC 
subset balance 
(A) BrdU expression on conventional CD4 and CD8+ T cells and NK1.1- DN T cells 3,5h after i.v. injection of BrdU (black) or 
PBS (white). (B) Kinetics of conventional CD4 (squares) and CD8 (circles) T cells and NK1.1- DN T cells (triangles) per 100ul 
blood after X31 infection. (C) CD11c DTR chimeric mice were injected with PBS or DT 1 day before infection with X31 virus 
or 7 dpi. CD4, CD8 and NK1.1- DN T cells in the lungs were quantified 9dpi. (D) Q-PCR analysis of the chemokine receptor 
repertoire of sorted CD4 (white bars), CD8 (black bars) and NK1.1- DN T (grey bars) cells from the lungs of mice infected 
with X31 8dpi; expression levels were normalized for expression of the housekeeping gene hprt. (E) Proportion of alive, 
apoptotic (Annexin V+) and dead (7AAD+) pulmonary DCs in culture after 36h of coculture with (black) or without 
(white) sorted DN T cells. (F) Proportion of the alive pulmonary DC subsets in culture after 36h of coculture with (black) or 
without (white) DN T cells. All experiments were performed two times and figures are representative for every separate 
experiment. ** = p < 0,01, * = p < 0,05, ns = not statistically significant different 
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activation, some T cells might downregulate TCR expression after cognate ligand-MHC  
recognition and downregulate CD8 membrane expression, which could also lead to a 
very similar phenotype of TCRint DN T cells38. Intracytoplasmic staining for CD4 and CD8 
did however not reveal evidence for selective downregulation of membrane CD4 
expression and only a small fraction of NK1.1- DN T cells showed intracellular CD8 
expression. The Vβ repertoire of the NK1.1- NKT cells was distinct from the Vβ repertoire of 
CD4+ and CD8+ T cells. Furthermore, the Vβ repertoire was not skewed towards a 
NKT57, 58 or MAIT cell58, 59 usage. However, staining with a Kb-NP tetramer did reveal some 
MHCI-restricted antigen-specificity shared with conventional CD8 cytotoxic T cells. 
Lineage specific transcription factor analysis also demonstrated that a part of the 
NK1.1- DN T cells were more related to CD8 than to CD4 T cells. Together, these data 
suggest that some 10% of NK1.1- DN T cells represent antigen specific CD8+ T cells that 
have lost surface expression of CD8, while maintaining it in the cytoplasm. Studies in 
human systemic lupus erythematosus patients have shown that DN T cells can originate 
from CD8+ T cells by upregulation of the CREMα transcription factor that in turn represses 
expression of the CD8A and CD8B gene60, 61. As we found residual cytoplasmic 
expression of CD8 in 10% of DN T cells, this is an unlikely scenario. One clear difference 
between lung CD8+ and NK1.1- DN T cells was the steady-state activation state in the 
lung. Indeed, the majority of lung NK1.1+ DN T cells were CD44hi, whereas a majority of 
CD8+ T cells was CD44neg in the mock-infected lung. Studying lymphocytes in the lung is 
not straightforward, as the lung is a highly vascularized organ and houses a major 
reservoir of recirculating naïve or Tcm lymphocytes in the lung capillaries. These 
lymphocytes cannot always be removed by flushing the lung vasculature with PBS via 
the pulmonary artery. One way of reliably studying conventional Trm cells is to in vivo 
label these cells by intravenous injection of antibodies to CD4 or to CD8, labeling 
mainly the intravascular pool of lymphocytes, followed by ex vivo staining for other 
surface markers, labeling all lymphocytes3, 62. Due to their tissue residence around large 
airways, Trm cells are protected from labeling by i.v. injected antibody. These studies 
have been performed using antibodies to CD4 or CD8, but these antibodies were not 
useful for identifying DN T cells in vivo. To delineate intravascular DN T cells and 
conventional T cells simultaneously, we developed an in vivo labeling method 
employing the pan leukocyte marker CD45, effectively labeling 100% of circulating 
peripheral blood CD3+ T cells and a majority of lung CD4 and CD8+ T lymphocytes, 
demonstrating that most of the lung conventional lymphocytes in the resting lung are in 
the lung vascular pool, even after extensive exsanguination and flushing. Only after IAV 
infection, 90% of lung conventional CD4 and CD8+ T cells were protected from in vivo 
CD45 labeling and these cells also variably expressed CD69, CD11a and CD103, as 
previously described for Trm cells and thus validating the use of CD45 labeling3, 15. On the 
contrary, the majority of lung NK1.1- DN T cells were already protected from CD45 in 
vivo labeling in the steady-state mock-infected lung, and expressed high levels of 
CD11a identifying these cells as Trm cells. This is also the reason why the levels of CD44 
were so different between CD8+ and NK1.1- DN T cells, as they were representing the 
differences between naïve and memory cells respectively. The activated phenotype 
was previously also reported in human patients with cutaneous leishmaniasis63 and 
tuberculosis64. The memory profile of NK1.1- DN T cells argues against a MAIT cell 
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phenotype or contamination since MAIT cell are reported to have a mostly naïve 
phenotype in mice65 and MAIT cell activation is not observed in in vitro viral infection 
models66. 
Heterosubtypic immunity to different strains of IAV that differ in hemagglutinin and 
neuraminidase is poorly understood but very desirable if we are to develop a universal 
IAV vaccine. It is generally believed to be mediated by T lymphocytes that reside in the 
lung as Trm cells, a phenotype also seen in NK1.1- DN T cells prior to and following 
infection. One striking finding in our study however was that reinfection with 
heterosubtypic virus did not lead to expansion of lung NK1.1- DN T cells, despite the fact 
that these cells expressed a phenotype of CD44hi, CD11ahi Trm cells, and some had 
specificity for viral nucleoprotein. A lack of further expansion upon reinfection with 
heterologous virus does not prove that these cells play no role in mediating 
heterosubtypic immunity. A study using depleting antibodies is however very difficult to 
design as NK1.1- DN T cells are defined by lack of expression of markers. We initially set 
up experiments in athymic nude mice so that we could use depleting anti-CD3 
antibodies to deplete DN T cells. Unfortunately however, lung DN T cells were already 
depleted in athymic mice. 
Previous studies on the function of DN T cells in lung immunity have led to conflicting 
results, possibly due to differences in models used. In a passive transfer model of DN T 
cells to immunodeficient mice, there was no protection offered against respiratory 
infection with Rhodococcus equi67. However, in a model of Francisella tularensis 
respiratory infection, DN T cells were found to be a prominent source of IFNγ and IL-17 
early, but not late after infection30. In our hands NK1.1- DN T cells made IFNγ but no IL-17 
after restimulation with NPASNENMETM peptide (data not shown) and IFNγ was 
downregulated by IAV infection. We have purified NK1.1- DN T cells and adoptively 
transferred them to other mice in an attempt to study the function of these cells that 
were recruited to the lungs after IAV infection (data not shown). Unfortunately, the 
numbers of cells were too low to perform conclusive adoptive transfer studies. We can 
therefore only speculate on the potential role of NK1.1- DN T cells in IAV, guided by 
experiments from the past.  
An important consideration is that NK1.1- DN T cells might have immunoregulatory 
capacity as they closely resemble the DN Tregs that control allograft rejection by 
specifically killing Ag specific effector T cells with the same specificity or by killing DCs in 
a FasL dependent manner51, 68. One striking observation was that 20% of the lung NK1.1- 
DN T cells expressed high levels of FasL in steady state lung. However, when we cultured 
lung NK1.1- DN T cells together with lung DCs, we found that the presence of DN T cells 
did not kill DCs, but rather led to a higher percentage of DCs in the culture, mainly 
attributable to an increased survival of CD11b+ cDC2 DCs and monocyte derived cells, 
while CD24+ cDC1 DCs were not affected by the presence or absence of DN T cells. 
Thus, interaction of DN T cells with certain DC subsets turns them less sensitive to 
apoptosis. As DN T cells were previously described to interact with other cell types such 
as CD8 and CD4 T cells, B cells, macrophages and NK cells69, it remains an interesting 
topic to study the interaction of DN T cells with several types of immune cells and to 
determine if they can exert different functions depending on the cell type they interact 
with.  
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In human studies, DN T cells are often reported to be correlated with progression or 
severity of disease. DN T cells decrease upon HIV disease progression70 and are inversely 
correlated with disease activity in rheumatoid arthritis71. In contrast, DN T cells are 
increased during severe M. tuberculosis infection compared to non-severe 
M. tuberculosis infections64 and during active Sjögren’s syndrome72 in which the level of 
DN T cells correlates with the degree of tissue inflammation73. Although the fact that DN 
T cells contract quickly after viral clearance (8dpi) and thus correlate with the kinetic of 
disease, we could not confirm a relationship with severity of infection since there was 
no significant difference between the amounts of DN T cells after X31 or PR8 infection, 
that cause different degrees of weight loss. Future experiments will have to address 
whether this subset of lung DN T cells has an influence on pulmonary immunity and 
regulates the severity of immunopathology to variants of IAV. 
In conclusion, we have carefully characterized a subset of NK1.1- DN T cells that resides 
as a preactivated Trm-like cell in the lung parenchyma, protected from i.v. labeling. This 
population rapidly expands in response to IAV infection in a process requiring CD11chi 
DCs, and has the capacity to balance the ratio of DC subsets. Future studies, in which 
these cells might be depleted selectively using genetic tools will have to address 
whether these cells are beneficial or harmful to the outcome of IAV infection. 
 
 
Materials and methods 
Mice 
C57Bl/6 and athymic nude-Foxn1nu mice (8-10w) were purchased from Harlan 
Laboratories. CD11c-DTR Tg (H2-Db) mice were bred and housed in specific pathogen-
free conditions. All experiments were performed on 4-6 mice per group, unless 
mentioned otherwise. 
 
Ethics statement 
All experiments were approved by the independent animal ethics committees 
“Ethische Commissie Dierproeven – faculteit Geneeskunde en Gezondheids-
wetenschappen Universiteit Gent” (identification number: ECD 13/05) and “Ethische 
Commissie Proefdieren – faculteit Wetenschappen Universiteit Gent en VIB-site 
Ardoyen” (identification number: EC 2013_002). Animal care and used protocols 
adhere to the Belgian Royal Degree of May 29th 2013 for protection of experimental 
animals. European guideline 2010/63/EU is incorporated in this Belgian legislation.  
 
Influenza virus infection 
Mice were infected intranasally with 105 TCID50 H3N2 X-31 influenza virus, 5 TCID50 H1N1 
PR8 influenza virus (Medical Research Council, Cambridge, England) or mock (allantoic 
fluid of uninfected eggs); all diluted in 50µl PBS. 
For reinfection experiments, mice were infected with 105 TCID50 X-31 or mock virus and 
were reinfected 30 days later with 3x105 TCID50 X-31, 5 TCID50 PR8 or mock virus diluted in 
50µl PBS. Weight loss was monitored daily. 
 
Isolation of lung cells 
Mice were sacrificed and bronchoalveolar lavage was performed by injecting 3 times 
1ml EDTA-containing PBS through a tracheal catheter before isolating the lungs. For 
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some experiments lungs were additionally flushed with 20ml PBS through the right heart 
ventricle before isolation. Single cell lung suspensions were prepared by digestion in 
collagenase/DNase solution for 30 minutes at 37°C. After digestion, the suspension was 
filtered over an 100µm filter and red blood cells were lysed with osmotic lysis buffer.  
 
Flow cytometry and cell sorting 
T cell staining was done by using CD3 (PE-Cy7 and eFl450, eBioscience; APC, BD 
biosciences), CD4 (conjugated to PE-TxR, Invitrogen; PE-Cy5 and FITC, eBioscience), 
CD8a (conjugated to efluor450 and PE-Cy7, eBioscience; PerCp, Biolegend; PE-Cy5, BD 
biosciences), CD19 (conjugated to APC, BD biosciences; AF700 and PE-Cy5, 
eBioscience), NK1.1 (conjugated to BV605, Biolegend; PE-Cy7, BD biosciences), CD1d 
tetramer (conjugated to PE and APC, NIH tetramer core facility), αβTCR (conjugated to 
APC-Cy7, Biolegend), γδTCR (conjugated to FITC, BD biosciences), NP tetramer 
(conjugated to PE, loaded with ASNENMETM peptide, Pelimer, Sanquin) and a fixable 
live/dead marker in eFl506 (eBioscience). Following additional extracellular markers 
were used: B220 (conjugated to PE, BD biosciences; AF700, eBioscience), CD44 
(conjugated to AF700, BD biosciences), CD127 (conjugated to PE-CF594, BD 
biosciences), KLRG1 (conjugated to APC, eBioscience), CD69 (conjugated to PerCp-
Cy5.5, BD biosciences), CD103 (conjugated to PE, eBioscience), FasL (conjugated to 
PE-Cy7, eBioscience), CD11c (conjugated to PE-TxR, Invitrogen), PD-1 (conjugated to 
PE-Cy7, Biolegend), annexin V (conjugated to PE, BD biosciences) and 7-AAD (BD 
biosciences). Granzyme B (conjugated to PE, Life Technologies Europe) and perforin 
(conjugated to APC, eBioscience) was stained intracellularly. The TCR repertoire was 
analyzed by using the mouse Vβ TCR screening panel (conjugated to FITC, BD 
biosciences) staining Vβ 2, 3, 4, 5.1 + 5.2, 6, 7, 8.1 + 8.2, 8.3, 9, 10b, 11, 12, 13, 14 and 17a.  
DC subsets were defined by using CD3 (conjugated to PE-Cy5, Tonbo Bioscience), 
CD19 (conjugated to PE-Cy5, eBioscience), CD11c (conjugated to PE-Cy7, 
eBioscience), MHCII (conjugated to APC-Cy7, Biolegend), CD11b (conjugated to 
BV605, BD bioscience), CD24 (conjugated to eFl450, eBioscience), FcεRI (conjugated to 
biotin, eBioscience) combined with SAV (conjugated to CF594, BD bioscience) and a 
fixable live/dead marker in eFl506 (eBioscience). 
Acquisition of 12-color samples was performed on a LSR II or Fortessa cytometer 
equipped with FACSDiva software (BD biosciences). Final analysis and graphical output 
were performed using FlowJo software (Tree Star, Inc.). 
For soring of T cells, cells were stained as described and cell sorting was performed on a 
FACSAria II (BD biosciences). The purity of sorted populations was >95%. 
 
Cytokine staining – in vitro restimulation 
Lung single cell suspensions were restimulated with NPASNENMETM peptide (10µg/ml, 
Anaspec) 5 hours at 37°C in the presence of Golgi stop (BD biosciences, 1/1500) at a 
concentration of 5x106 cells/ml. After restimulation, cells were washed and stained 
extracellular, washed with PBS and fixed with 2% PFA, permeabilized with 0,5% saponin 
and stained intracellularly for IFNγ (Conjugated to PerCp-Cy5.5, eBioscience). 
 
In vivo CD45 labeling 
3µg anti-CD45 antibody (AF700, eBioscience) was injected i.v. Mice were killed 5 
minutes later, blood was collected immediately before performing bronchoalveolar 
lavage. To remove blood from the capillary bed of the lungs, the lungs were flushed by 
injecting 20ml PBS through the right ventricle. To protect the in vivo CD45 staining, lungs 
were dispersed mechanically instead of enzymatically by smashing them through an 
40µm filter before lysis of red blood cells.  
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BrdU incorporation assay 
Mice were injected i.p. with 200µl of 10µg/ml BrdU (Sigma, 2µg total/mouse) 6dpi and 
were killed 3,5 hours after BrdU treatment. Lung cells were isolated as described above. 
Extracellular stained T cells were fixed and permeabilized by using the BrdU Flow Kit (BD 
biosciences) according to the manufacturer’s protocol in combination with an eFl450 
labeled anti-Brdu antibody (eBioscience).  
 
Depletion of CD11chi cells 
C57Bl/6 mice were irradiated sublethally (9Gy) and reconstituted with 2x10^6 bone 
marrow cells i.v. from CD11c DTR transgenic donor mice 4 hours after reconstitution. 
Mice were used for experiment at least 10 weeks after reconstitution. CD11c DTR 
chimeric mice were injected intraperitoneally with 200ng diphteria toxin (DT) diluted in 
200µl PBS or with PBS 24h before infection or 7 dpi. Lungs were analyzed 9 dpi. 
 
Real-time quantitative RT-PCR. 
Quantitative RT-PCR for Thpok, Runx3, Ccr1, Ccr2, Ccr3, Ccr4, Ccr5, Ccr7, Cxcr1, Cxcr2 
and Cxcr3 were performed on cDNA samples obtained from sorted lung T cell subsets. 
Total RNA was extracted using Tripure reagent (Roche) according to the 
manufacturer’s protocol. RNA was resuspended in Diethyl-polycarbonate (DEPC, 
Sigma) treated water. A total of 1µg RNA was used for reverse transcription using the 
Transcriptor High Fidelity Reverse Transcriptase kit (Roche) according to the 
manufacturer’s protocol.  
The subsequent target amplification on triplicates of each cDNA sample was 
performed using the Universal Probe Library system from Roche (that contains 
fluorescent hydrolysis probes of 8 loked nucleic acids (LNA). Primers were designed with 
the help of the web-based application Probefinder (https://qpcr.probefinder.com) and 
a minimum of 2 primer pairs per target were analyzed. Primers were validated first using 
the LC480 SybrGreenI Master (Roche) with melting curve analysis (TM calling) in the 
LC480 Software and then using the LC480 Probes Master. Aspecific primer pairs were 
discarded. Table 1 shows a comprehensive view of the primer/probe combinations 
chosen. PCR conditions were: 5’ pre-incubation at 95°C followed by 45 amplification 
cycles of 10” at 95°C, 10” at 60°C and 20” at 72°C using a Lighcycler 480 (Roche). PCR 
amplifications for the housekeeping genes encoding Hprt or L27 were performed during 
each run for each sample to allow normalization between samples.  
 
Pulmonary DC-DN T cocultures 
Pulmonary DCs were sorted from the lungs of IAV infected mice at 9dpi as lineage-, 
alive, CD11c+ MHCII+ cells. DN T cells were sorted from lungs of infected mice at 9dpi as 
previously described and cocultured with DCs in a 3,5:1 ratio in cell culture medium 
containing 10% FCS for 36 hours.  
 
Statistical analysis. 
All experiments were performed using 4-6 animals per group, unless mentioned 
otherwise. All experiments were performed at least two to three times. The difference 
between groups was calculated using the Mann-Whitney U test for unpaired data 
(Prism version 6; GraphPad Software, Inc.). Data are depicted as mean +/- SEM. 
Differences were considered significant when P<0,05. 
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Supplementary material 
 
 
Figure S1  
Intracellular expression of CD4 and CD8 in NK1.1- DN T cells, that stained negative for extracellular CD4 and CD8, 
compared with T cells that have expression of extracellular CD4 (left) and CD8 (right). DN T cells are represented as 
black dots, CD4+ and CD8+ T cells are represented as a grey contour plot.  
 
 
 
Figure S2  
Depletion check in CD11c DTR chimeric mice. Mice received PBS (left) or DT (right) i.t. and lung DCs were analyzed one 
day later. 
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Abstract 
Inducible Bronchus Associated Lymphoid Tissue (iBALT) is a long lasting tertiary lymphoid 
tissue that can be induced following influenza A virus (IAV) infection. Previous studies 
have shown that iBALT structures containing germinal center (GC) B cells protect 
against repeated infection by contributing locally to the cellular and humoral immune 
response. If we are to exploit this in vaccination strategies, we need a better 
understanding on how iBALT structures are induced. One hypothesis is that the strength 
of the initial innate response dictates induction of iBALT. In the present study, we 
investigated the role of IL-1 and IL-1R signaling on iBALT formation. 
Mice lacking the IL-1R, had a delayed viral clearance and thus a prolonged exposure 
to viral replication, leading to increased disease severity compared to wild type mice. 
Contradictorily, iBALT formation following clearance of the virus was heavily 
compromised in Il1r1-/- mice. Quantification of gene induction after IAV infection 
demonstrated induction of IL-1α and to a much lesser extent of IL-1β. Administration of 
recombinant IL-1α to the lungs of wild type mice early but not late after IAV infection, 
led to more pronounced iBALT formation and an increased amount of GC B cells in the 
lungs. Bone marrow chimeric mice identified the stromal compartment as the crucial 
IL-1 responsive cell for iBALT induction. Mechanistically, Q-PCR analysis of lung 
homogenates revealed a strongly diminished production of CXCL13, a B cell attracting 
chemokine, in Il1r-/- mice during the early innate phase of IAV infection.  
These experiments demonstrate that appropriate innate IL-1α  - IL-1R signaling is 
necessary for IAV clearance and at the same time instructs the formation of organized 
tertiary lymphoid tissues through induction of CXCL13 early after infection. These 
findings are discussed in the light of recent insights on the pathogenesis of TLO 
formation in the lung in various diseases where the IL-1 axis is hyperactive such as 
rheumatoid arthritis and COPD.  
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Introduction 
Influenza A virus (IAV) is a respiratory pathogen that causes seasonal or pandemic 
outbreaks with severe outcome in elderly and immune compromised patients. Epithelial 
cells are the first target cells for IAV infection1, 2 and also coordinate the innate immune 
defense to prevent spreading of the virus, via production of type I interferons (IFNs). 
Interleukin (IL)-1α and IL-1β are among the first cytokines that are secreted by epithelial 
cells and macrophages at sites of IAV replication3. Secretion of IL-1β requires activation 
of the Nlrp3 inflammasome that leads to activation of caspase-1 and cleavage of 
pro-IL-1β into IL-1β. Infection with IAV leads to activation of the Nlrp3 inflammasome in a 
process requiring the type I IFN induced RNAse L/OAS system, while the virus actively 
suppresses IL-1β production and Nlrp3 activation via the NS1 protein4-6. IL-1 induces the 
expression of endothelial adhesion molecules that promote the entry of innate 
inflammatory cells like neutrophils, NK cells, dendritic cells (DCs) and monocytes 
resulting in a double effect on the host. On the one hand it promotes survival by killing 
virus infected cells, clearing debris and alarming the adaptive immune response. On 
the other hand, overzealous neutrophil recruitment can also cause inflammatory 
pathology that can ultimately lead to diffuse alveolar damage and death6-10. Not 
surprisingly, the outcome of genetic deficiency of key components in IL-1 generation or 
signaling has been very different depending on the severity of the IAV infection2, 9, 11.  
Simultaneously with the activation of the innate immune response, adaptive immune 
responses are initiated in the draining lymph nodes by antigen presenting migratory 
DCs. The architecture of lymph nodes promotes contact between antigen presenting 
DCs and rare antigen-specific T cells and B cells of the adaptive immune system to 
maximize the immune response against a certain antigen. Antigen specific T 
lymphocytes undergo clonal proliferation upon encounter with antigen presented by 
antigen presenting cells and migrate back to the site of inflammation as T effector 
memory (TEM) cells or become central memory T cells (TCM) or T resident memory (TRM) 
cells12. Antibody production is initiated from B-lymphocytes that differentiate into 
plasmablasts immediately, or become plasma cells after going through a germinal 
center (GC) reaction that promotes somatic hypermutation and affinity maturation of B 
cells13.  
The coordinated events of T and B cell activation induced by virus-laden DCs mainly 
occur in secondary lymphoid organs (SLOs) like lymph nodes and spleen that develop 
during embryogenesis at predefined areas, often at the crossroads of lymphatic 
vessels14. However, highly organized structures of T and B cells can also be formed in the 
lung after birth as an adaptation to the increased demand for a localized immune 
response. Various names such as lymphoid tissue neogenesis, ectopic lymphoid tissue 
and tertiary lymphoid structures have been used to describe these structures. 
Furthermore they are often named after the anatomical region in which they occur. In 
the lungs for example, lymphoid aggregations can often be found in close proximity to 
bronchi, and hence these are called inducible bronchus associated lymphoid tissues 
(iBALT). As they resemble SLOs anatomically and functionally, yet only develop after 
birth as a result of chronic immune stimulation, they can also be called tertiary 
lymphoid organs (TLOs), even when found within the boundaries of another organ.  
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TLOs have been implicated in protection against IAV. Mice that lack secondary 
lymphoid organs can mount a rapid CD8 T cell response during IAV infection due to the 
induction iBALT15, induced after clearance of IAV infection. Such TLO structures are 
generally formed in close proximity to bronchi after IAV infection, but can also be 
observed in the lung interstitium and are fully formed 17dpi. iBALT structures that are 
induced in mice with functional lymph nodes can serve as an additional priming site for 
T cells16 and can also contribute to the humoral immune responses17. Once formed, 
iBALT structures can mount high affinity immune responses to other antigenic stimuli 
than the initiating stimulus due to the presence of germinal centers that allow somatic 
hypermutation and affinity maturation complementing the immune response in the 
draining lymph nodes16, 18. Furthermore, iBALT structures could be the perfect 
environment for depots of viral antigen that were described long after viral clearance 
and recovery from viral infection, and possibly related to the induction or maintenance 
of virus-specific TRM cells19, 20.  
 
Despite morphological and functional similarities between SLOs and TLOs, the pathways 
that control formation and maintenance of TLOs are less clear. Generally, the 
molecular pathway that organizes T and B cells in discrete areas resembles the highly 
regulated inductive pathway for SLO development. Production of CCL19, CCL21, 
CXCL12 and CXCL13 by stromal cells and B cells helps to organize and retain T and B 
cells in discrete areas21-26. Also IL-7 seems required for TLO formation, e.g. in joints of 
rheumatoid arthritis patients and mouse models27-30 and lungs of idiopathic pulmonary 
hypertension (IPAH) patients31. It is more controversial which cells give the initial 
instruction for stromal cells to produce these chemokines. During SLO development in 
the fetal period, this is the distinct task of lymphoid tissue inducer (LTi) cells, a cell type 
that develops from Flt3+ and Flt3- a4b7 integrin positive common progenitors that also 
forms innate lymphoid cells (ILC), and get expanded in response to Flt3L injections32, 33.  
During formation of the lymph nodes and spleen, LTi cells provide signals for lymphoid 
organogenesis like lymphotoxin-beta (LTβ) acting on the LTβR on stromal cells, but the 
precise signals might differ from organ to organ.  Flt3l-/- mice for example have reduced 
LTi cells and lack Peyer’s patches but still have lymph nodes33. However, research in 
Id2-/- and Rorc-/- mice, which lack LTi cells, showed that LTi cells were dispensable for the 
initial TLO induction after IAV infection or other forms of TLO induction 15, 34-37 38. Although 
LTi cells seem not strictly necessary for TLO induction, an instructive LTβ-LTβR signal 
remains essential for proper TLO development25, 39. B cells, T cells and DCs are heavily 
induced during inflammatory processes and all express LTα1β2 on their cell 
surface17, 35, 40, 41 therefore they are perfect candidates to function as a substitute for LTi 
cells.  
Whatever the precise molecular mechanisms of TLO induction might be, these TLO 
structures are virtually always seen at sites of inflammation. Yet, which inflammatory 
cytokines contribute to TLO induction is currently unknown. After many insults to the 
lung, including viral or bacterial infection, interleukin (IL)-1α and IL-1β are among the first 
cytokines to be secreted3. IL-1 secretion induces the expression of endothelial adhesion 
molecules that promote the entry of innate and adaptive immune cells, and could thus 
promote TLO formation. On the other hand, it is also known that IL-1R-/- mice have a 
*	  
	  130 
delayed viral clearance and thus a longer exposure to viral particles7. Chronic immune 
stimulation is often assumed to lead to TLO formation42. If IL-1 limits viral replication, it 
could reduce the trigger for TLO induction.  
In this paper we addressed the role of IL-1 and IL-1R in TLO formation in the lung.  We 
show that the iBALT-inducing events are initiated early after infection, long before the 
virus is cleared. More specifically we show that early IL-1R signaling is necessary for 
proper IAV-associated iBALT and germinal center (GC) induction and that prolonged 
viral presence does not automatically lead to iBALT induction. 
 
 
Results  
Il1r1-/- mice have prolonged viral load but are unable to induce iBALT  
To assess the immune response to IAV infection in mice lacking signaling via IL-1R, we 
infected Il1r1-/- mice and monitored weight loss and viral load in the lungs. Wild type 
mice showed maximum weight loss around 6dpi and bodyweight was fully restored 
around 10dpi. Il1r1-/- mice lost weight with slower and prolonged kinetics, and reaching 
a nadir at 8dpi. Like wild type mice they did manage to gain weight again, but did not 
recover to their starting bodyweight before 17dpi (Fig 1A). This difference in the weight 
loss curve was also reflected in the viral load in the lungs (Fig 1B). Viral load in wild type 
mice peaked around 6dpi yet was cleared at 8dpi. Il1r1-/- mice had systematically 
higher viral loads during the entire course of infection and did not clear the infection 
completely at 8dpi as an estimated remaining titer of 100 000 viral particles is detected 
at this time point. 
Viral clearance depends on induction of adaptive immunity by dendritic cells that 
activate CD8 and CD4 T cells and a humoral immune response by B cells. Total 
numbers and kinetics of increase of T and B cells and conventional dendritic cells (DCs) 
were not altered in Il1r1-/- mice in response to IAV infection. Lung conventional DCs 
consist of various subsets that have different functions and can be discriminated based 
on cell surface markers CD11b and CD10343, 44. As soon as there is inflammation in the 
lung, monocytes can also be recruited and these can rapidly differentiate into a 
MHCII+CD11c+ cell type (so called monocyte-derived cells, MC) that also expresses the 
macrophage marker CD6445. In contrast to the conventional CD103+ and CD11b+ DCs, 
the accumulation of CD11c+CD64+ MCs was reduced in the lungs of Il1r1-/- mice 
(Fig 1C). 
To evaluate the effect of the higher and prolonged viral exposure on IAV-associated 
iBALT formation, we visualized iBALT structures in the lungs by hematoxilin staining. 
Generally clusters of cells near the bronchi were more readily detected in wild type 
mice than in Il1r1-/- mice (Fig 1D). Because a hematoxilin stain did not allow us to 
evaluate if the inflammatory clusters of cells were organized and immunologically 
active iBALT structures, we stained frozen lung sections for B cells, T cells, DCs and GC B 
cells and analyzed them by confocal microscopy. In wild type mice we could easily 
detect organized structures composed of B cells, T cells and DCs and B cell aggregates 
that contain GC B cells, but we were unable to detect similar infiltrates in Il1r1-/- mice 
(Fig 1E). To quantify the presence or absence of iBALT structures we measured the 
proportion of GC B cells in the lungs at 17dpi by flow cytometry as a measure for 
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biologically active iBALT. As GL7+ GC B cells are not found in the lungs of mice in the 
absence of iBALT, we believe this is a good approximation of the amount of iBALT 
formed17. Wild type mice showed an induction of GC B cells upon IAV infection, but this 
induction was absent in Il1r1-/- mice (Fig 1F). Taken together, these data suggest that 
although Il1r1-/- mice had a higher and prolonged exposure to viral particles in the lung, 
they were unable to form organized iBALT structures in the lung, pointing to an essential 
role for IL-1 cytokines in TLO induction following influenza virus infection.  
 
Figure 1 - Il1r1-/- mice have a prolonged viral load in the lungs, but do not develop iBALT structures 
(A) Weight loss curve as percentage of the initial bodyweight for wild type (squares) and Il1r1-/- mice (circles) that have 
been infected with mock (white) or X31 (black) virus. (B) Viral titers in the lung of wild type (white) or Il1r1-/- (black) mice 
determined by hemagglutination assay after culture with MDCK cells. (C) Numbers of T and B cells, CD103+ cDC1 and 
CD11b+ cDC2 DCs and monocyte derived cells (MC) in the lungs of wild type (white) and Il1r1-/- mice (black). (D) 
Hematoxylin-stained lung sections 17dpi of wild type and Il1r1-/- mice. Images are representative for at least 3 mice per 
group. (E) Confocal images of lung sections of wild type and Il1r1-/- mice at 17dpi. Sections were stained with either B220 
(red), CD11c (Green), CD3 (Grey) and dapi (blue) or B220 (red), GL7 (Green) and dapi (Blue). Shown images are 
representative for 5 mice per group. (F) Proportion of germinal center B cells (GL7+) in the lungs of wild type and Il1r1-/- 
mice infected with mock (white) or X31 (black) virus at 17dpi determined by flow cytometry. All experiments were 
performed at least twice with 4-6 mice per group. * = p<0,05 
 
 
IL-1α administration promotes induction iBALT structures in the lung 
As the mere presence of viral particles was not enough to trigger the iBALT initiation and 
IL-1R signaling was necessary we quantified expression of IL-1α and IL-1β, which signal 
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both via IL-1R, in the lungs after IAV infection. Both cytokines were induced after 
infection in a bimodal curve with a first peak around 4dpi and a second, but smaller, 
peak around 10dpi (Fig 2A). In general, the induction of mRNA for IL-1α was more 
pronounced compared with IL-1β. 
We next addressed if administration of IL-1 cytokine would be enough to further boost 
iBALT induction in IAV infected mice. Since IL-1α and IL-1β have similar effects on the 
IL-1R, and as induction of IL-1α was more pronounced after IAV infection, we chose to 
only administer IL-1α. When recombinant IL-1α was administered i.t. 2 days post IAV 
infection in wild type mice, clustering of inflammatory cells could be detected more 
readily on lung sections compared to PBS treated IAV infected mice (Fig 2B). To 
quantify biologically active iBALT we again quantified the proportion of GC B cells by 
flow cytometry. Administration of recombinant IL-1α at 2dpi resulted in a higher 
proportion of GC B cells in the lungs 17dpi compared to PBS administration (Fig 2C). 
However, when the administration of recombinant IL-1α was only initiated at 10dpi, no 
differences in the proportion of GC B cells could be observed between IL-1α and PBS 
treated groups (Fig 2C). This suggests that early, but not late IL-1R signaling is necessary 
and sufficient to promote GC B cell positive iBALT structures.  
 
 
Figure 2 - Early IL-1α signaling is sufficient and necessary for iBALT induction 
(A) mRNA expression of IL-1α (white) and IL-1β (black) relative to the housekeeping gene L27 in the lungs of wild type 
mice. (B) Hematoxylin-stained lung sections 17dpi of mice treated with PBS or recIL-1α 2dpi. Images are representative 
for at least 3 mice per group. (C) Proportion of germinal center B cells 17dpi in the lungs of wild type mice treated with 
PBS (white) or recombinant IL-1α (black) i.t. 2 or 10dpi.  
All experiments were performed at least twice with 3-5 mice per group. ns = not significant, ** = p<0,01 
 
 
IL-1R signaling on stromal cells is necessary to induce GC B cells 
As early IL-1R signaling is necessary to induce iBALT structures in the lung, we sought to 
identify the cell type that is responsive to IL-1 signals. Therefore we constructed bone 
marrow chimeric mice in which either the radiosensitive hematopoietic or the 
radioresistant stromal compartment was deficient for Il1r1. As a control we also 
reconstituted Il1r1-/- mice with Il1r1-/- bone marrow as a substitute for intact Il1r1-/- mice 
and control for irradiation effects. Il1r1-/- mice that received wild type bone marrow 
followed a weight loss curve characterized by a longer weight loss and slower recovery, 
as observed in Il1r1-/- mice. In contrast, wild type mice that were reconstituted with 
Il1r1-/- bone marrow cells followed a weight loss curve that resembled the one observed 
in wild type mice with a maximum of approximately 15% weight loss. Surprisingly, Il1r1-/- 
mice that were reconstituted with IL-1R sufficient bone marrow had a tendency to lose 
more weight than the Il1r1-/- mice that were reconstituted with IL-1R-deficient bone 
marrow (Fig 3A). We also counted the proportion of GC B cells in the lung. Wild type 
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mice with IL-1R-deficient hematopoietic cells were able to induce a higher proportion 
of GC B cells than Il1r1-/- mice with normal hematopoietic cells, suggesting that IL-1 
boosts the formation of iBALT structures by signaling to radioresistant stromal cells.  
 
 
 
Figure 3 - IL-1R signaling on stromal cells is necessary to induce germinal center B cells in the lung  
(A) Weight loss curve after infection with X31 virus as percentage of the initial bodyweight for wild type (squares) and 
IL-1R-/- (circles) mice reconstituted with wild type (black) or IL-1R-/- bone marrow (white). (B) Proportion of germinal center 
B cells 17dpi in the lungs of wild type (squares) and IL-1R-/- (circles) mice reconstituted with wild type (black) or IL-1R-/- 
bone marrow (white). ns = not significant, * = p<0,05, ** = p<0,01 
 
 
CXCL13 expression is reduced in Il1r1-/- mice 
To define which downstream iBALT-instructive signals are induced by IL-1R signaling in 
radioresistant cells, we measured the expression level of the chemokines CXCL12, 
CXCL13, CCL19 and CCL21 which all have been implicated in iBALT formation. The 
chemokines CCL19 and CCL21 instruct the organization of T cell zones in iBALT 
structures, but were not impaired in Il1r1-/- mice (Fig 4A). The chemokine CXCL12 is 
important for B cell lymphopoiesis but expression of this chemokine was only slightly 
reduced early after infection in Il1r1-/- mice. The chemokine CXCL13 functions as an LTi 
and B cell chemoattractant and its expression was reduced 4dpi in Il1r1-/- mice (Fig 4A). 
None of the chemokines involved in iBALT formation and organization was differentially 
expressed at 17dpi, when iBALT had fully developed in wild type mice, showing that the 
instructive chemokine signals are given early after infection when the virus is not yet 
cleared from the lungs. Although CXCL13 expression was impaired early after infection, 
the total amount of B cells in the lungs was not significantly altered at the time iBALT 
was present (Fig 1C), suggesting that it is not recruitment of B cells to the lungs that is 
impaired in Il1r1-/- mice, but that the B cells in the lung fail to cluster into organized iBALT 
structures. Whether this is a direct or indirect effect of defective IL-1R signaling on 
stromal cells remains a subject for future experiments.  
 
 
Discussion and review of the literature 
The IL-1 axis has been described previously to be responsible for inflammatory 
pathology in the lung, resulting in increased mortality, increased viral titers and 
neutrophil recruitment following IAV infection7. Il1r1-/- mice indeed suffered more from 
the mild X31 IAV infection and displayed a tendency to higher viral titers in the lung, but 
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Figure 4 - Il1r1-/- mice have a defect in the production of the iBALT-inducing chemokine CXCL13  
(A) mRNA expression levels of the chemokines involved in iBALT induction: CXCL12, CXCL13, CCL19, CCL21 relative to the 
expression of housekeeping gene L27.  
The experiment was performed twice with 3-5 mice per group. ns = not significant, * = p<0,05.  
 
 
did manage to clear infection with delayed kinetics, leading to a presumably higher 
viral exposure over time. Despite this increased viral exposure, they hardly formed iBALT 
structures in the lung. Conversely, when recombinant IL-1 was administered early after 
IAV infection to wild type mice, the formation of iBALT structures was facilitated. 
Mechanistically, we found impaired CXCL13 chemokine induction early after infection 
in Il1r1-/- mice. Later, at the time when iBALT was fully formed in wild type mice, we 
could not detect any differences in CXCL13 levels, suggesting that the instructive 
signals that condition the lung for clustering adaptive immune cells are given very early 
(2-4dpi) after infection. By studying iBALT formation in chimeric mice, we found that 
IL-1R expression on stromal cells is necessary for proper iBALT formation. The exact cell 
type of stromal cells that is needed to induce GC B cells however still needs to be 
defined. Whether this stromal cell type is directly responsible for the CXCL13 production 
needed to initiate iBALT formation or an intermediate cell type is involved remains a 
matter of debate.  
As we observed a decreased induction in MCs and these cells are previously described 
as being major cytokine and chemokine producers45, it is a possibility that these cells 
are involved in the CXCL13 induction. Alternatively, LTβ-sufficient B cells can support the 
progression towards mature, fully structured TLOs35, 46 most likely via a positive feedback 
loop of CXCL13 production and LTβ expression24. According to this hypothesis B cells are 
activated via TLR signaling, induce expression of LTβ on their surface and interact on its 
turn with LTβR bearing B cells. This LTβ signaling will induce CXCL13 production and 
release, which attracts more B cells and upregulates LTβ expression. It is an attractive 
hypothesis that IL-1 might also induce LTβ expression on B cells, although this is hard to 
reconcile with our observation that a radioresistant cell type responds to IL-1 in our 
model. 
We can only speculate about the source of IL-1α. Previous research has shown that IL-1α 
can be released by dying cells47. In this respect virus-infected lung epithelial cells might 
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be a possible source of IL-1α as it has been observed that IL-1α can feedback on 
epithelial cells and induce a second cytokine and chemokine wave during innate 
immune responses in the lung3, 48. We have only measured the mRNA for IL-1β. Secretion 
of bioactive IL-1β requires activation of the Nlrp3 inflammasome that leads to activation 
of caspase-1 and cleavage of pro-IL-1β into IL-1β. Infection with IAV leads to activation 
of the Nlrp3 inflammasome in a process requiring the type I IFN induced RNAse L/OAS 
system, while the virus actively suppresses IL-1β production and Nlrp3 activation via the 
NS1 protein4, 5. Although others have shown that the NLRP3 inflammasome controls 
severity of infection9, 11, 49, 50, future studies will have to address if lack of key components 
of this inflammasome also leads to reduced iBALT formation. 
 
Generally TLOs are absent in the lungs of healthy adults51, but bronchus associated 
lymphoid tissue can be observed in the lungs of children that are frequently infected by 
respiratory viruses52 and in the lungs of adults that suffer from rheumatoid arthritis53, 54, 
transplant rejection55, COPD56 and IPAH31. We can only speculate that IL-1 might also 
be involved in the formation of these TLO structures. IL-1 is certainly a cytokine that has 
been implicated in the pathogenesis of rheumatoid arthritis, and targeting the IL-1 
pathway via IL1RA (anakinra) has been used as an alternative biological treatment in 
patients failing therapy on TNFα blockade. A very common risk factor for rheumatoid 
arthritis development is smoking, which also leads to COPD.  End stage COPD is also 
accompanied by TLO formation in the lungs, and these can be sites of production of 
antibodies to citrullinated antigens, typical of RA patients.  In a preclinical model of 
smoking induced TLO formation, the production of autoantibodies and TLO structures 
was reduced in Il1r1-/- mice, accompanied by a reduced CXCL13 production in the 
lungs57. 
 
During development neuronal cells give an LTα1β2-independent instructive signal to 
local fibroblasts to produce CXCL13 and hereby attract CD3-CD4+CD45+ LTi cells58, 59. 
The crucial step for SLO development is the interaction of LTi cells with stromal lymphoid 
tissue organizer (LTo) cells. This process happens via interaction of LTβ expressed on LTi 
cells and the LTβR expressed on LTo cells. Upon this interaction, LTo cells produce 
homeostatic chemokines that drive the recruitment of lymphocytes. T cells and DCs are 
attracted by chemokine CC ligand (CCL)19 and CCL21; B cells are attract by 
chemokine CXC ligand (CXCL)13. Expression of vascular cell adhesion molecule 
(VCAM)1, intercellular adhesion molecule (ICAM)1, mucosal addressin cell adhesion 
molecule (MADCAM)1 allow the attracted cells to cluster together. IL-1 has been very 
well known for its effects of stimulating adhesion molecules on endothelial cells60. It is 
tempting to speculate that the effects of IL-1 on radioresistant cells is via induction of 
the crucial adhesion molecules that initially tether a LTi like cell to the circulation and 
subsequently to initiate a communication between stromal cells and lymphoid cells, 
that initiates the CXCL13 production. 
 
The LTi-potential of T cells was first addressed in a model of thyroid overexpression of 
CCL21, where it was shown that CD3+CD4+ activated T cells interacted with DCs at sites 
of chronic inflammation, and subsequently acted as LTi cells in the absence of Id2 
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activity37. It has also been suggested that IL-17 signaling is involved during the initiation 
phase of iBALT formation by inducing CXCL13, but this role for IL-17 remains 
controversial34. In two studies on neonatal mice exposed to endotoxin inhalation and 
on mice with experimental autoimmune encephalomyelitis respectively, an activated 
Th17 CD4 T cell population was found to be involved in inducing TLO structures34, 61. 
RORC+ IL-17–producing cells were also found inside lung TLOs of patients with IPAH. In 
humans, Th17 cells express the CCR6 receptor, and in the bloodstream of IPAH patients 
circulating CCR6+ cells were fewer, while the ligand CCL20 was produced in the 
perivascular TLOs31. However, TLOs seem to develop normally in Ccr6-/- mice 34. The 
induction of TLOs by Th17 cells was dependent on expression of podoplanin, but why 
this is the case remains unknown. One possibility is that podoplanin is required for 
retention of Th17 cells at sites of TLO formation34, 61. The role of Th17 as LTi-like cells is still 
under debate and it remains to be seen whether all forms of TLO depend on IL-17 
production, and whether IL-17A and/or IL-17F is involved. In this regard, iBALT induced 
by infection with modified vaccinia virus Ankara or influenza virus is not affected by 
deficiency of IL-17A while Pseudomonas Aeruginosa-induced iBALT is dependent on 
IL-17 signaling35, 62. As IL-17 production by γδ T cells and Th17 cells can be induced by 
IL-163-66 we also considered the possibility that IL-17 is part of the cascade leading to 
IL-1α driven iBALT formation. In our hands, IAV infection indeed gave rise to a higher 
amount of IL-17+ CD4 T cells, but treatment with IL-1α 2dpi could not increase the 
amount of IL-17+ CD4 T cells in the lung, and experiments in which we administered IL-1 
to IAV infected Il17ra-/- mice were inconclusive (data not shown). This suggests that, in 
contrast to SLO formation, the instructive signals can differ depending on the source of 
initiating antigen or the inflammatory stimulus that is elicited by the used model.  
 
In almost all TLO structures that have been described, the T cell area contained 
antigen-presenting DCs17, 31. As DCs activate T cells, it has been suggested that DCs are 
sufficient for TLO induction67. This hypothesis is supported by the observation that 
repeated injection of DCs into the lungs of mice is sufficient for induction of iBALT 
structures accompanied by induction of myofibroblast differentiation17, 68. During 
formation of Peyer’s patches, a CD11c+ cell type expressing LTαβ accumulates at the LN 
anlagen and is necessary for instruction of stromal cells59. DCs might also directly instruct 
stromal cells irrespectively of their effects on T cells. In TLO structures induced in the 
thymus, DCs were specifically necessary for induction of lymph angiogenesis from 
stromal cells 69 but how DCs induce TLOs is less clear. In virus-induced iBALT, mainly 
CD11b+ DCs or monocyte-derived cells accumulate; these cells express instructive 
LTα1β2 while also producing the homeostatic chemokines CXCL13 and CCL19/CCL2117. 
However, in some models mostly pDCs accumulate, suggesting a functional role for 
type I IFN. As is the case in TLOs found in end-stage COPD patients and in a murine SLE 
model56, 70. Three studies have shown that depletion of DCs leads to disappearance of 
existing TLO structures, suggesting that DCs are necessary for structural organization and 
maintenance of TLOs, most likely through transpresentation of chemokines, or by 
providing a continuous source of antigen presentation to T cells16, 17, 69. We did observe 
reduced numbers of monocyte-derived DCs in Il1r1-/- mice, but have not performed 
experiments in which only DCs lacked Il-1R to study if the effects of IL-1 were cell-intrinsic 
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or resulting from effects of IL-1 on epithelial cells. Indeed, IL-1R triggering on lung 
epithelial cells is a very well known trigger for the production of GM-CSF, one of the 
major cytokines driving activation of monocytes to adopt a DC-like phenotype48. 
 
In conclusion, we have described a novel role for early IL-1 production in IAV infection 
to control the formation of iBALT structures via induction of CXCL13 in a stromal cell 
compartment. Future studies will have to address if this effect of one of the best-known 
proinflammatory and innate cytokines is a general feature of TLO formation at sites of 
acute and chronic immune stimulation such as infectious disease and autoimmune 
pathologies and if this can be exploited to induce iBALT formation as part of a mucosal 
vaccination strategy71. 
 
 
Materials and methods 
Ethics statement 
All experiments were approved by the independent animal ethics committee “Ethische 
Commissie Proefdieren – faculteit Wetenschappen Universiteit Gent en VIB-site 
Ardoyen” (identification number: EC 2013_070). Animal care and used protocols 
adhere to the Belgian Royal Degree of May 29th 2013 for protection of experimental 
animals. European guideline 2010/63/EU is incorporated in this Belgian legislation.  
 
Mice 
C57Bl/6 mice (8-10w) were purchased from Harlan Laboratories. IL-1R-/- mice were bred 
in-house and housed in specific pathogen-free housing. 
To create chimeric mice, IL-1R-/- or wild type acceptor mice were irradiated sublethally 
(9Gy) and reconstituted with 2x106 bone marrow cells i.v. from wild type or IL-1R-/- donor 
mice respectively 4 hours after irradiation. Mice were used for experiment at least 10 
weeks after reconstitution. 
 
Influenza virus infection  
Mice were infected intranasally with 105 TCID50 H3N2 influenza virus X-31 (Medical 
Research Council) or mock (allantoic fluid of uninfected eggs); diluted in 50µl PBS. 
Weight loss was monitored daily. For suppletion assays, mice were treated 
intratracheally with 80µg carrier free recombinant IL-1α (R&D) at 2 or 10 dpi.  
 
TCID50 assay viral titers  
Lungs were homogenized with a tissue homogenizer in 1ml PBS and centrifuged (5min, 
400g) to remove cellular debris before storage at -80°C. Titers of infectious virus were 
determined in triplicate by titration on MDCK cells in serum-free TPCK-treated trypsin-
containing medium. Viral titers were determined by measuring chicken red blood cell 
agglutination activity in the cell supernatant after 7 days of infection of MDCK cells by 
using the calculation method of Reed and Muench. 
 
Isolation of lung cells 
Mice were sacrificed and the lungs were removed. Single cell suspensions were 
prepared by digestion in collagenase/DNase solution for 30 minutes at 37°C. After 
digestion, the suspension was filtered over a 100µm filter and red blood cells were lysed 
with osmotic lysis buffer (10mM KHCO3, 155mM NH4Cl, 0,1mM EDTA in ddH20).  
 
*	  
	  138 
 
Flow cytometry 
Lung cells were stained extracellularly with anti-CD3 (17A2, conjugated to AF700, 
eBioscience), anti-CD19 (1D3, conjugated to APC, BD Bioscience), anti-IgM (R6-60.2, 
conjugated to PerCp-Cy5.5, BD Bioscience), anti-IgD (11-26c.2a, conjugated to PE, BD 
Bioscience), anti-CD95 (Jo2, conjugated to PE-Cy7, BD Bioscience), anti-GL7 (GL7, 
conjugated to Fitc, BD Bioscience) and a fixable live-dead marker (conjugated to 
eFl506, eBioscience).  
Acquisition of samples was performed on a LSR II or Fortessa cytometer equipped with 
FACSDiva software (BD biosciences). Germinal center B cells were defined as CD3-
CD19+IgM-IgD-CD95+GL7+. Final analysis and graphical output were performed using 
FlowJo software v9 (Tree Star, Inc.). 
 
Real-time quantitative RT-PCR. 
Quantitative RT-PCR for IL-1α, IL-1β, LTβ, CCL19, CCL21, CXCL12 and CXCL13 were 
performed on RNA obtained from whole lung homogenates. Total RNA was extracted 
using Tripure reagent (Roche) according to the manufacturer’s protocol. RNA was 
resuspended in Diethyl-polycarbonate (DEPC, Sigma) treated water. A total of 1µg RNA 
was used for reverse transcription using the Transcriptor High Fidelity Reverse 
Transcriptase kit (Roche) according to the manufacturer’s protocol. The subsequent 
target amplification on triplicates of each cDNA sample was performed using the 
Universal Probe Library system from Roche (that contains fluorescent hydrolysis probes 
of 8 locked nucleic acids (LNA). Primers were designed with the help of the web-based 
application Probefinder (https://qpcr.probefinder.com) and a minimum of 2 primer 
pairs per target were analyzed. Primers were validated first using the LC480 SybrGreenI 
Master (Roche) with melting curve analysis (TM calling) in the LC480 Software and then 
using the LC480 Probes Master. Aspecific primer pairs were discarded. Table 1 shows a 
comprehensive view of the primer/probe combinations chosen. PCR conditions were: 
5’ pre-incubation at 95°C followed by 45 amplification cycles of 10” at 95°C, 10” at 
60°C and 20” at 72°C using a Lightcycler 480 (Roche). PCR amplifications for the 
housekeeping genes encoding Hprt or L27 were performed during each run for each 
sample to allow normalization between samples.  
 
Histology 
Lungs were inflated with 1ml 1:1 PBS-OCT (Tissue Tec), snap frozen in liquid nitrogen and 
stored at -80°C. Frozen 8µm sections were fixed in 4% PFA and blocked in a 1% blocking 
buffer (Roche).  
Immunofluorescence staining was performed by staining for B220 (RA3-6B2, Rat-a-
mB220 conjugated to PE, BD Bioscience) + Goat-a-Rat conjugated to AF555, 
Invitrogen), CD4 (RM4-5, Rat-a-CD4 conjugated to Fitc, eBioscience + Rab-a-Fitc 
conjugated to AF488, Invitrogen), CD8 (53-6.7, Rat-a-CD8 conjugated to Fitc, BD 
bioscience + Rab-a-Fitc conjugated to AF488, Invitrogen), CD11c (N418, Hamster-a-
mCD11c conjugated to AF647, eBioscience), GL7 (GL7, Rat-a-mGL7 Fitc, BD bioscience 
+ a-Fitc conjugated to HRP, Jackson + a-HRP conjugated to Fitc, Jackson). Where 
necessary, slides were incubated with 10% normal rat serum to prevent aspecific 
binding of antibodies. Slides were counterstained with Dapi and digitized on a LSM710 
microscope (Zeiss). All depicted pictures are representative of at least five mice per 
group. Images were analyzed using Imaris software (Bitplane). 
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Statistical analysis 
All experiments were performed using 3-6 animals per group. All experiments were 
performed at least two times. The difference between groups was calculated using the 
student t test for unpaired data (Prism version 6; GraphPad Software, Inc.). Data are 
depicted as mean +/- SEM. Differences were considered significant when p<0,05. 
Analysis of the repeated relative body weight data was performed using the residual 
maximum likelihood (REML) as implemented in Genstat v17 (Payne, 2013). The following 
linear mixed model (random terms underlined) was fitted to the data:  
Yijkt = µ + genotypej + treatmentk + timet + (genotype.treatment)jk + (genotype.time)jt + 
(treatment.time)kt +(genotype.treatment.time)jkt + (mouse.time)it + residualijkt, where Yijkt 
is the relative body weight of i-th mouse having genotype j, k-treated and measured at 
time point t (t = 3 – 17 days; unequally spaced), and µ is the overall mean calculated 
for all mice considered across all time points. A first order antedependence covariance 
structure was used to model the within-subject correlation. The significance of the 
comparison between WT-X31 and KO-X31 across time was assessed by an F-test. 
A log-linear model (Poisson distribution and log link) was fitted to the amount of viral 
particles measured by hemagglutination inhibition assay. The dispersion parameter was 
set as free. Significance of main effects GENOTYPE and TIME and the GENOTYPE.TIME 
interaction effect was assessed by an F test.  
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Every winter period many people are affected by an influenza infection. While for the 
majority of people infected this does not cause severe illness or death, it does have a 
significant economical impact due to the associated medical costs and days lost from 
work or school. The threat of influenza pandemics is constantly present. Due to the 
genetic variability of influenza virus strains, the circulating viruses need to be monitored 
continuously and the vaccine composition needs to be adapted yearly. Currently no 
general vaccination strategy exists. Therefore it is crucial to enhance the knowledge 
about the molecular mechanisms behind genetic variability but also about the immune 
response against influenza infections.  
The main immune responses against influenza virus infection are well understood. The 
epithelial layer provides a first natural barrier against infection, once this barrier is 
broken, influenza viruses can infect these epithelial cells. Innate immune cells like NK 
cells and neutrophils will recognize these foreign antigens and provide a first 
non-specific defense mechanism. Dendritic cells will sample viral antigens and present 
it to CD4+ and CD8+ T cells in the lung-draining lymph nodes (LNs). Antigen specific T 
cells will be activated, proliferate and migrate back to the lung environment where a 
second encounter with their cognate antigen will activate them to exert their effector 
functions: cytotoxic killing by CD8 T cells and Th1-mediated. Also in the LNs, 
antigen-specific B cells will be activated and will produce virus-specific antibodies to kill 
infected cells or limit viral spread. Once the infection is cleared, memory T and B cells 
will remain in the tissue and the secondary lymphoid organs that provide a rapid 
defense mechanism by reinfection with a homologous or heterologous virus. 
In this thesis, different aspects of the immune response to influenza A virus infection 
were addressed – DC-mediated immunity, T cell immunity and iBALT formation – by 
using a mouse model for mild seasonal influenza infection and with the main focus on a 
better understanding of the heterogeneity of the different arms of the immune system.  
In chapter 3 we examined the different populations of dendritic cells (DCs) present in 
the lung and LNs during influenza infection. Dendritic cells are the crucial link between 
the innate and adaptive immune responses, sampling antigen during the innate 
response and initiating the adaptive response by presenting such antigens to naïve T 
cells in the LN. As DCs are a crucial link to shift from a non-specific innate immune 
response towards a very specific adaptive immune response, better understanding of 
the DC biology can aid to improve or accelerate the generation of a powerful and 
more optimal T cell response during vaccination or treatment strategies. Our analysis of 
the DC subsets revealed that in addition to the presence of cDC1s, cDC2s and 
monocyte derived cells (MCs), which are also found in the lung during homeostasis, 
mild seasonal influenza infection (X31 virus, H3N2) resulted in the presence of a new 
subset of cDCs. These cDCs resembled cDC2s, however they also expressed the 
prototypical monocyte-marker MAR-1. We termed these novel cDC2s MAR-1+ cDC2s. 
We found that MAR-1 expression was induced in a type 1 IFN dependent manner and 
that these cells were more mature than conventional cDC2s. Additionally, and 
somewhat surprisingly, these MAR-1+ cDC2s also acquired expression of the cDC1-
related transcription factor IRF8. Functionally, IRF8 induction controls a functional 
module in cDC2s responsible for maturation and antigen presentation. During the 
process of defining the ontogeny of this MAR-1+ DC, we came across some limitations 
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of widely used techniques for dissecting DC ontogeny. We first attempted to use 
Flt3l-/- and Ccr2-/- mice to define the pre-cDC or monocyte-derived cells respectively1, 2 
but this was not that straightforward as several bystander effects occurred in these 
transgenic mice. Flt3l-/- mice also have a defect in lymphocyte, NK cell and neutrophil 
development3 that can influence the course of infection and obscure the results. CCR2 
dependency is typically used to identify cells of monocytic origin. However, we noted a 
significant reduction in cDC1s and cDC2s upon inflammation in Ccr2-/- mice which 
would theoretically indicate that these cells are of monocytic origin however, we know 
this is not the case as it is well established that cDCs arise from progenitors committed 
to the cDC lineage namely the pre-cDCs. Additionally, the WT:CCR2-/- competitive 
chimeras that we generated suggested that the MAR-1+ DCs were CCR2-dependent 
and hence one would normally conclude that these are thus of monocytic origin. 
However, when we performed adoptive transfer of monocytes or pre-cDCs, it became 
apparent that these MAR-1+ DCs arose from pre-cDCs and not monocytes 
demonstrating them to be a cDC population. Thus adoptive transfer of progenitors 
appears to be the most valid method of investigating and confirming DC ontogeny. 
Importantly, this is not the first time that CCR2-dependency has been described in a 
cDC population. In the gut it has previously been reported that a subset of CD103-
CD11b+ cDC2s express CCR2 and are dependent upon it4. Additionally, in our lab it has 
recently been shown that cDCs in the heart also express CCR2 and these are also 
reduced in Ccr2-/- mice (Van Der Borght et al. submitted for publication). This is the first 
time that a typical monocyte marker is described to be expressed on conventional 
DCs. This questions of course the classification of MAR-1 as a monocyte marker. 
Together with the analysis of gene expression data, we showed that caution should be 
taken when analyzing DC subsets in inflammatory models since the expression levels of 
many genes and surface markers change upon inflammation, which can influence the 
classification system. Gene expression analysis showed that XCR1 and SIRPα are good 
markers to separate cDC1s and cDC2s respectively as XCR1 expression remains cDC1 
specific upon IAV infection and the expression of SIRPα remains shared between MCs 
and cDC2s. As SIRPα expression is shared with MCs, a good monocyte and 
conventional marker remains necessary to split up MCs and cDC2s. Two possible 
candidates we identified in this project are MerTk and CD26. This confirms the gating 
strategy that can be applied on human, mouse and macaque DC subsets that was 
empirically developed in our lab by Dr. Charlotte Scott and Prof. Martin Guilliams in 
collaboration with the labs of Prof. Bernard Malissen and Prof. Florent Ginhoux which 
they described as “a global key” to define DC subsets (Guilliams et al., Immunity, in 
press).  
As mentioned above MAR-1+ cDC2s were found to express the transcription factor (TF) 
IRF8. TFs such as IRF8 can induce and/or repress a substantial amount of genes and 
therefore we hypothesized that the upregulation of IRF8 in cDC2s would have major 
effects. Indeed, we found that both the maturation status (signal 2 for T cell activation) 
and the capacity to produce IL-12 (signal 3 for T cell activation) were increased in 
MAR-1+ cDC2s compared with MAR-1- cDC2s. This led us to investigate the antigen 
presenting potential of these cells. Remarkably, MAR-1+ cDC2s acquire a good 
capacity to present antigen to CD8+ T cells and to induce their proliferation, a function 
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that is mostly attributed to cDC1s during IAV5, 6. Nevertheless, some research groups also 
attributed this function to CD11b+ DCs, consisting of both true cDCs and MCs7. 
Retrospectively, the ratio of MCs and cDCs in this population might be influencing the 
outcome of antigen presentation assays as we have shown that MCs do not fall in the 
MHCIIhi DC population of the LN (suggesting that they do not migrate from the lung to 
the LN) and that MCs of the lung are not capable of inducing CD8+ T cell proliferation. 
Therefore, when they are highly present in the sorted population, they might dilute the 
antigen presenting capacity of the cDCs in the population. The contrary is also true, 
antigen presentation capacity of cDCs will only be picked up in a model where the 
induction of MAR-1+ cDC2s is high compared to the MAR-1- cDC2s as these are poor 
antigen presenters in a MHCI context and thus can also dilute the effect of the MAR-1+ 
cDC2s in antigen presentation assays.  
In conclusion, the correct identification of the DC subsets is crucial and only once the 
distinct subsets are evaluated can the consequences of different viral strains, infectious 
doses and routes of administration be compared. Thus we believe that the gating 
strategy presented in this thesis provides a significant step forward in the field as it allows 
the distinct subsets present during IAV to be comprehensively evaluated. The next step 
will be to see if this holds true in humans so that once we understand the specific 
functions of the cells we can aim to boost the DC response of the most powerful subset 
to aid in viral elimination. 
Philosophically we can wonder why the immune system would instruct a cell to acquire 
a hybrid phenotype (MAR-1+ cDC2) when a specialized cell (cDC1) is already present 
to perform a certain function. One hypothesis is that in the context of inflammation and 
more specifically IAV infection, the pressure on the immune system to limit the spread of 
the virus is high. We and others have previously made the observation that the amount 
cDC1s in the lungs is not strongly increased shortly after IAV infection and cDC1 DCs 
disappear from the trachea at that time, which might limit the strength of the CTL 
response8, 9. It is possible that induction of the IRF8-dependent module is an emergency 
rescue for allowing additional CTL induction by DC subsets that normally do not 
(cross)present viral antigens to CD8 T cells, driven by type I interferons10. One can 
assume that in this way a maximum capacity of antigen transport to the draining lymph 
nodes is maintained as cDC2s migrate proficiently also later in infection. Additionally, it 
would be beneficial to the host to send cells to the lymph node that can combine 
different immune functions. In this way, the MAR-1+ cDC2 acquire a capacity to induce 
the CTL response (a function traditionally attributed to cDC1) while maintaining the 
capacity to mount a strong antiviral state (a feature shared with MCs and cDC1). As 
there are also genes that are specifically induced by IAV only in MAR-1+ cDC2s and 
MCs (cluster 4 genes), we speculate that closer study of those genes might offer 
explanations why DCs adopt a hybrid phenotype.  
New tools are urgently needed to address the exact in vivo role of the MAR-1+ cDC2s. 
The use of CD11c Cre mice to create conditional knock-out mice has the 
disadvantage that the whole DC population is targeted. Additionally, as alveolar 
macrophages also express CD11c these are also targeted in these mice. Recently, two 
interesting new mice lines have been created. Zbtb46 Cre mice target the 
conventional DCs (i.e. cDC1 and cDC2) specifically while the Xcr1 DTR mice allow the 
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specific removal of cDC1s through administration of diphtheria toxin. Crucially, 
however, a cDC2 specific mouse line is still missing and considering the fact that cDC2s 
share all their genes with either cDC1s or MCs, it will be almost impossible to develop 
such a line. The MAR-1 antibody that we used to define MCs and that is also expressed 
on a subset of cDC2s is generated to react specifically to an antigenic site of the FcεRI. 
By studying the DC subsets in FcεRI-/- mice we found that the amount and distribution of 
the different subsets, nor the intensity of MAR-1 staining on DCs is affected in these 
mice, while expression of FcεRI on mast cells and basophils is indeed absent. This means 
that the antibody potentially has a cross reactivity with other proteins. Hence, if we can 
identify the gene product that is targeted by our MAR-1 antibody, we could develop 
new mouse tools. First, we could develop a mouse line lacking the MAR-1 epitope 
based on Cre-Lox technology (floxing the gene of interest, encoding the MAR-1 
epitope) and crossing it to the Zbtb46 Cre mice. In this way, we will create a mouse that 
is unable to express the unknown MAR-1 epitope on the cDCs, while still allowing 
expression on MCs. Hence we can address the effect of lack of MAR-1 induction in the 
cDC2 population on for example CD8+ T cell responses in vivo. A tool to specifically 
deplete the MAR-1+ cDC2 subset would involve creating a knock in of loxSTOPlox-DTR in 
the “MAR-1” gene, and subsequent crossing of these mice to the Zbtb46-Cre line. This 
should allow specific targeting of MAR-1+ cDC2s, while sparing MCs. 
Besides improving murine experimental tools, it is also necessary to develop tools to 
investigate whether MAR-1+ cDC2s can also be detected in humans. Currently there is 
no human MAR-1 antibody available. This means that the MAR-1+ cDC2s can until now 
only be identified as an IRF8 expressing population within the total cDC2 population. If 
human cDC2s also segregate into two different activation states (being an IRF8 
expressing population and an IRF8- population), it would be of great interest of the DC 
vaccination field to screen for correlation between disease severity, duration of the 
disease and induced direct antiviral and memory responses.  
 
As described above, cDCs are crucial in the initiation of adaptive immune responses 
through the presentation of antigen to naïve T cells. Thus having investigated the 
distinct DC populations during IAV, in chapter 4, we next turned our attention to the T 
cell response during IAV infection. Specifically, we focused on the CD4-CD8- double 
negative (DN) T cell population, as these cells are often neglected from analysis, and 
compared their phenotype with the already intensively described CD4+ and CD8+ T 
cells. DN T cells are true T cells as they express the T cell receptor and are not NKT cells, 
as they don’t react with the αGalCer CD1d tetramers. They are thymically derived and 
in contrast to the conventional T cells, they reside in the lung parenchyma rather than 
in the lung vasculature already in steady-state conditions where they have a Trm 
phenotype. Although they had a memory phenotype, they did not react to reinfection 
with a heterologous virus, showing that viral replication is necessary for their expansion. 
In the field of transplant rejection it is believed that DN T cells are activated CD4 T cells 
that downregulate the expression of the CD4 coreceptor11. We were not able to 
confirm that during IAV infection classical CD4+ or CD8+ T cells give rise to the DN T cells 
population. Our arguments against this hypothesis are that the Vβ repertoire of the TCR 
is not similar to that of either CD4+ or CD8+ T cells and that intracellular staining for CD4 
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and CD8 could not reveal significant expression of CD4 and CD8 inside DN T cells. 
Moreover it was recently shown that thymically-derived DN T cells from the gut 
epithelium have a different TCR repertoire than other T cells, with a specificity different 
from the currently existing MHCI- and MHCII-restricted specificities12. These observations 
led to the hypothesis that DN T cells are playing a non-redundant role in the protection 
against invading pathogens especially under conditions of immune evasion as 
well-developed conventional pathways are often the target of immune evasion 
strategies. This hypothesis is well applicable to the IAV infection model as influenza 
viruses developed several immune evasion strategies based on protection mechanisms 
at different levels of the immune response13. Therefore it would be interesting to study 
the TCR repertoire in more detail, e.g. with the cloning strategies used by the Cheroutre 
group. Functionally, DN T cells have immunoregulatory capacities as they enhanced 
the survival of CD11b+ cDC2 and MCs during in vitro cocultures. The inhibition of 
apoptosis in part of the DC subsets indicates that DN T cells can prolong the survival of 
certain cell types when immune pressure is present. A substantial part of the DN T cells 
expressed high levels of FasL, a protein involved in cell dead induction. Therefore it was 
surprising that DN T cells actually prolonged the survival of certain DC subsets in vitro. 
This suggests that DN T cells might either have different functions or that they represent 
a mixed population composed of cells with opposite functions. In the first scenario, DN T 
cells might exert a different function depending on the cells they interact with. 
Previously, they have been described to suppress B cells14 and T cells15. Therefore it 
might be of interest to coculture them with different cell types and compare the effect 
of presence of DN T cells with the cells to address whether they react differently 
depending on the interacting cell type.  
As these cells are defined by negative markers, it is difficult to do functional in vivo 
studies, as we cannot deplete them with depleting antibodies. Therefore it would be 
interesting to perform single-cell RNA sequence analysis to evaluate if this population is 
homogenous or a mixture of different cell types. Further, we can use these data to 
define a discriminating marker to facilitate in vivo functional studies on these cells.  
 
Long after the virus has been cleared from the lung by specific T cell and B cell 
responses, iBALT structures can be observed in the lungs. These tertiary lymphoid 
structures often form at the branching of the bronchi and are composed of B cells, T 
cells and DCs, similar to classical secondary lymphoid organs such as the spleen and 
lymph nodes. Consequently they can be a local induction site for protective immune 
responses in case of viral or bacterial infections. Therefore it is of great interest to have 
an in-depth knowledge about the developmental mechanisms and signals to sustain 
iBALT structures in the lung. The development of TLOs is very similar to SLOs, but in 
contrast to the well-defined developmental pathway of SLOs, the development of TLOs 
is subjected to more variation depending on the model. Especially the early initiating 
steps are still unclear. For example, the typical lymphoid tissue inducer cells are 
dispensable for iBALT formation, but the true nature of the cell or signal that is necessary 
to induce iBALT is still under debate. In chapter 5 we questioned whether the intensity of 
the early innate response is influencing the outcome of iBALT formation. We have 
shown that the instructive signals for iBALT formation are already given very early (2dpi) 
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after infection and that it is the innate cytokine IL-1α that can boost germinal center 
formation in the lung. Before, it was shown that IL-17 plays an important role in iBALT 
induction during IAV infection16. As there is a link between IL-1 signaling and IL-17 
production17-20, we also questioned whether IL-17 is involved in our model. However, 
studies in Il17r-/- mice could not reveal a difference in iBALT formation and the 
administration of recombinant IL-1 did not influence the magnitude of the Th17 
response in our model. We deliberately chose a mild seasonal influenza virus infection 
(X31, H3N2) whereas mostly PR8 (H1N1), a more pathological virus strain, is used to study 
iBALT induction. Additionally, the Randall group already primed neonatal mice with LPS 
before influenza infection at 6 weeks of age. Given the big amount of LPS to which the 
lungs are exposed we can assume that the natural environment of the lung is already 
changed before the actual influenza infection. In our lab, Martijn Schuijs studied the 
effect of LPS exposure on asthma development. LPS pretreatment appeared protective 
for later asthma development and histological analysis of the lungs revealed a major 
presence of iBALT structures whereas the normal house dust mite-driven model of 
asthma development generally does not lead to iBALT formation. So it remains a 
question if the Randall group rather studied LPS-driven iBALT formation rather than 
influenza-driven iBALT formation. The group of Förster has confirmed that iBALT formation 
caused by different respiratory infections can have different developmental 
mechanisms as infection with Vaccinia Ankara virus leads to iBALT formation in an IL-17 
independent manner whereas Pseudomonas-induced iBALT does require IL-17 signals21.  
We have previously shown that repeated injections of GM-CSF cultured bone marrow 
DCs can induce iBALT formation22. As we noticed that MCs are decreased during the 
course of IAV infection in IL-1R-/- mice and that MCs were previously described to be 
major chemokine producers, it might be that IL-1 signaling results in MC recruitment and 
these MCs might be the producers of CXCL13. We also observed a decrease in MAR-1+ 
cDC2 induction (data not shown), so it would be informative to address the 
iBALT-inducing capacity of injected MCs and MAR-1+ cDC2s and compare them with 
macrophages as it was recently shown that GM-CSF DCs are a mixture of cDC2s and a 
macrophage-like monocyte-derived cell23. 
The fact that germinal centers are present in these structures enables them to mount 
specific immune responses to invading pathogens. Therefore, they are of interest to be 
exploited during vaccination24. Our study identified an innate cytokine that boosts iBALT 
formation. It would be interesting to see if repeated exposure of the lungs to IL-1α 
without the presence of a pathogen also induces iBALT. Secondly, iBALT structures are 
present in the lungs of children with recurrent respiratory infections25, but are generally 
absent in the lungs of healthy adults26 suggesting that they disappear over time when 
there are not enough insults. Thus it would not only be interesting to study if IL-1α can 
induce iBALT but also if repeated exposure after formation of iBALT structures can 
prevent the disappearance. 
Before iBALT can be used as a vaccination strategy, it is however crucial to investigate 
how we can prevent that, as a side effect, iBALT structures can also generate 
autoantibodies and thus induce auto-immune diseases. Another issue that is hampering 
translation to humans is the fact that invasive techniques are essential to assess the 
presence of iBALT structures in the lungs.  
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All together, we generated several insights that can improve future research to the 
immune response against influenza virus infection. Firstly, we identified a maturation 
status of cDC2s that acquires typical cDC1 functions and might be a strategy of the 
immune response to optimize the immune response by combining the most necessary 
immune functions in one cell type, a finding that could be exploited to create novel 
vaccination strategies, if we could find vaccines that specifically elicit IRF8+MAR-1+ 
cDC2s. In addition, this research has raised the consciousness about the fact that 
caution should be taken when using cell subset “specific” markers or transcription 
factors – generally regarded as the gold standards of lineage definition – in 
inflammatory models. Secondly, we gained more insight in the phenotype of DN T cells. 
More in-depth analysis of the TCR specificity of these cells will however be necessary to 
evaluate if these cells exert an antigen-specific function or not. Moreover single-cell 
analysis will be crucial to exclude that these cells are a heterogeneous population. 
Lastly, we showed that innate immune signals condition the lung for iBALT formation 
after viral clearance, creating the awareness that the first nonspecific immune response 
is crucial for later adaptive immune reservoirs. Again, better understanding of such 
innate signals that boost the formation of iBALT structures that are emerging as 
important structures in long lasting immune protection could greatly improve vaccine 
design in the future. 
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Elke winter worden heel wat mensen getroffen door de griep, veroorzaakt door infectie 
met een influenza virus. Voor de meerderheid leidt griep infectie gelukkig niet tot 
ernstige ziekte of zelfs de dood. Toch heeft dit een aanzienlijke economische impact 
door de medische kosten die het met zich mee brengt en de afwezigheid op het werk 
of school. Bovendien is er de continue dreiging dat er een pandemie ontstaat. Doordat 
het genoom van influenza virussen zeer variabel is moeten de circulerende virussen 
constant gescreend worden en moet de samenstelling van de vaccins voor het 
komende griepseizoen op basis van voorspellingen aangepast worden. Daardoor is er 
nooit een volledige zekerheid dat het vaccin perfect afgestemd zal zijn op de virussen 
die daadwerkelijk mensen gaan infecteren. Bovendien is er nog geen uitzicht op een 
universele vaccinatiestrategie die de variabiliteit van het influenza virus omzeilt. 
Daarom is het belangrijk om de kennis over de moleculaire mechanismes die de 
genetische variabiliteit drijven en over de afweerreactie tegen influenza virussen uit te 
bouwen.  
De algemene principes van de afweerreactie tegen influenza virus infectie zijn al goed 
gekarakteriseerd. Het epitheel van de longen vormt een eerste natuurlijke barrière, 
maar eens deze barrière omzeild is, kan het virus de epitheelcellen infecteren. 
Aangeboren (innate) afweercellen zoals NK cellen en neutrofielen zullen de vreemde 
partikels herkennen en een eerste aspecifieke afweerreactie induceren. Dendritische 
cellen nemen stukjes van het virus op en presenteren dit antigen aan de T cellen in de 
lymfeknopen. Op deze plaats zullen T cellen die deze stukjes herkennen geactiveerd 
worden, migreren naar de long en daar hun functies uitoefenen. Veder zullen er in de 
lymfeknopen ook B cellen geactiveerd worden en deze cellen zullen uiteindelijk 
antilichamen produceren om geïnfecteerde cellen te doden of om de verspreiding 
van het virus tegen te gaan. Eenmaal de infectie geklaard is zullen T en B cellen in de 
weefsels en lymfoïde organen achterblijven die een “geheugen” hebben over hun 
functie en specificiteit en hierdoor zullen zij een snelle maar heel specifieke 
afweerrespons kunnen induceren wanneer het lichaam getroffen wordt door een 
reïnfectie met hetzelfde of een sterk gelijkend virus.  
In dit proefschrift hebben we verschillende takken van de afweerrespons tegen 
influenza virussen bestudeerd: de heterogeniteit van dendritische cellen en T cellen en 
de vorming van iBALT structuren.  
 
In hoofdstuk 3 werden de verschillende types dendritische cellen (DCs) bestudeerd in 
de long en de lymfeknopen die de long draineren. Omdat DCs een cruciale link 
vormen tussen de overgang van een aspecifieke aangeboren afweerreactie naar een 
specifieke afweerrespons, is het belangrijk om de biologie van de DCs goed te 
begrijpen. Deze kennis kan immers bijdragen tot het verbeteren of versnellen van een 
optimale T cel respons tijdens vaccinatie- of behandelingsstrategieën. Tijdens onze 
onderzoeken hebben we een type 2 DC geïdentificeerd die de oppervlakte merkers 
van een monocyte-afgeleide cel (MC) verkrijgt, maar ook functies kan uitvoeren die 
voornamelijk aan type 1 DCs werden toegewezen. Dit zou een strategie van het 
afweersysteem kunnen zijn om de meest noodzakelijke functies in één celtype te 
combineren. Deze bevindingen kunnen gebruikt worden om te onderzoeken of we 
vaccins kunnen ontwikkelen die specifiek dit celtype induceert. Tijdens dit onderzoek 
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hebben we er ook op gewezen dat het gebruik van merkers en transcriptiefactoren die 
eerder beschreven werden als specifiek voor een bepaald type cel vaak geen stand 
houdt tijdens inflammatoire reacties. 
 
Aangezien DCs verantwoordelijk zijn voor het induceren van een specifieke 
(adaptieve) afweerreactie door antigenen te presenteren aan T cellen, zijn we in 
hoofdstuk 4 dieper ingegaan op de T cel respons tegen influenza virus infectie. We 
hebben hierbij voornamelijk de focus gelegd op de zogenaamde “dubbel negatieve T 
cellen” die heel vaak niet geanalyseerd worden wanneer men de verschillende types T 
cellen bestudeert. Als eerste hebben we aangetoond dat dit weldegelijk echte T cellen 
zijn aangezien ze de T cel receptor op hun oppervlakte dragen. Verder hebben we het 
fenotype van deze cellen grondig vergeleken met dat van de CD4+ en CD8+ T cellen. 
Hieruit bleek dat deze cellen al in basale condities een geheugen fenotype hebben en 
eerder in het weefsel dan in de bloedvaten van de long verblijven. Functioneel 
hebben we aangetoond dat deze cellen het overleven van type 2 DCs en MCs, maar 
niet van type 1 DCs, tijdens in vitro culturen verlengen. Verder onderzoek moet uitwijzen 
of deze cellen een homogene populatie vormen of een samenstelling zijn van 
functioneel verschillende types T cellen.  
 
Na het klaren van de infectie blijven er vaak iBALT structuren achter in de long. Deze 
lymfoïde structuren liggen dicht bij de vertakkingen van de van de luchtpijp. Hun 
samenstelling is sterk vergelijkbaar met die van de lymfeknopen en functioneel kunnen 
ze ook een plaats zijn waar T en B cel responsen geïnduceerd worden. In hoofdstuk 5 
hebben we bestudeerd of de intensiteit van de vroege aangeboren afweerreactie 
invloed heeft op latere iBALT vorming. Uit de proeven bleek dat de signalen voor iBALT 
vorming al heel vroeg na infectie moeten gegeven worden en dat het cytokine IL-1 het 
ontstaan van iBALT structuren kan bevorderen. Een experimenteel model waarin 
gekeken wordt of IL-1 toediening enerzijds de vorming van iBALT structuren kan 
induceren zonder blootstelling aan pathogenen en anderzijds de al gevormde iBALT 
structuren in stand kan houden zou een interessante onderzoekslijn zijn om de mogelijke 
toepassing van iBALT als vaccinatiestrategie te bepalen. Echter, een belangrijke 
kanttekening bij het potentieel van iBALT structuren als vaccinatiestrategie is het feit dat 
deze structuren naast een nuttige afweerrespons tegen virale infecties ook een 
afweerrespons zou kunnen induceren tegen lichaamseigen eiwitten en zo 
auto-immuun ziektes zou kunnen veroorzaken.  
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